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Chapter 1 
Introduction 
  
  
Life on earth is dependent on the catalytic activity of a number of different metal ions 
in their polypeptide scaffold. Among these metals, iron is widely used for catalysis of many 
reactions by living organisms. Iron is an essential element for cellular survival (1). In 
mammals, its participation in heme and iron-sulfur cluster (ISC)-containing proteins allows 
the involvement of iron in a variety of vital functions, including oxygen transport 
(hemoglobins), DNA synthesis (ribonucleotide reductase), oxygen metabolism (catalases and 
peroxidases) and cellular respiration electron transfer (cytochromes) (2). Using iron in an 
oxygenic environment requires organisms to precisely control intracellular availability of free 
Fe(II) and Fe(III), which are the two most common oxidation states of iron. Free Fe(II) will 
donate an electron to molecular oxygen, and as a result superoxide radical, which is a reactive 
oxygen species (ROS), and free Fe(III) will form, as a result of iron participation in the 
Fenton reaction, (equation 1). 
Fe2+ + H2O2 → Fe3+ + OH– + OH•     (1) 
Fe(III) is insoluble under physiological conditions (solubility 10−18 M) (3) and 
precipitates as Fe(III) oxide species. Instead, ROS trigger oxidative stress, lipid peroxidation, 
and DNA damage, which can lead to genomic instability and DNA repair defects that 
ultimately compromise cell viability and promote programmed cell death (4). These 
deleterious effects are prevented by regulatory mechanisms that maintain systemic and 
cellular iron homeostasis (5) through: the cooperation of functional compartments (erythroid 
and proliferating cells), uptake and recycling systems (enterocytes and splenic macrophages), 
storage elements (hepatocytes), and mobilization processes that allow iron trafficking through 
polarized cells and their corresponding organs (6). 
 
1.1 Systemic iron metabolism 
In healthy individuals, the amount of body iron is maintained within a range of ∼3−5 
g of iron (7) by a strict control of its absorption, mobilization, storage, and recycling. The 
majority is present as heme in hemoglobin of erythroid cells (>2 g) or myoglobin of muscles 
(∼300 mg). Macrophages in the spleen, liver, and bone marrow maintain a transient fraction 
of iron (∼600 mg), while excess iron is stored in the liver within ferritin (∼1000 mg). All 
other cellular iron-containing proteins and enzymes are estimated to bind a total of ∼8 mg of 
iron (8). Iron is delivered to erythroblasts and to most tissues via circulating transferrin (Tf), 
  
which carries ∼3 mg of the metal. Plasma iron is predominantly recycled by macrophages and 
to a small extent (∼1−2 mg/day) by absorption from the diet, mediated by duodenal 
enterocytes. The macrophages acquire iron primarily via erythrophagocytosis and the 
enterocytes by internalization of heme or inorganic iron from the intestinal lumen (9). The 
absorption of inorganic iron involves: reduction of Fe3+ to Fe2+ by ascorbate and/or 
membrane-associated ferrireductases such as duodenal cytochrome b (DcytB), coupled to 
transport of Fe2+ across the apical membrane by divalent metal transporter 1 (DMT1) (7). The 
mechanism of heme internalization remains poorly defined and may involve either direct 
transport of heme or receptor-mediated endocytosis (10). Macrophages and enterocytes 
catabolize heme in a reaction catalyzed by heme oxygenase-1 and -2 (HO-1 and HO-2, 
respectively), which liberate inorganic iron. Both cell types export Fe2+ to plasma via the 
transmembrane transporter, ferroportin (Fpn) in a process coupled to the oxidation of Fe2+ to 
Fe3+. This is mediated by the circulating ferroxidase ceruloplasmin or its homologue, 
hephaestin, which is expressed on the basolateral membrane of duodenal enterocytes and 
physically interacts with Fpn. Exported iron is scavenged by plasma Tf, which maintains it in 
a redox inert state and delivers it to tissues. Systemic Fe homeostasis is ensured by a body 
sensor, hepcidin, a peptide hormone produced by the liver in response to iron and 
inflammation (Fig. 1). Upregulation of hepcidin prevents duodenal iron uptake and entry into 
circulation, recycling from red blood cells heme-iron and release from iron stores. This 
hormone binds to Fpn on the plasma membrane of enterocytes, macrophages, hepatocytes, 
and other cells, promoting its internalization that leads to its lysosomal degradation (11). 
Since Fpn is the only exporter of inorganic iron in mammalian cells, its inactivation causes 
intracellular iron retention. Additionally, hepcidin has also been shown to promote 
proteasomal degradation of DMT1 (11).  
  
 
 
1.2 Cellular iron metabolism 
Cells have evolved metabolic strategies for safely managing iron. Regulation of iron 
uptake, intracellular trafficking, storage and utilization is critical for the maintenance of 
cellular iron homeostasis (Fig. 2). 
Figure 1 - Regulation of systemic iron metabolism. Reprinted from Biochemistry 2012, 51, 5705−5724. 
Duodenal enterocytes absorb dietary iron via DMT1 located on the apical surface upon reduction of Fe3+ to 
Fe2+ by DcytB. Spleenic reticuloendothelial macrophages recycle iron from senescent red blood cells. Both cell 
types release iron via ferroportin with the aid of hephaestin, which oxidizes Fe2+ to Fe3+. Iron is also oxidized 
by ceruloplasmin in the circulation. Plasma Tf captures and circulates iron in the body. Hepatic hormone 
hepcidin regulates the efflux of iron from these cells by regulating the stability of ferroportin. Iron levels in the 
body, as well as conditions that affect iron metabolism indirectly such as inflammation, ER stress, 
erythropoiesis, and hypoxia influence the synthesis and secretion of hepcidin by hepatocytes. 
  
 
 
1.2.1 Iron uptake  
Cell membranes and tight junctions between cells prevent the free flow of iron. Cells 
therefore have transporters, chaperones, and chelators, which allow iron crossing through 
membranes and facilitate intracellular trafficking. Most mammalian cells acquire iron from 
circulating Tf, upon binding to transferrin receptor 1 (TfR1). Tf, an 80 kDa glycoprotein, is 
synthesized and secreted mainly by the liver. Tf binds iron in plasma and extracellular fluids 
such as lymph and cerebrospinal fluid. It is equally distributed between plasma and 
extracellular fluids. Tf is a homodimeric β-globulin, which binds two molecules of ferric iron 
with high affinity (Kd = 10
−23 M). TfR1 provides the physiological route for entry of Tf-bound 
Figure 2. Cellular iron metabolism. Reprinted from Cell, 2010, 142(1), 24-38. A generic cell is depicted. 
Most cells acquire plasma iron via transferrin receptor 1 (TfR1)-mediated endocytosis of transferrin-bound 
iron. In endosomes, iron is freed from transferrin and reduced to Fe(II) by STEAP metalloreductases prior its 
release into cytosol via divalent metal transporter 1 (DMT1); transferrin and TfR1 return to the plasma 
membrane to be used for further cycles. DMT1 also functions in the apical absorption of dietary iron after 
reduction by DCYTB and possibly other ferrireductases. Other iron acquisition pathways are symbolized (e.g., 
acquisition of heme iron from red blood cells by macrophages). Iron uptake systems feed the so-called labile 
iron pool (LIP). The LIP is utilized for direct incorporation into iron proteins or iron transport to mitochondria 
via mitoferrin (Mfrn), where the metal is inserted into heme and Fe/S cluster prosthetic groups. The fraction of 
the LIP that is not utilized for metalation reactions can be exported via ferroportin, which works together with 
ferroxidases for iron loading onto transferrin, or stored in a nontoxic form in ferritin shells. Ferritin can be 
released into the extracellular milieu by unknown mechanisms and interact with specific receptors on the cell 
surface. 
  
iron into cells. It is expressed by most nucleated mammalian cells, and its levels correlate with 
cellular iron requirements. TfR1 is a disulfide-linked transmembrane glycoprotein that forms 
a homodimer with a molecular mass of 180 kDa, where each subunit binds one Tf molecule 
(12). Iron is released from Tf within endocytic vesicles due to acidification through the action 
of a v-ATPase proton pump. In a cooperative manner, Tf and TfR1 undergo conformational 
changes in the acidified endosome leading to iron release (13). 
The released Fe3+ is then reduced to Fe2+ by STEAP 3 (six- transmembrane epithelial 
antigen of prostate-3), a member of the metalloreductase family (14). Fe2+ is transported 
across the endosomal membrane into the cytosol by DMT1 in most cells or by its homologue 
Nramp 1 (natural resistance-associated macrophage protein-1) in macrophages. In this regard, 
DMT1 is a dual-function protein, which regulates both systemic and cellular iron 
homeostasis. DMT1 inactivation in mice and humans leads to iron deficiency anemia (15). 
Newly assimilated cytosolic iron is transported to intracellular sites either for local use or for 
storage in ferritin. Hepatocytes may take up Tf-bound iron via both TfR1 and TfR2. However, 
while TfR1 is almost ubiquitously expressed, the expression of TfR2 is restricted to liver 
hepatocytes and to differentiated erythroblasts. Additionally, there is the portion of non 
transferrin bound iron (NTBI) that comprises all forms of plasma iron that are bound to 
ligands other than Tf. Cells can also acquire iron that is in complexes with other proteins or 
small molecules. For instance, internalization of ferritin via ferritin-specific receptors such as 
Scavenger receptor family class A member 5 (Scara5) facilitates iron import (16). Heme 
ingested from the diet also serves as an important source of iron. The importance of this route 
of iron uptake is exemplified by the enhanced heme uptake observed in iron deficiency. Cells 
are thought to internalize heme via a receptor-dependent process or indirectly with the aid of a 
heme carrier protein-1 (HCP-1), also known as proton-coupled folate transporter (PCFT) (17). 
 
1.2.2 Iron trafficking 
Iron taken up by Tf-dependent or -independent routes presumably enters into a labile 
intermediary pool or labile iron pool (LIP). The LIP is also termed as the “exchangeable”, 
“regulatory”, or “chelatable” iron pool, because its presence has been documented by using 
metal chelators (18). It is defined as a low molecular weight pool of weakly chelated iron, 
including both Fe2+ and Fe3+ and represents a minor fraction of the total amount of cellular 
iron (∼3−5%). The LIP links cellular iron uptake with iron utilization, storage, or export. The 
  
other source of iron for this pool is the degradation of non-heme and heme iron-containing 
proteins. Iron within the LIP is thought to be in steady state equilibrium and is proposed to 
bind diverse low-molecular weight chelates, such as organic anions (phosphates, citrates, and 
carboxylates) and polyfunctional ligands such as polypeptides and siderophores. 
Mitochondria are central for the regulation of cellular iron metabolism, and the majority of 
iron imported into the cell is utilized within this organelle for the synthesis of heme and ISCs 
(19). Mitoferrin-1 (Mfrn1) and Mitoferrin-2 (Mfrn2) are crucial for the import of 
mitochondrial iron into erythroid and non-erythroid cells, respectively (20). Heme synthesis 
begins and ends in mitochondria, but intermediate steps occur in the cytoplasm (21). As 
regarding the synthesis of ISCs, these cofactors consist of iron cations and sulfide anions. 
They are assembled on scaffold proteins and then targeted to specific proteins via sulfur of 
cysteine residues. In mammals, the scaffold protein is “ISC assembly protein U” (IscU) (22). 
Loading of iron onto IscU is very likely mediated by mitochondrial frataxin (23), which 
thereby plays an important role in mitochondrial iron metabolism. Besides the biosynthesis of 
heme and ISCs, iron in excess in mitochondria is stored in the mitochondrion-specific iron 
storage protein mitochondrial ferritin or mitoferritin (FtMt) (see below). 
 
1.2.3 Iron regulation 
While systemic iron metabolism is mainly regulated at the transcriptional level, 
cellular iron balance is largely controlled by post-transcriptional mechanisms. Inside the cell, 
a machinery involving the Iron Regulatory Proteins (IRPs) and the Iron Responsive Elements 
(IREs) controls the iron levels. The IREs structural motifs are within untranslated regions 
(UTRs) of several mRNAs. The mRNAs encoding TfR1 and ferritin are typical examples of 
coordinate post-transcriptional regulation by IRE-IRP interactions (24). IREs are 
evolutionarily conserved stem loop structures of 25−30 nucleotides. In iron deficiency, IRPs 
bind with high affinity (Kd ~10
−12 M) to target IREs. This results in stabilization of TfR1 
mRNA and steric inhibition of ferritin mRNA translation. Under these conditions, 
accumulation of TfR1 promotes the uptake of cellular iron from plasma Tf, while inhibition of 
ferritin biosynthesis prevents storage of iron, allowing its metabolic utilization. Conversely, in 
response to excess cellular iron, IRPs are inactivated, which leads to TfR1 mRNA degradation 
and ferritin mRNA translation. This minimizes further internalization of iron via TfR1 and 
promotes the storage of excessive intracellular iron into ferritin. Interestingly, mutations in the 
  
L-ferritin IRE that prevent IRP binding are causatively linked to hereditary hyperferritinemia-
cataract syndrome (HHCS), an autosomal dominant disorder characterized by overexpression 
of serum ferritin (without iron overload) and early onset cataract (25). IRP1 and IRP2 are 
homologous to mitochondrial aconitase and other members of the ISC isomerase family, 
which possess a cubane ISC in their active site. In iron starvation, IRP1 assembles an ISC and 
functions as cytosolic aconitase (catalyzing the conversion of citrate to iso-citrate via a cis-
aconitate intermediate). The ISC keeps IRP1 in a closed conformation, which precludes 
access of IREs. Iron deficiency promotes the loss of the ISC and a resulting structural 
rearrangement of the protein that acquires IRE binding activity. Thus, IRP1 is a bifunctional 
protein that is regulated by an ISC switch. Despite its extensive homology with IRP1, IRP2 
does not assemble an ISC and is regulated by a distinct mechanism. It remains stable in iron-
starved or hypoxic cells and undergoes ubiquitination and proteasomal degradation in 
response to iron and oxygen. 
 
1.2.4 Iron export 
Cellular iron export occurs in specialized cells such as enterocytes and macrophages 
that are involved in iron absorption and recycling, respectively. The main purpose of iron 
export is to maintain adequate plasma iron levels and to meet systemic needs. Iron export 
involves coordination between many enzymes and proteins. First, iron is reduced in 
endosomes prior to being released into the cytoplasm. Thus, Fpn exports Fe2+, which has to be 
oxidized to Fe3+ upon its release into plasma for binding to Tf (26). This is mediated by the 
blue copper ferroxidases ceruloplasmin (soluble in serum or plasma membrane-associated in 
some cell types) and hephaestin (expressed on the plasma membrane of enterocytes and other 
cell types). These enzymes thus work in concert with Fpn to coordinate iron export and 
oxidation. As copper is essential for ferroxidase activity, adequate levels of this metal are 
required for proper iron balance. Cells may also export iron bound to ferritin or to heme. 
Feline leukemia virus subgroup C receptor 1 (FLVCR1) facilitates the efflux of heme from 
hematopoietic cells. In addition to the list of heme exporters, an ATP binding cassette family 
member, ABCG2, has also been implicated in cellular heme export. 
 
  
1.2.5 Iron storage 
Cellular iron storage is carried out by ferritin, ubiquitous nanocage protein that can 
accommodate up to thousands of iron atoms inside its cavity. Twenty-four subunits assemble 
to make a hollow spherical protein with octahedral symmetry. Ferritin binds and oxidizes 
Fe(II) and subsequently stores the Fe(III) product inside its cavity as a ferrihydrite-like 
mineral core. In mammals, ferritin is a heteropolymer of 24 subunits of two different 
polypeptides: heavy chain (H) and light chain (L) (see below for detailed description).  
 
1.3 The superfamily of ferritin 
The ferritin family consists of three sub-families, the classical ferritins (Ftn), the 
bacterioferritins (Bfr) and the ‘DNA-binding protein from starved cells’ (Dps proteins) (27). 
Besides the above-cited proteins, the ferritin superfamily encompasses proteins that have a 
four α-helix bundle structure such as soluble methane monooxygenase, ribonucleotide 
reductase, rubrerythrin, Dps-like proteins and the recently identified archaeoferritin (28). 
Ftn’s are found in all three domains of life. They are composed of 24 subunits that form a 
rhombic dodecahedron. Instead, Bfr proteins are restricted to the bacterial and archaeal 
domains of life even if they possess the same quaternary structure as Ftn. Both Bfr and Ftn 
proteins can be composed of more than one (homologous) subunit type. The main difference 
between the Ftn and Bfr proteins is the presence of b-type heme within the Bfr shell. Up to 12 
hemes are located between pairs of subunits, within a binding pocket positioned towards the 
inner protein surface. Dps and Dps-like proteins have a spherical-shape structure composed of 
12 identical subunits that form a smaller molecule (9.5 nm rather than 12 nm outer diameter) 
with a lower iron-storage capacity (500 rather than 4500 iron atoms) than the Ftn and Bfr 
proteins. 
 
1.3.1 Structure and biological role of human ferritins 
Twentyfour-mers ferritins (called maxi-ferritins) are spherical nanocaged proteins of 
~480 kDa of around 12 nm in external diameter with an internal cavity of 8 nm able to host up 
to 4500 iron atoms (Fig. 3 A and B). The extraordinary compact architecture confers to the 
protein the ability to resist at extreme pH conditions (3<pH<9), high temperatures (at least up 
  
to 80°C) and high concentrations of denaturant agents (for example 6 M urea or guanidine) 
(29). Each subunit shares a 4-helix bundle conformation characterized by four antiparallel α-
helices (I-IV) and a smaller fifth α-helix(V) tilted by 60° with respect to the bundle axis. 
Helices I and III are solvent-exposed together with a long loop that connects helices II and III, 
while II and IV are buried inside the protein. The subunit ends with helix V at the C-terminal. 
 
Figure 3. Overview on ferritin structural features. A) 24-mer polymer and the four-helix bundle 
conformation of each subunits, characterized by four antiparallel helices (I-IV) with a fifth smaller helix (V) 
placed at the C-terminal. B) The cavity of 8 nm can host up to thousands of iron atoms. C) A dimer of 
antiparallel monomers along the 2-fold symmetry axis; D) the C3 channel and E) the C4 channels. 
 
This system is highly symmetric with a 4,3,2 (octahedral) symmetry (Fig. 3 C,D,E). 
Along the twelve 2-fold symmetry axes (C2), two subunits come in contact giving rise to 
dimers that assemble to form the cage structure. Along 3-fold (C3) and 4-fold (C4) symmetry 
axes, where three or four subunits are in contact, the so-called C3 and C4 channels are placed. 
The former are mainly hydrophilic and characterized by the presence in their bottom end of 
prevalently negatively charged amino acid side chains belonging to helices I and III. The 
electrostatic gradient created by this charge distribution along the channels is the basis for 
their role as iron entry channels. The C4 channels are more hydrophobic and neutral, with a 
still unclear function and delimited by the C-terminal portion of 4 helices V (30).
In humans, as in vertebrates in general, ferritin are heteropolymers constituted by two 
highly homologous subunits: L “light” (20 kDa) and H “heavy” (22.8 kDa) subunits (31) that 
  
share 53% of sequence identity. A third subunit M “middle” (21 kDa) has been found in 
bullfrog ferritin (32). Hereafter, only human ferritins will be discussed. They are the products 
of the assembly of 24 H- and/or L-subunits, in different ratios depending on the tissues. The 
H-subunit contains a binuclear ferroxidase center that catalyzes Fe(II) oxidation. This 
antioxidant activity consumes Fe(II) and dioxygen or hydrogen peroxide (the overall and 
intermediate reactions are shown in equations 2-5) (33, 34), the reagents that produce toxic 
free radicals in the Fenton reaction. 
2Fe2+ + O2 → [Fe(III)-O-O-Fe(III)]                                                     (2)
  [Fe(III)-O-O-Fe(III)]+ H2O → H2O2 + [Fe(III)-O-Fe(III)]                   (3)  
[Fe(III)-O-Fe(III)] + (H2O)x+2 → Fe2O3(H2O)x + 4H+                           (4)
2Fe2+ + O2 + (H2O)x+3 → Fe2O3(H2O)x + 4H+ + H2O2                          (5)
 
In the first step (equation 2) two ferrous ions are oxidized and coupled to form a 
diferric-peroxo (DFP) species at the binuclear ferroxidase center. DFP is a transient 
intermediate that decays to form diferric-oxo complexes (equation 3). The ferric products that 
form at the catalytic site are precursors of the ferric hydrated biomineral that grows at the 
cavity level, while the second product H2O2 goes into solution (where catalases 
disproportionate H2O2 to harmless water and oxygen) or is recycled by the ferritin nanocage 
for further iron oxidation steps. On the contrary, the L-subunit lacks enzymatic activity; yet 
they are still able to store iron as a caged ferric biomineral, although biomineralization 
proceeds at a much slower rate. The L-subunit contains a high number of carboxyl groups 
lining the ferritin cavity, which have been proposed to serve as iron nucleation sites, although 
the identification of this site was still lacking before this thesis work. Thus, H-richer ferritins 
are preferentially expressed in tissues requiring fast iron metabolism (heart, muscle and brain) 
while L-richer ferritins are found in tissues involved in long-term storage of iron (liver and 
spleen). 
The mechanism by which iron is delivered to ferritin remains elusive. Experimental 
evidence suggests the involvement of the cytosolic iron chaperone poly(rC)-binding protein 1 
(PCBP1) (35).  
The mechanism of iron release from ferritin is also unclear. However, it is known that 
degradation of ferritin is coupled to the supply of available metabolic iron under iron-
starvation. In fact, treatment with iron chelators or expression of Fpn accelerates ferritin 
degradation (36). Changes in iron availability regulate ferritin gene expression mainly at the 
post-transcriptional level via the IRE−IRP system. Additionally, ferritin expression is 
  
regulated transcriptionally, which determines the tissue distribution of H and L chains. 
Ferritin is transcriptionally activated under oxidative stress via an upstream antioxidant 
response element (ARE) in the promoter region of the ferritin genes. In contrast, extracellular 
H2O2 inhibits ferritin mRNA translation by activating the IRE−IRP regulatory system (7). By 
sequestering redox-active iron, ferritin plays an important antioxidant role and promotes cell 
survival. Thus, overexpression of ferritin decreases the LIP, impedes the generation of ROS, 
and confers resistance to oxidative damage. Conversely, H-ferritin depletion caused by 
genetic deletion of Fth1 gene (encoding H-ferritin), results in embryonic lethality suggesting 
that its ferroxidase activity is critical (37). Mutations in L-ferritin are associated with an 
autosomal dominant neurological disorder (neuroferritinopathy), characterized by brain iron 
overload and entrapment of iron in mutant ferritin shells, which causes functional iron 
deficiency (38). 
 
1.3.2 Human ferritin distribution 
Ferritins is mainly cytosolic but it is also present in i) serum, ii) mitochondrion and iii) 
nucleus.  
 i) A glycosylated, primarily composed by L-subunits ferritin circulates in serum and 
exhibits a low iron loading capacity. Serum ferritin does not contain a signal peptide for 
secretion; some studies proposed hepatocytes, macrophages and Kupffer cells as sources able 
to secrete ferritin (39). The levels of serum ferritin increase in response to systemic iron load 
or infection (7). Ferritin secretion might function limiting iron storage after a shift from high 
to low iron concentrations, and before the activation of IRPs (31).  
ii) The mitochondrial subunit is encoded by a different mRNA, which lacks the IRE 
sequence for the iron-dependent translation control. The 242 amino acid FtMt precursor 
includes a long N-terminal targeting signal peptide (around 60 residues) which is cleaved after 
the import in the mitochondrion. It shares 79% of sequence identity with H-ferritin and 
complete conservation of the ferroxidase centers (31, 40). Differently to cytosolic ferritin, it 
has restricted tissue expression (in testis and brain) and it is found as a homopolymer. More 
importantly, FtMt has been found to incorporate iron more efficiently than H-ferritin and its 
over-expression caused iron deficiency (41). Thus, FtMt serves as a molecular sink to prevent 
accumulation of iron in mitochondria protecting the organelle against iron’s toxicity. It has 
  
been postulated that FtMt is important to protect mitochondria with high metabolic activity 
and ROS production, while it may be harmful in the less active mitochondria. Moreover, the 
unique distribution and the overexpression during oxidative stress strongly correlate it with 
numerous neurological pathologies, indicating that this protein could be involved in the 
pathogenesis of a series of diseases (42). 
iii) Several studies over the last two decades have reported also the presence of ferritin 
in nuclei, specifically H-ferritin, in developing neurons, hepatocytes, corneal epithelial cells 
and some cancer cells (43). Analysis of the H-ferritin sequence does not reveal a typical 
nuclear localization signal peptide. Analysis of H-ferritin sequence showed several putative 
O-glycosylation sites, whereas only one is present in L-ferritin. In light of the evidence 
suggesting that H-ferritin is the preferred subunit for nuclear translocation, it has been 
hypothesized the involvement of O-glycosylation in this process. Deletion and truncation 
studies are underway to evaluate the importance of several O-glycosylation sites in the 
nuclear translocation of ferritin (44). Even phosphorylation of serine residues is another 
possible modification that can mediate the nuclear translocation (45). Others propose the 
existence of a specific nuclear chaperone for ferritin delivery into the nucleus, called ferritoid 
(46). Despite of what it is known about the involvement of O-glycosylation and 
phosphorylation in nuclear translocation of ferritin, the specifics of this mechanism are still 
unclear. As concerning the ferritoid chaperone, its specificity to the corneal epithelium cells 
limits the possibility to be considered a candidate for ferritin nuclear transport. All these 
observations encouraged a new role for ferritin beyond its classical iron storage function, such 
as the regulation of iron accessibility to nuclear components, DNA protection from iron-
induced oxidative damage, and transcriptional regulation. 
 
1.4 Ferritin in biomedicine 
In recent years, the interest in nanoscale systems in biomedicine has grown up. 
Nanotechnology applied to the diagnosis and treatment of diseases, such as cancer, is a 
recently born technology that deals with the development of new delivery systems able to 
target specific sites using nanoparticles (nanocarriers). Basically a good nanocarrier increases 
the bioavailability of drugs or diagnostic probes in specific organs or cells and over a period 
of time, lowering side-effects and the amount of needed doses.  
  
Nanoparticle-based delivery systems provide a high cargo-loading capacity for 
delivery and a versatile surface that can be used to add functional groups that improve the 
aqueous solubility of desired cargoes, as well as to attach targeting ligands (47). Various types 
of chemical ligands, short peptides, and antibodies have been used as targeting moieties of 
nanoparticle-based delivery systems to enhance their efficiency of delivery. For the localized 
release of therapeutics and target-specific early diagnosis, nanocarriers have been designed to 
release encapsulated drugs and to exhibit diagnostic signals upon changes, for example, in 
pH, light, proteolysis and temperature (48-50). 
 
Figure 4. Examples of nanoparticle-based delivery systems. Reprinted from Advanced Drug Delivery 
Reviews 79–80 (2014) 107–118. Multi-valent, multi-functional and stimuli-responsive nanocarrier delivery 
systems for tumor targeting. Examples of nanocarrier delivery vehicles include (left to right) liposomes, 
polymers, micelles, engineered antibodies and nanoparticles decorated with stimuli-responsive cleavable stealth 
coatings (blue rectangles), targeting moieties (arrows), and anti-cancer drugs or imaging agents (stars and suns). 
 
Nanoparticle-based delivery systems are generally prepared from synthetic polymers, 
inorganic nanomaterials and biomaterials derived from various types of biological sources 
(Fig. 4). 
  
Among biomaterials, there are the natural protein cages that have well-defined hollow 
spherical architectures. Protein cages, including ferritins, viral capsids, and heat shock 
proteins, are precisely self-assembled from multiple copies of a limited number of subunits, 
thus resulting in highly symmetric and uniformly sized architectures.  
Ferritin is a promising nano-vehicle thanks to its intrinsic features: i) a large cavity 
that once depleted of iron can encapsulate and protect the cargo during the delivery; ii) an 
endogenous origin that prevents immunological responses; iii) a versatile surface composition 
that allows various type of functionalization to target specifically different types of cells; iv) 
the presence of receptor-mediated endocytosis mechanism by TfR1 (Transferrin receptor 1) 
for H-rich cages and SCARA5 (Scavenger receptor class A type 5) for L-rich cages that 
allows the accumulation of ferritin in particular tissues or cells. 
So far, plenty of molecules have been encapsulated inside ferritin: doxorubicin (51), 
curcumin (52), cisplatin (53) and desferrioxamine B (54) are only few examples. Approaches 
to encapsulate bulky molecules and ionic species in the interior of ferritin, once depleted of 
iron, followed the observation of Webb that apoferritin can be reversible disassociated and 
reassociated by simple adjustment of the pH to pH 2 or above pH 7, respectively (55). Once 
trapped, molecules were sequestered in the protein cage if they are too large to escape. 
Otherwise, if the species to be internalized are small enough to pass across channels, as in the 
case of metal ions, inclusion occurs by simple diffusion.  
Unfortunately, so far none of these drug-ferritin carrier system has been approved for 
clinical use owing to the complexity of designing particles that can meet all of the design 
criteria of targeted drug delivery (56). Only one protein-based nanoparticle has entered the 
clinic so far: albumin-nanoparticle-bound paclitaxel (nab-paclitaxel; Abraxane®). It is used 
for the therapy of breast cancer, non-small-cell lung cancer and pancreatic cancer. Paclitaxel 
is a cytotoxic compound isolated from the bark of the pacific yew tree (Taxus brevifolia).  
 
1.5 Aims and topics of the research 
During the three years of my PhD program, I was involved in the structural and 
functional characterization of the family of ferritins, with a special focus on those of human 
  
origin. Through the development of heterologous expression in engineered E. coli strains, 
recombinant ferritins were prepared and purified to be available for biochemical studies. 
There is an intense ongoing debate in the literature about the mechanisms by which the 
different ferritins operate. Identifying the pathway of iron from the uptake to the ferroxidase 
site of ferritin is a challenging task. When I started my PhD program, none iron-loaded 
structures in maxiferritins had been solved by X-ray crystallography, with few exceptions (see 
Section 3.1). Other metal ions were loaded inside human ferritin to mimic the behavior of the 
natural iron substrate. The identification of iron-binding sites was more difficult owing to the 
quite rapid reaction turnover. For this reason, part of my research addressed the clarification 
of the mechanisms adopted by H/H’- and L- homopolymeric ferritins for iron “handling”, 
mainly by X-ray crystallography and electronic spectroscopy with the help of site-directed 
mutagenesis to identify the role of specific amino acids. 
In the frame of PRIN 2012 “Innovative chemical tools for improved molecular 
approaches in biomedicine”, we established collaborations with research groups involved in 
the investigation of different aspect of ferritin chemistry. 
Besides its iron storage function, new roles have been proposed for this protein. The 
interaction study with HoSF (horse spleen ferritin) with a pool of lipids, was performed with 
ligand-based NMR experiments accompanied by mineralization assays through UV/visible 
measurements, aimed at verifying whether a functional coupling between mineralization and 
ferritin/lipid interactions do exist.  
Only in 2001, a mitochondrial ferritin subunit has been discovered. Thanks to a signal 
peptide, it is specifically imported in mitochondria where its maturation ends with the signal 
cleavage. The mitochondrial isoform is a crucial player in the cellular iron homeostasis. 
Since, an electron transfer (ET) between ferritin and cytochrome c has been reported, we 
decided to investigate deeply by NMR, the inter-protein ET process trying to see whether it 
occurs via specific protein-protein interactions. 
Additionally, ferritin represents a good scaffold to develop successful drug delivery 
nano-systems. The stable architecture with its endogenous origin and the ability to be 
recognized by specific cellular receptors, make ferritin a good candidate nanocarrier.  
In this view, encapsulation of the antimetastatic Ru-based drug inside human H- and 
L-ferritin has been investigated with the goal to prepare a drug-ferritin adduct with improved 
  
pharmacokinetic properties. It is well known that PEGylation of biological drugs, such as 
proteins, provides reduced renal clearance, increased stability to degradation, and a reduced 
immunogenic response. PEGylation unfortunately prevents crystallization of protein for X-ray 
analysis. A new methodology, based on solid state NMR of PEG-protein in a pelleted state, 
has been developed in order to confirm that PEGylation does not compromise the native 
structure/function of proteins. PEG-ferritin has been chosen as a case study to build this new 
approach. 
Finally, an iron-loaded ferritin was proposed as a therapeutic agent. The 
administration of iron-loaded H-Ferritin (100% H chain) and Horse Spleen Ferritin (15% H 
chains and 85% L chains) as a novel nanotherapy in cancer has been investigated in HeLa 
cells. The capacity of these proteins to deliver high amounts of iron was exploited with the 
scope to trigger mechanisms of cell damage and death associated with a persistent LIP 
increase.  
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Chapter 2 
Proteins production 
  
  
During my PhD, I mainly worked on the structural and functional characterization of 
the family of human ferritins. All the ferritin variants studied during my doctorate activities 
were produced according to home-made protocols that I developed. Tables 1 and 2 list all the 
protein samples I prepared. Table 1, reports: i) the nomenclature with the complete names and 
their abbreviations used throughout the text; ii) the eventual mutations introduced by site-
directed mutagenesis; iii) the isotopic labelling, if present; iv) the publications (or draft 
manuscripts) resulting from the production and characterization of these proteins. 
Table 1. Overview of all recombinant proteins produced and purified for the doctorate’s projects. 
 
 
1. Bernacchioni C., Ciambellotti S., Theil E.C. and Turano P. Biochim Biophys Acta. 2015. 1854(9):1118-22.  
2. Pozzi C., Di Pisa F., Bernacchioni C., Ciambellotti S., Turano P. and Mangani S. Acta Crystallogr D 2015. D71, 1909–
1920. 
3. Ravera E., Ciambellotti S., Cerofolini L., Martelli T., Kozyreva T., Bernacchioni C., Giuntini S., Fragai M., Turano P. 
and Luchinat C. Angew Chem Int Ed Engl. 2016, 55(7), 2446-9. 
4. Pozzi C., Ciambellotti S., Bernacchioni C., Di Pisa F., Mangani S. and Turano P. Chemistry at the protein-mineral 
interface in L-ferritin: assisted assembly of a functional (μ3-oxo)tris[(μ2-peroxo)] triiron cluster Submitted  
5. Interaction studies of ferritin with lipids. In preparation  
6. “Ferritinoxis”: a route to induce cancer cell death by the administration of ferritins. In preparation 
7. Spectral Investigation of the NAMI A/ferritin system. In preparation 
 
In Table 2, I added further details on the samples cited above. In particular, I 
summarized the optimal expression and purification conditions developed for each protein. 
 
 
Source Protein Mutations 
Name  
abbreviation 
Isotopic 
labelling 
Publications 
Bullfrog H’(M) ferritin H54A H54A / 1 
Human H-chain ferritin WT HuHf / 2,5,6,7 
Human H-chain ferritin WT HuHf 
15
N, 
13
C 3 
Human H-chain ferritin 
W94G, E95K, 
ins96I, 
ins93G, 
ins99FEE 
EF hand-HuHf / / 
Human L-chain ferritin WT HuLf / 4,6,7 
Human L-chain ferritin 
E60A, E61A, 
E64A 
E60AE61AE64A / 4 
Human 
Mitochondrial 
ferritin 
WT FtMt / / 
  
Table 2. Expression and purification conditions with related protein yields. 
* 65°C = after lysis of cell by sonication, the crude lysate is treated at 65°C for 15 minutes;  
AE= anionic exchange chromatography; 
SE= size exclusion chromatography; 
70% AmS= precipitation in ammonium sulfate at 70 % of saturation. 
 
Proteins listed in these tables were all produced as recombinants through the 
heterologous expression in E. coli. Essentially, after several expression trials, the best 
expression conditions in terms of E. coli competent cellular strain, temperature of incubation, 
time of induction and concentration of inductor were selected. Mutants were prepared with 
site-directed mutagenesis consisting in a PCR reaction with mutations-containing primers 
elongated by a high-fidelity DNA polymerase performed with a temperature cycler. 
QuikChange® Site-Directed Mutagenesis kit was used and the reactions performed according 
to the related protocol. 
As regarding the detailed descriptions of each expression and purification procedure, 
they are available in the “Materials and Methods” sections of corresponding publications or 
draft manuscripts in the “Annexes” section. 
Besides the in cell expression approach with E. coli bacteria, I produced HuHf also 
through the cell-free methodology with the RTS 100 E. coli HY Kit purchased from 
Eppendorf. This methods consists in protein synthesis in vitro through a coupled 
Source Name Strain 
Isotopic 
labeling 
Induction 
conditions T(°C), 
t(h), IPTG (mM) 
Purification*  
Yield 
(mg/L) 
Bullfrog H54A BL21(DE3)pLysS / 37°C, 4h, 1 mM 65°C, AE, SE 100 
Human HuHf BL21(DE3)pLysS / 37°C, 4h, 1 mM 65°C, AE, SE 110 
Human HuHf BL21(DE3)pLysS 
15
N, 
13
C 37°C, O/N, 1 mM 65°C, AE, SE 70 
Human EF hand-HuHf BL21(DE3)pLysS / 17°C, 48h, 0.2 mM 65°C, AE, SE 100 
Human HuLf BL21(DE3)pLysS / 17°C, 48h, 0.2 mM 
65°C, 70% 
AmS, AE, SE 
45 
Human E60AE61AE64A BL21(DE3)pLysS / 17°C, 48h, 0.2 mM 
65°C, 70% 
AmS, AE, SE 
35 
Human FtMt BL21(DE3)pLysS / 37°C, 4h, 1 mM 65°C, AE, SE 60 
  
transcription/translation reaction. An expression plasmid carrying the gene of interest is added 
to the reaction compartment to induce the synthesis. The DNA is first transcribed from the 
template vector into mRNA by T7 RNA polymerase, followed by translation by the ribosomal 
machinery present in the E. coli lysate. Expressed protein accumulates in the reaction 
compartment and is harvested after few hours. This kit allowed us to express functionally 
active HuHf in a 50 μl reaction from circular pET-9a plasmid carrying the H-ferritin gene 
within 6 hours. To evaluate the efficiency of protein expression, the kit provided the DNA 
template for GFP expression as a control. After the reaction, an SDS-PAGE analysis (Fig. 1) 
was performed to confirm the presence of the protein. 
 
Figure 1. SDS-PAGE analysis of cell-free HuHf expression. In parallel the results of GFP and HuHf 
expressions. Black arrows indicate the bands corresponding to the molecular weights of the two proteins (30 kDa 
GFP, 20 kDa HuHf). 
 
After the purification, the final protein yield was of 5 µg as measured by Bradford 
assay. The biomineralization capacity was verified by TEM analysis, showing the formation 
of the characteristic ferric core with a diameter size around 5nm (Fig. 2), and thus 
demonstrating that under cell-free expression the subunits self-assemble to produce the 24-
mer cage. 
   M   GFP  HuHf kDa 
 
116 
 
66.2 
 
45 
 
35 
 
25 
 
18.4 
 
14.4 
  
 
Figure 2. TEM analysis of HuHf expressed with the cell-free approach. Reconstituted HuHf with 960 Fe2+ 
per cage in Tris 20 mM pH 7.5 buffer. This buffer condition is not ideal to mineralize the protein but due to the 
very low quantity of available protein, a buffer exchange was not feasible. 
  
  
 
 
 
 
 
 
 
 
 
 
Chapter 3 
Iron pathways in ferritin nanocages 
  
  
3.1 Ferritin: a peculiar diiron catalytic site 
As already mentioned, each subunit of 24-mers ferritins is enzymatically active (H-
type) except in animal ferritins, which coproduce a catalytically inactive subunit (L-type) that 
is responsible for the nucleation of the growing biomineral (1, 2). Amphibians have a further 
catalytically active type of subunits, called H′ (or M). Homopolymeric animal ferritins 
composed by catalytically active subunits have been extensively studied as model systems for 
the ferroxidase-driven iron biomineralization reaction.  
Iron-binding sites in maxi-ferritins have been identified by conventional X-ray 
crystallography only for those from the extremophilic archaeon Pyrococcus furiosus (3), the 
prokaryote Escherichia coli (4) and the eukaryotic pennate diatom Pseudo-nitzschia (5). No 
iron-bound crystal structure was available until few years ago for ferritins from higher 
eukaryotes, but only structures with non-functional divalent cations as redox-stable alternative 
for Fe(II), namely, Zn(II) in human H ferritin and Mg(II) in H′ frog ferritin (RcMf) (6, 7). 
Those structures showed a dimetal center in the internal central position of the four-helix 
bundle with different number and nature of the metal ligands with respect to the ferroxidase 
sites in bacterial ferritins and bacterioferritins and in the catalytic sites of nonheme di-iron 
enzymes. Binuclear nonheme iron enzymes catalyze a variety of reactions using a largely 
conserved ligand set at the active site. Among the most studied there are ribonucleotide 
reductase (R2), which converts ribonucleotide into deoxyribonucleotides, and methane 
monooxygenase (MMO), which catalyzes the oxidation of methane to methanol. 
Spectroscopic and crystallographic studies of these proteins have shown that the catalytic sites 
contain two Fe(II) atoms that are weakly coupled through two bridging carboxylate ligands, 
and act as cofactors that are retained at the active site after the catalytic cycle. Dioxygen 
reacts with Fe(II) in the catalytic sites to form diferric peroxo intermediates, and in MMO and 
R2; these convert to high-valent intermediates (8). Instead, the ferritins with binuclear active 
sites accommodate two Fe(II) atoms as substrates. The substrate ions catalytically react with 
dioxygen to form diferric oxo/hydroxo products (9-11). The difficulty in detecting iron at the 
ferroxidase site in eukaryotic ferritins has been ascribed to the transient nature of this site 
where, at variance with R2 and MMO metalloenzymes, iron is not a cofactor at the catalytic 
center, but is a substrate that, after oxidation, has to be released to migrate toward the 
nanocavity to form the biomineral. 
  
3.2 The structure of the ferroxidase site and the discovery of accessory iron 
binding sites in the catalytic cavity 
Mangani et al. have developed a new crystallographic method that consists on flash-
freezing ferritin crystals at different time intervals after exposure of apoferritin crystals to a 
crystalline ferrous salt. This approach lead for the first time to the identification of the two 
iron sites (called Fe1 and Fe2) in the dinuclear ferroxidase center of a vertebrate ferritin, 
RcMf (12, 13). The iron-coordinating residues in RcMf are Glu58, which bridges the two iron 
ions Fe1 and Fe2, monodentate Glu23 and His61 as Fe1 ligands and bidentate Glu103 as Fe2 
ligand. Furthermore, multiple binding sites were identified in close proximity of the 
ferroxidase center and proposed to define the iron path from the entry ion channels to the 
oxidoreductase sites. Among these amino acid side chains, His54 was found to be differently 
populated at different times of free diffusion of Fe(II) through the ferritin crystals. The 
imidazole ring of His54 faces the inner cavity of ferritin and upon binding metal ions swings 
between two main conformations, named distal and proximal. This movement could be 
important to capture iron from the inner cavity and drag it into the 4-helix bundle channel. On 
the other hand, it could also constitute an exit strategy for the ferric products produced at the 
ferroxidase site and migrating into the inner cage cavity. To clarify the role of His54, we 
produced the H54A variant of RcMf to remove any possibility of binding metal ions at this 
position and evaluated the effect of this substitution on the ferritin activity (Annex I). In the 
H54A variant of RcMf, where the coordination imidazole ring is substituted by a non-
coordinating aliphatic side chain, we observed a speeding up of the reaction, which becomes 
more evident at high turnover numbers (Fig. 1). 
From this study, His54 appears to control the access of iron to the active site avoiding 
overloading before the catalytic reaction has been completed and the ferric-oxy/hydroxo 
products have been released towards the inner cavity. His54 could also have a defense role by 
trapping non-natural divalent cations, thus keeping them far from the dinuclear iron site, 
where they compete with iron inhibiting the reaction. Consistently, His54 has been observed 
to stably bind other transition metal cations such as Co(II) and Cu(II), trapping them out from 
the metal binding site (12, 14). His54 in RcMf corresponds to Gln58 in HuHf. Since the 
residues at the catalytic sites of RcMf and HuHf are highly conserved, the H54Q mutant of 
RcMf was studied to mimic the behavior of human ferritin. H54Q did not show any 
significant difference with wild type RcMf, neither in terms of activity nor in terms of ability 
  
to transiently bind iron in crystals, indicating that the human and amphibian proteins do not 
differ for the function of the residue at this position. 
 
Figure 1. Kinetics of products formation in WT and H54A by rapid-mixing, UV–vis spectroscopy. A) 
Reaction progress at high iron:protein ratio (20 Fe2+/subunit; 480 Fe2+/cage) monitored as (Fe3+O)x products 
(A350 nm) formation; the right panel shows an enlargement of the first 100 s. B) Formation and decay of DFP 
intermediate (A650 nm) (left) and formation of (Fe3+O)x products (A350 nm) (right)measured after the addition of 4 
Fe2+/subunit (upper panels) or 2 Fe2+/subunit (lower panels); the right panels show enlargements of the first 0.5 s 
to highlight the differences in the initial rates. Each graph shows a set of curves (mean±SEM) of a representative 
experiment of at least three. C) Table reporting the fold change over WT (set as 1) of the initial rates of 
formation of the various species. calculated from three independent analyses. *Significantly different from the 
corresponding value in wild type; P < 0.05. WT: blue curves, H54A: pink curves. 
  
The wide ferritin panorama still lacked the identification of the iron-binding sites in a 
mammalian ferritin. To fill this gap, the crystallographic determination of iron adducts of 
HuHf was obtained (Annex II) by applying the same experimental method as used for 
previous study of RcMf. 
A comparative analysis of the iron sites in RcMf and HuHf identified the same 
ferroxidase site but underlined clear differences in the pattern of ligands that defined the 
additional iron sites that precede the oxidoreductase binding sites along this path (Fig. 2). 
 
Figure 2. Superimposition of the Oxidoreductase Site (OS) of HuHf (pale blue ribbon) and RcMf (pale 
yellow ribbon). The different locations and ligands of the Fe3, Fe4 and Fe5 iron-binding sites are evident. The 
amino acids are represented as sticks coloured following the colour of the parent protein backbone. 
 
Stopped-flow kinetics assays revealed that HuHf has different levels of activity 
compared with RcMf counterpart, which were attributed to the different nature of these 
accessory binding sites. Time-lapse anomalous data allowed us to follow the progressive 
population of a series of iron binding sites. Taken together, the time-lapse pictures from the 
present study delineate a pathway for the incoming Fe(II) ions that starts with the electrostatic 
attraction and hydrogen-bonding interactions of the Fe(II) hexa-aqua ions with the Asp131 
and Glu134 residues in the threefold channel and continues with Glu140, Glu61, His57 and 
Gln58 to reach the Fe1 and Fe2 sites. The residues identified as active-site ligands in HuHf 
(i.e. Glu107, Glu62, His65 and Glu27) are all conserved in RcMf (the RcMf sequence 
  
numbering is shifted by -4 with respect to HuHf) (Fig. 2). Glu62/Glu58 acts as a bridging 
ligand between the two metals Fe1 and Fe2; the metal at Fe1 is also bound to His65/His61 
and monodentate Glu27/Glu23 while the metal at Fe2 binds bidentate Glu107/Glu103 
(HuHf/RcMf numbering, respectively).  
Accessories transient metal sites (Fe3, Fe4 and, in some cases, Fe5) have been also 
identified. There are meaningful differences in the amino-acid composition of the 
oxidoreductase site residues proposed to be additional transient iron-binding sites between the 
two ferritins. In RcMf Fe3 is bound only to His54; Fe4 is bound to Glu57 and to Asp140. A 
further binding site Fe5 is bound to Glu136. In HuHf Fe3 is bound to Gln58 and Glu61 and 
occupies a different location with respect the RcMf Fe3; Asp140 (RcMf) is substituted by the 
non-coordinating Ala144 (HuHf). The crystal structure of HuHf confirmed that Gln58 is 
involved in controlling the access of iron into the Fe1 and Fe2 iron binding sites in a dynamic 
process, as shown by the structural disorder present in this portion of the cavity. The fourth 
iron ion is bound to His57 in HuHf, which replaces Glu53 in RcMf. In HuHf there are no 
evidences of a Fe5 site. The replacement of RcMf residues Glu53, His54 and Asp140 with 
HuHf His57, Gln58 and Ala144, respectively, results in the net loss of two negative charges 
and in different ligand strengths towards iron ions in the HuHf oxidoreductase site. 
Consequently, it is not surprising that the kinetic data show different reaction rates for the 
same iron loading of the two enzymes and markedly different decay rates of the DFP 
intermediate (Fig. 3 A and B). Nevertheless, for both RcMf and HuHf, stopped-flow kinetic 
measurements reveal that the same intermediate species form during the reaction, although 
with different kinetics. In both cases, at least a stoichiometry of two Fe(II) ions per subunit is 
needed for the activity at the OS to clearly observe the formation of the DFP intermediate, its 
rapid decay (through a monoexponential process) as well as the formation of the ferric oxo 
species. As demonstrated in the structures solved in collaboration with Mangani et al., a 
distinguishing feature of the ferritin diiron substrate catalytic centers is the weaker Fe(II) 
ligands in the Fe2 site that contrast with diiron cofactor catalytic centers. Ferritin diiron 
substrate centers lack one of the two carboxylate ligands of the diiron cofactor sites of R2 and 
MMO, which, like iron in the ferritin substrate sites, react with O2 to form a DFP 
intermediate. Only four of the six iron ligands at the ferroxidase catalytic centers of ferritins 
are present in diiron enzyme cofactor centers (Fig. 4 A-C). 
  
  
 
Figure 3. A) The catalytic reaction rates in HuHf and RcMf are differently modulated by the Fe2+:subunit ratio. 
Comparison of the reaction kinetics of the formation of (upper panels) the intermediate DFP (A650 nm) and (lower 
panels) the products DFO(H) (A350 nm) after the addition of one, two, three and four Fe2+ ions per subunit to 
HuHf (left) and RcMf (right). B) The panels show the dependency on the Fe2+:subunit ratio of the initial rates of 
the formation of DFP (left), the decay of DFP (middle) and the formation of DFO(H) (right). 
 
The two divergent residues in the ferritin catalytic centers are both in the Fe2 site, 
namely, a conserved glutamine at position 141 in ferritins against glutamate in the cofactor 
sites (where it acts as a second metal bridge) and a variable residue at position 144 (HuHf 
numbering) such as alanine, aspartate or serine instead of conserved histidine in the cofactor 
sites. These differences in the ferritin catalytic centers residues are associated with a weaker 
Fe(II) binding environment and a more open structure with a single carboxylate bridge 
between the two Fe atoms in structures of ferritin diiron substrate sites compared with the 
  
stronger binding environment and more closed structures in the R2 and MMO diiron cofactor 
sites. 
 
Figure 4. Diiron catalytic sites: iron cofactor Vs iron substrate. A) View of the catalytic site of MMO with 
iron coordinating residues represented in cyan sticks (PDB id 1FYZ. B) R2 catalytic site and iron coordinating 
residues in yellow sticks (PDB id 1PFR). C) HuHf catalytic sites with iron coordinating residues represented in 
orange sticks (PDB id 4OYN). 
 
In all bacterioferritins’ structures, two metal ions have been found in the ferroxidase 
center just like in Ftns; however, the coordination environment of sites Fe1 and Fe2 is 
different. In fact two glutamate residues act as bridging ligand for the metal ions in sites Fe1 
and Fe2; while in Ftns one of the glutamate residues is replaced by a glutamine. The second 
difference is in one of the residues of site Fe2 that is highly variable in organisms as 
Pyrococcus furiosus Ftn (Glu130) or in HuHf (Ala141), while this residue in bacterioferritin 
appears to always be a histidine. The coordinating amino acid residues to the iron in the 
ferroxidase center of bacterioferritins are identical to those of the diiron catalytic site in 
dioxygen-activating enzymes. 
In summary, the X-ray data on HuHf helped defining some key structure/function 
relationships:  
1. The binuclear ferroxidase site is maintained in different vertebrates’ ferritins, 
with common ligands for Fe1 and Fe2. 
  
2.  Metal ions at the ferroxidase site are loosely bound when compared to those of 
diferric metalloenzymes. 
3. The ability to release reaction products from the ferroxidase site, as required by 
the ferroxidase reaction turnover, is realized through the presence of accessory iron binding 
sites that, shuttle new incoming irons towards the ferroxidase site. 
4. The accessory sites are provided by iron ligands that are different between H 
and M ferritins and this influence the ferroxidase reaction rates. 
 
3.3 Biomineralization 
As already stressed, the multistep biomineralization process in ferritin remains largely 
elusive. The entire process is governed by a number of specific, but weak, interactions 
between the protein shell and the iron species moving across the cage. This situation 
constituted the major problem for crystallography; the approach of solid-to-solid iron 
diffusion followed by flash freezing allowed us to detect the iron in its path through the C3-
channels and in the ferroxidase cavity.  
We also tried to obtain information of the events occurring after iron oxidation at the 
ferroxidase site that lead to the formation of the iron oxide caged biomineral. Understanding 
the chemical structure of the ferritin core may also help, for example, to elucidate the 
alteration or dysfunction of ferritin and its role in the development of degenerative diseases. 
The existing knowledge on the biomineralization process was very limited. The only 
low-resolution structural data on the biomineral precursor in ferroxidase-active ferritins 
originated from NMR. Here at CERM an original NMR approach was designed and used to 
characterize the interaction with iron of the 480 kDa RcMf ferritin cage. NMR analysis of 
ferritin represented a challenge for two main reasons: spectral crowding and signal 
broadening. Large molecular assemblies generally imply a signal crowding; the RcMf 
nanocage represents a favorable case of high molecular weight assembly because of its 
homopolymeric composition in a highly symmetric arrangement; in practice, the number of 
observed signals equals that expected for a single subunit. Nevertheless, the resolution of 1H 
experiments is compromised by signal line width broadened beyond detection. Neither 
producing perdeuterated sample (up to 90% of deuteration) is sufficient to use solution 1H 
  
detection NMR. Starting from those considerations, Turano et al. developed an original 
combination of solution and solid state experiments on the model homopolymeric RcMf 
enriched with 2H, 13C, 15N isotopes based on 13C-detection NMR (15). Briefly, the sequential 
assignment obtained for 59 over 176 residues with 13C-13C DARR at the solid state was 
transferred to solution 13C-13C NOESY, since the spectra were essentially superimposable. To 
study the reaction of ferritin with iron, they used the assigned residues as probes to locate 
paramagnetic ferric species in the protein cage following the increasing line broadening on the 
resonances of nearby residues. Increasing the equivalents of Fe(II) added in ferritin solution 
the broadening even beyond detection suggested that: 
The ferric products that form at the first catalytic turnover remain bound at the 
ferroxidase site, which therefore is always occupied in the non-apo protein. This finding is 
fully consistent with our X-ray data (see Section 3.2). The ferric products that form in 
subsequent turnovers move from the catalytic site in the middle of the four-helix bundle 
toward the short fifth helix at the C-terminus of each subunit. Moreover, magnetic 
susceptibility measurements suggested that the species emerging from the OS formation iron 
clusters of increasing nuclearity (dimers, tetramers and octamers of iron), as derived from 
bulk susceptibility measurements. 
These two findings together with the presented X-ray data confirm a push-pull 
mechanism as the driving force of the successive turnovers that is driven by the nature of the 
residues in the accessory iron binding sites (as discussed in Section 3.2). They also propose 
the formation of multimeric iron clusters as mineral precursors. The existence of such clusters 
has been also proposed by Mossbauer (16). Nevertheless, X-ray crystallography is unable to 
observe both biomineral precursor clusters and the biomineral itself. 
Here, the formation of the iron-oxo core has been monitored by transmission electron 
microscopy (TEM) using unstained iron-loaded protein. A mineral of 4.74 ± 0.26 nm for 
HuHf versus 5.37 ± 0.29 nm for RcMf was observable for iron:cage ratio of 1920:cage (Fig. 
5). 
  
 
Figure 5. Biomineral core characterization. Representative TEM micrographs of HuHf and RcMf caged 
biominerals obtained from 3.0 µM solutions of each protein mineralized with ferrous sulfate (80 Fe2+ ions per 
subunit). Bright-field TEM let us to observe the formation of an iron-oxo core without contrast dying of the 
protein, thanks to the high electron density of the ferric biomineral. The proteins, both HuHf and RcMf, were 
reconstituted with 80 Fe2+ ions per subunit. The TEM micrographs showed a quite regular shape with 
comparable size in spite of the different rates of the catalytic reactions descripted above. 
 
The same protein samples analyzed via X-ray crystallography did not show any trace 
of biomineralized iron. X-ray crystallography can only locate biomineral precursors or 
biomineralized iron if they show architectural consistency arranged over the crystal lattice; 
apparently, this is not our case. On the other, TEM only detects the final stages of the 
biomineralization, when the iron oxide particles have a measurable size.  
AADF-STEM has been used by López-Castro et al (17) to show that the fine structure 
of the biomineral is slightly different between H- and L-cages. In the latter it seems that the 
iron core grows starting from nucleation sites at the inner cage surface giving rise to a fine 
structure of the biomineral under the form of discrete electron-dense cores. Although the 
ferritin mineral core was traditionally described as ferrihydrite (18), other studies based on 
TEM, SAXS and XANES on L-ferritin, have revealed a polyphasic structure, consisting of 
ferrihydrite and other phases, including a magnetite-like phase (19, 20). The different phases 
do not coexist within a single core; magnetite appears to form along the inner surface of the 
protein shell, while hematite and ferrihydrite are more prevalent closer to the center of the 
mineral (Fig. 6). These two studies can be reconciled assuming that the magnetite (i.e. Fe3O4) 
forms in correspondence of the nucleation sites of L subunits. 
  
 
Figure 6. Composition of the ferritin mineral core. Reprinted from J. Am. Chem. Soc. 130 (2008) 8062–
8068. A schematic core-shelled ferritin iron core structure. 
 
3.4 Nucleation site of human L-ferritin 
It is generally accepted that in ferritin cages lacking (like the human L ferritin) or 
containing a low number of ferroxidase-active subunits (like the heteropolymer found in horse 
spleen), the core biomineral formation proceeds via oxidation of Fe2+ at specific, yet 
unobserved, nucleation sites that facilitate the subsequent growth of the biomineral. L-
subunits lack the ferroxidase site, whereas a number of other residues are conserved with 
respect to the H-subunit (homology 53% between human L- and H-chains; Fig. 7) (21). 
Consequently, iron incorporation in nanocages rich in L-subunits is much slower. 
Nevertheless, even homopolymeric L-ferritins are able to biomineralize iron. 
 
Figure 7. Alignment of amino acid sequences of HuHf and HuLf (FRIH_HUMAN and FRIL_HUMAN 
respectively), performed by Clustal Omega. All sequences are depleted of the initiator methionine. In light 
blue, the residues binding the metal cluster in L-ferritin. In orange, the iron-binding amino acids in the 
ferroxidase site of the catalytically active H-subunit and the corresponding amino acids in HuLf (lacking the 
ferroxidase site). In magenta, the amino acids in the conserved pore responsible of iron entry. 
 
  
With a similar X-ray method as introduced above for HuHf, we solved the crystal 
structure (1.98 Å resolution) of the iron-loaded recombinant homopolymeric L-human ferritin 
(HuLf) and detected for the first time iron bound at inner cage sites of L-subunits in the form 
of a triiron(III) triperoxo cluster (Fig. 8 A and B) (see Annex III). The protein acts as a 
template for the anchoring of the metal cluster providing glutamic acid side chains of Glu60 
(bridging Fe1 and Fe3), Glu61 (bridging Fe2 and Fe3) and Glu64 (bridging Fe1 and Fe2). 
Glu57 acts as a monodentate ligand to Fe3 and seems to shuttle towards the cluster incoming 
iron under the form of ferrous aqua ions (human H-chain aligned numbering, see Fig. 7). 
 
Figure 8. Different views of the trinuclear iron binding site in HuLf. A) Electrostatic surface representation 
of the trinuclear cluster binding site. Iron ions and water molecules are represented as cyan and red spheres, 
respectively. Peroxide molecules are shown as red ball-and-stick models. B) Structure of the oxo-centered 
trinuclear iron cluster. Coordinating glutamates are highlighted as sticks. Iron ions, water and peroxide 
molecules are represented as in “A”. Coordination bonds to iron ions are shown as dashed red lines; coordination 
distances (Å) are also displayed. Two different orientations are proposed in panels A and B to better appreciate 
the structural features of the protein site and metal cluster. 
 
A similar metallocluster was observed in the lower resolution (2.22 Å) structure of 
horse spleen ferritin, a natural heteropolymer where more than 85% of subunits are L-type, 
suggesting that it represents a common feature of mammalian ferritins. 
More in details, three iron ions are coordinated to the above carboxylate side chains, 
generating a 3-oxo centered trinuclear cluster. The carboxylate groups of Glu60, Glu61 and 
Glu64 symmetrically bridge the three Fe couples on the same side of the cluster. On the 
  
opposite side, each pair of iron ions results connected by an elongated electron density 
compatible with a diatomic molecule. The observed densities have been interpreted as due to 
three peroxide anions generating a second series of bridges. A likely explanation of the 
described arrangement of the iron ions in this site, is that we have detected a (3-oxo)tris[(2-
peroxo)(2-glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) anion. The comparison 
with the iron-free HuLf structure reveals that the formation of the oxo-centered trinuclear iron 
cluster occurs without modification of the protein fold, but with a rearrangement of the 
glutamate side chains involved in iron coordination. The cluster structure is unprecedented in 
biological systems although it shows striking structural similarities to a synthetic hexanuclear 
iron cluster (Fig. 9), proposed about 20 years ago as a possible model of ferritin biomineral 
(22).  
 
Figure 9. Synthetic hexanuclear iron cluster proposed as a possible model for ferritin biomineral. 
Reprinted from J. Am. Chem. Soc. 1997, 119, 1037-1042. 
 
The structural similarity between the two cluster supports: 
i) our interpretation of the elongated electron densities as due to peroxide species, 
which could form as a consequence of iron oxidation at the nucleation site;  
ii) the presence of iron ions in the ferric state resulting in an overall trinegative charge 
of the assembly in HuLf, which can provide the driving force to attract new iron(II) ions to 
promote oxidation and biomineralization, as exemplified by the observed fourth iron ion 
approaching the cluster via Glu57.  
To corroborate X-ray data and establish a functional significance for the observed 
patch of carboxylate side chains and the resulting cluster, site-directed mutagenesis was 
  
applied to produce E60AE61AE64A mutant in order to prevent iron coordination at these 
sites. The comparison of the iron oxidation kinetics in the wild type and E60AE61AE64A 
variant of HuLf nanocage showed a significantly lower reaction rate for the mutant especially 
at low iron content (Fig. 10). For comparison purposes, we report also the oxidation kinetic of 
Fe(II) in the absence of ferritin to show the fundamental role of the protein cage, that 
maintains soluble the Fe(III) species that otherwise precipitate at physiological pH. The latter 
process is shown by the blue curves, where the absorbance at 350 nm falls down with time 
due to precipitation of the ferric oxo species (Fig. 10 A-D).  
 
Figure 10. Kinetic measurements in WT and E60AE61AE64A HuLf variant. Kinetics of oxo-ferric species 
formation followed spectrophotometrically as the change in absorbance at 350 nm over 16 hours (960’). 
Different concentrations of Fe2+ were incubated, at room temperature, in 200 mM MOPS 200 mM NaCl pH 7 
buffer with 25 µM protein subunits of WT HuLf (red curves) and triple mutant E60AE61AE64A (green curves) 
or without protein (blank, blue curves). Addition of: A) 3 Fe2+ ions per subunit; B) 6 Fe2+ ions per subunit; C) 9 
Fe2+ ions per subunit; D) 18 Fe2+ ions per subunit. 
 
We therefore proposed that the observed metal cluster corresponds to the suggested 
(23, 24) nucleation site of animal L-ferritins.  
As a perspective work, we plan to investigate deeply the proposed role of Glu57 in 
iron shuttling; a further mutant has been designed, called E57AE60AE61AE64A. The tetra-
mutant will be subjected to the same functional analysis as the wild type and its triple-mutant. 
 
  
3.5 Highlights 
In summary, our studies on H nanocages have led to the definition of the ferroxidase 
diiron centers where Fe1 and Fe2 sites contain iron ions that are more loosely bound that in 
dicarboxylate diferric sites due to the lower number of protein ligands and where the 
flexibility of the amino acid ligands allows to modulate the distance between the two metal 
ions as a function of their oxidation state. In H ferritin, we might have been able to trap 
dioxygen bound to the diferrous center.  
In L cages, we have identified a novel trinuclear iron cluster, which is unprecedented 
in bioinorganic chemistry and might represent the nucleation site in ferroxidase-inactive 
subunits.  
Beside shedding light on the mechanism of ferritin reactions, these results contribute 
to expand the ensemble of metal cofactors in metalloproteins. 
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Chapter 4 
Ferritin-based nanocarriers 
  
  
Ferritin and its structural and biochemical features have been widely exploited in 
bionanotechnology applications ranging from the production of metal nanoparticles to 
templated production of semi-conductors as well as scaffold nanocage for vaccine design and 
drug delivery. In this thesis section, I will describe experiments related to the use of human 
ferritins as a drug delivery system, especially for cancer therapy. The ability of ferritin cages 
to disassemble and reassemble under pH control has allowed for the loading of a number of 
potentially therapeutic compounds (see Section 1.4). The combination of modifiable interior 
and exterior surfaces, and the presence of hydrophobic and hydrophilic channels across the 
cage, allows the inclusion or attachment (chemical cross-linking) of both water-insoluble and 
soluble drugs for delivery. 
 
4.1 Nanocarriers in cancer therapy 
Nanotechnology offers opportunities in disease prevention, diagnosis and therapy (1). 
Among the various approaches for biomedical applications, nanocarriers offer some unique 
advantages as delivery, sensing and imaging agents (2). Many drugs used for 
pharmacotherapy, while have a beneficial action, can also exhibit side effects that may limit 
their clinical application. For example, cytotoxic compounds used in cancer therapy can kill 
target cells, but also normal cells in the body. In order to achieve better therapeutic 
application, nanocarriers are considered for target-specific delivery of drugs and gene to 
various sites in the body in order to improve the therapeutic efficacy, while minimizing 
undesirable side effects. Loading of drugs into nanocarriers can increase their in vivo stability, 
extend compound's blood circulation time and allow for controlled drug release and 
accumulation preferably at the tumor site. This phenomenon is known as enhanced 
permeability and retention effect (EPR). Summarizing there are five advantages to use 
nanocarriers to vehicle drugs instead of administering drugs alone. First, nanoparticles may 
help to overcome problems of solubility and chemical stability of anti-cancer drugs. Second, 
they can protect anti-cancer compounds from biodegradation or excretion and thus influence 
the pharmacokinetic profile of a compound. Third, nanosystems can help to improve 
distribution and targeting of anti-tumor therapy. Distribution of anti-cancer drugs is defined 
by their physico-chemical properties and is limited by drug penetration into tumor tissue. 
Both passive and active targeting strategies are used to redirect anti-cancer drugs (see below). 
Fourth, nanocarriers can be designed to release their payload upon a trigger resulting in 
  
stimuli-sensitive nanomedicine therapeutics. Finally, targeted nanomedicine therapeutics may 
decrease resistance of tumors against anti-cancer drugs. Generally, specific uptake reduces the 
probability for unspecific efflux pump-driven elimination. 
As mentioned above, there are essentially two kind of specific delivery: passive and 
active targeted delivery (Fig. 1). 
The majority of tumour-targeted nanomedicines systems utilize the so-called ‘passive 
targeting’ concept. By designing the systems such that a long circulation time is achieved, 
significant accumulation in tumours is obtained, especially in those tumour areas with active 
angiogenesis. Passive targeting refers to the extravasation of the nanomedicine-associated 
drug into the interstitial fluid at the tumour site, exploiting the locally increased vascular 
permeability. In addition, solid tumours tend to lack functional lymphatics, and extravasated 
(nano)materials are retained within the tumour site for prolonged periods of time. The 
exploitation of this so-called ‘enhanced permeability and retention’ (EPR) effect is currently 
the most important strategy for improving the delivery of low-molecular-weight 
(chemo)therapeutic agents to tumours (3-5). 
The active-targeting concept utilizes the specific binding affinities of targeting ligands 
that are bound to the drug or drug-carrier systems used to selectively target site receptor 
structures. This approach also takes advantage of the EPR effect for accumulation of the drug-
carrier system into the interstitial fluid of the tumor. Some delivery systems has been 
developed in order to bind to specific surface receptors that are endocytosis prone (5, 6), such 
as the folate receptor that is upregulated and numerous in many cancers, while has low access 
in normal cells (7), the transferrin receptor that internalizes continuously even if the ligand is 
not bound (8) and the epidermal growth factor receptor (EGRF). 
  
 
Figure 1. Overview of the clinically most relevant drug targeting strategies. Reprinted from British 
Journal of Cancer (2008) 99, 392–397. A) Upon the intravenous injection of a low-molecular-weight 
(chemo)therapeutic agent, which is often rapidly cleared from blood, only low levels of the drug accumulate in 
tumours and in tumour cells, whereas their localization to certain healthy organs and tissues can be relatively 
high. B) Upon the implementation of a passively targeted drug delivery system, by virtue of the enhanced 
permeability and retention (EPR) effect, the accumulation of the active agent in tumours and in tumour cells can 
be increased substantially. C) Active drug targeting to internalization-prone cell surface receptors 
(over)expressed by cancer cells generally intends to improve the cellular uptake of the nanomedicine systems, 
and can be particularly useful for the intracellular delivery of macromolecular drugs, such as DNA, siRNA and 
proteins. D) Active drug targeting to receptors (over)expressed by angiogenic endothelial cells aims to reduce 
blood supply to tumours, thereby depriving tumour cells from oxygen and nutrients. E) Stimuli-sensitive 
nanomedicines can be activated (i.e., induced to release their contents) by externally applied physical triggers, 
such as hyperthermia, ultrasound, magnetic fields and light. 
 
In addition to targeted delivery, a number of studies, especially in cancer therapy, have 
shown that stimuli-responsive nanocarriers can provide significant advantages. The use of 
stimuli-responsive nanocarriers offers an interesting opportunity for drug delivery where the 
delivery system becomes an active participant, rather than passive vehicle, in the optimization 
of therapy. The benefit of stimuli responsive nanocarriers is especially important when the 
stimuli are unique to disease pathology, allowing the nanocarrier to respond specifically to the 
pathological “triggers”. Select examples of biological stimuli that can be exploited for 
targeted drug delivery include pH, temperature and redox microenvironment (2). Besides the 
classical structural ferritin characterization, my PhD activities regarded also the development 
of different ferritin nanocarriers of different types, as described in Sections 4.2-4.4/5). This 
part of my research project has been supported by PRIN 2012 namely “Innovative chemical 
tools for improved molecular approaches in biomedicine”. 
  
In Section 4.2, functionalized ferritin at the surface are introduced describing the 
possible advantages of PEGylation in nanomedicine especially for drug-delivery. In Sections 
4.4 and 4.5, ferritins loaded with two different metal-based antitumor molecules are proposed. 
Due to the fact that ferritin cages are recognized by specific cellular receptors (see Section 
1.4), in principle, they can be all exploited for active targeting any time those receptors are 
overexpressed at the target site allowing specific receptor-mediated endocytosis. 
Nevertheless, in case of ferritins, SCARA 5 and TfR1 for L and H cages respectively are 
expressed in several types of cells, making more difficult to obtain a localized internalization. 
To increase this probability and to prevent accumulation in undesired sites, a further 
functionalization of ferritin surface can be applied, as in case of PEGylated HuHf. This 
particular modification causes the protein to become stealth even for TfRs increasing its life-
time circulation and the possibility to reach in a passive targeting way the tumour site 
exploiting the EPR effect. 
 
 4.2 PEGylated ferritin 
Biological drugs (biologics) are the fastest-growing category of approved therapeutics. 
Most biologics are proteins that are the closest proxy of a “natural” help against disease. 
Unfortunately, proteins have poor pharmacokinetic and safety profiles. Protein solubility, 
route of administration, distribution and stability are all factors that can hinder the successful 
application of a protein therapy (9). Proteins are large molecules with both hydrophilic and 
hydrophobic properties that can make entry into cells and other compartments of the body 
difficult. The half-life of a therapeutic protein can be drastically affected by proteases, 
protein-modifying chemicals or other clearance mechanisms. Another important challenge is 
that the body may cause an immune response against the therapeutic protein (10).  
In order for a protein or a protein-based nanocarrier to achieve the desired benefits, it 
must be present in the bloodstream long enough to reach or recognize their target site of 
action, as described in five points in Section 4.1. Opsonization and phagocytosis are two 
common mechanisms considered the major obstacles to the realization of these goals. The 
macrophages of the mononuclear phagocytic system (MPS), also known as the 
reticuloendothelial system (RES), have the ability to remove unprotected nanoparticles from 
the bloodstream within seconds of intravenous administration, rendering them ineffective as 
site-specific drug delivery devices (11). These macrophages, which are typically Kupffer 
  
cells, or macrophages of the liver, cannot directly identify the nanoparticles themselves, but 
rather recognize specific opsonin proteins bound to the surface of the particles (12). Several 
methods of camouflaging or masking nanoparticles have been developed, which allow them 
to temporarily bypass recognition by the MPS and increase their blood circulation half-life 
(11, 13, 14). Many of these systems make use of surface treatments that interfere with the 
binding of opsonin proteins to the particle surface as a means of imparting stealth 
characteristics to nanoparticles. Such limitations can be addressed, for example, through the 
production of PEGylated versions of therapeutic proteins. PEG coating provides reduced renal 
clearance, increased solubility and stability to degradation and a reduced immunogenic 
response, improving the pharmacokinetic and pharmacodynamics properties of polypeptide 
drugs (15). For protein nanocarriers, PEGylation is even more important. PEG coating makes 
them larger so they are cleared more slowly and their life-times become longer protecting 
them from the activity of the reticuloendothelial system. The purpose of these PEG chains is 
to create a barrier layer to block the adhesion of opsonins present in the blood serum, so that 
the particles can remain invisible to phagocytic cells. PEGylated HuHf has been proposed by 
Tsukamoto et al. (16) aiming at masking the protein from its physiological receptors 
(Transferrin receptor 1) and at decreasing the uptake by the reticuloendothelial and 
mononuclear phagocytic systems thus resulting in an increased blood circulation time (17). 
Obviously, preservation of the three dimensional structure and activity of the PEGylated 
protein is mandatory for human use. While activity can be easily measured in vitro, structural 
characterization at atomic resolution of PEGylated proteins and protein-based nanocarriers is 
almost impossible. PEG coating prevents crystallization for X-ray crystallography and causes 
an increase in protein mass that makes in unsuitable for solution NMR studies. Conversely, 
solid-state NMR (ssNMR) is a valid alternative to study proteins because it does not suffer 
from molecular-weight limitations and high resolution spectra can be obtained for multimeric 
assemblies, but the best resolution is usually obtained for crystalline materials, which are 
exactly what cannot be achieved for PEGylated proteins.  
In 2011, the so-called SedNMR (solid state NMR on sedimented sample) was 
implemented for the first time on ferritin sample (18). Relatively large proteins in solution, 
spun in NMR rotors for solid samples at typical ultracentrifugation speeds, sediment at the 
rotor wall. The sedimented proteins provide high-quality solid-state-like NMR spectra 
suitable for structural investigation. Sedimentation is a transient phase since the proteins fully 
revert to the native solution state when spinning is stopped. NMR of transiently sedimented 
  
molecules under fast magic angle spinning has the advantage of overcoming protein size 
limitations of solution NMR without the need of sample crystallization/precipitation required 
by solid-state NMR. Inspired by SedNMR, we showed here that highly resolved ssNMR 
spectra can be obtained also for PEGylated proteins in the pelleted state (Annex IV). It was 
shown that the simple comparison of a standard two-dimensional ssNMR spectrum of the 
pelleted PEGylated protein with that of the crystalline state of the native protein can reveal 
whether the three-dimensional structure is maintained in the PEGylated form. The 
applicability of the approach was demonstrated in the PEGylated forms of three proteins of 
increasing size: human CuII-ZnII-Superoxide Dismutase (SOD), E.coli L-asparaginase II 
(ANSII) and human H ferritin (HuHf). In particular, I worked directly on the characterization 
of HuHf that has been chosen as a case study being a huge molecular assembly and due to its 
relevance in the family of protein-based nanocarrier. SDS-PAGE analysis showed that each 
monomer was functionalized with 3–4 PEG chains, thereby increasing the size of the tetramer 
from 504 kDa up to 600–650 kDa. On the other hand, stopped-flow kinetic measurements 
confirmed the maintained biological activity upon PEG-functionalization. PEGylated HuHf 
was still able to sediment easily and the SedNMR spectra of the pelleted PEGylated protein 
and the crystalline native protein were largely superimposable (Fig. 2), thus demonstrating for 
the first time a negligible effect of PEG coating on ferritin structure and assembly. 
 
Figure 2. Comparison of native or PEGylated ferritin spectra. 2D 13C-13C correlation spectra of A) native 
crystalline (red spectrum), B) native pelleted (black spectrum) and C) PEGylated (blue spectrum) HuHf. 
  
  
4.3 Design of a responsive HuHf mutant 
In order to make the targeting more specific, the design and production of a HuHf 
variant able to load/release molecules under specific conditions, were performed. We 
produced an engineered HuHf with EF-hand domains (called EF hand-HuHf). This domain is 
typically present in calmodulin and consists of two alpha helices, E and F, linked by a short 
loop region of 12 amino acids that bind calcium ions. When the calcium ion binds, helix F 
moves from a closed to an opened conformation. Our working hypothesis was to insert a 
motif able to change conformation in presence of calcium and make the cage more prone to 
uptake/release molecules. According to the consensus sequence of the 12 amino acids-loop 
region, we designed the opportune mutations or insertions on the long loop connecting helices 
II and III in HuHf (seven mutations: insertion G93, W94G, E95K, insertion I96, insertions 
FEE99) that according to our structural analysis might affect the viability of the pores at the 
C4 axes. This HuHf variant resulted in seven mutations: We tried to verify our hypothesis 
applying X-ray crystallography to determine whether in the presence and in the absence of 
Ca(II) ions, some conformational changes could be induced changing the structure of the C4 
pores. Until now, our crystallization trails failed. Attempts to crystallize EF hand-HuHf in 
conditions similar to those of WT protein were unsuccessful. This was not completely 
unexpected as suggested from previous X-ray studies on ferritins mutated in the solvent-
exposed loop region (19). Even modifying only one residue, as in the case of D80K in M 
ferritin from bullfrog (19), it could compromise solubility and stability protein properties. 
Furthermore, modifications of the surface charge distribution not only affect the physical 
properties of the protein but may also contribute to differences in crystal packing. NMR could 
represent an alternative approach for solving the structure of our mutant. Nevertheless, the 
residue assignment of human ferritins is not available yet. The main limitation in approaching 
NMR ferritin-structure determination is the elevated cost of isotopic labeling for protein 
preparation that is needed to afford specific residue assignment in a so huge system.  
 
4.4 Ru-based metal drug loaded into human ferritins 
Due to its natural tendency to bind metal ions, ferritin readily encapsulates metal 
containing drugs (for example cisplatin and the iron chelator desferrioxamine B). With this in 
mind, we chose a Ru-based drug called NAMI A, that corresponds to the acronym of Novel 
  
anticancer metastasis inhibitor of class A (20). Why NAMI A? Ruthenium drugs have been 
developed to overcome the limitations of the platinum containing drugs. Even if cisplatin and 
its analogues carboplatin and oxaliplatin have been approved by FDA and became the most 
widely used compounds for cancer therapy (at least as part of patients’ treatment), they are 
not effective against many common type of cancer, drug resistance is frequent and they cause 
several side effects (21). Ru-compounds tend to cause fewer and less severe side effects 
compared to platinum drugs (22). NAMI A is active against secondary tumour cells (the 
metastases which form after cells from the primary tumour and move to a different organ, e.g. 
via the bloodstream). Currently there are very few treatment options for metastatic cancers. 
To date, NAMI A is being evaluated in phase II clinical trials (23). In spite of flexibility in 
ruthenium oxidation states, ruthenium complexes display relatively slow ligand exchange 
rates in water, with kinetics on the timescale of cellular reproduction (mitosis), meaning that 
if a ruthenium ion does bind to something in the cell, it is likely to remain bound for the 
remainder of the cell’s lifetime. Furthermore, ruthenium tends to form octahedral complexes, 
which gives the chemist two more ligands to exploit compared with Pt(II) complexes, which 
adopt a square planar geometry. Ruthenium can also form strong chemical bonds with a range 
of different elements of varying chemical ‘hardness’ and electronegativity, meaning that 
ruthenium can bind to a range of biomolecules, not just DNA. The chemical structure of 
NAMI A consists of a hexacoordinated Ru(III) center linked to four chlorides as equatorial 
ligands and to DMSO and imidazole as axial ligands (Fig. 3). 
 
Figure 3. Chemical structure of NAMI A. 
 
However, a major limitation in ruthenium drug discovery is the unknown mode of 
action of its compounds. Very recent findings suggest that NAMI A is not internalized easily 
  
into cells and consequently, it acts at an extracellular level. Likely, interactions with actin-
type proteins on the cell surface or with collagens of the extracellular matrix occur, which 
lead to reduced mobility of invasive cancer cells.  
The fact that iron and ruthenium are in the same chemical group (Group 8) has led to 
hypothesize that it is capable of taking iron’s place in some proteins, most notably in the 
chaperone and uptake protein transferrin (24). Owing to the analogy of ruthenium to iron, we 
wondered whether NAMI A might interact also with ferritin (Annex V). We therefore 
analyzed the direct reaction of NAMI A with human homopolymeric H- and L-ferritins. 
When NAMI A is added in buffer solution the classical spectral evolution is noticed where the 
band centered at 390 nm is assigned, this bands disappears progressively being replaced by an 
absorption at 345 nm. This spectral change have been assigned to the replacement of the first 
chloride ligand by a water molecule (20). Replacement of a second chloride by water was also 
described, again accompanied by characteristic spectral changes, namely the disappearance of 
the absorption at 340 nm. Further aquation and/or oligomerization process take place 
afterward. Thanks to these characteristic time dependent changes of spectral profile in the 
UV-visible region, we could detect differences in the NAMI A hydrolysis process attributable 
to the presence of HuHf and HuLf. The rate of hydrolysis appears to be much faster with both 
proteins (Fig. 4). 
 
Figure 4. Hydrolysis of NAMI A in presence of HuHf (left) and HuLf (right). Molar ratio protein: NAMI A 
1:2 (protein 5* 10-5 M in subunits). 
 
  
The formation of a Ru-adduct with HuHf was established by UV-visible and circular 
dichroism (CD) spectroscopy. The appearance of a characteristic band around 500 nm in 
HuHf was observed, which is responsible of the observed pink color of this adduct.  
In addition, kinetics measurements showed inhibition of the ferroxidase activity of 
HuHf. Nevertheless, the observed inhibition of the ferroxidase activity in HuHf could be 
explained by Ru-binding at the ferroxidase center. The different spectroscopic properties of 
HuHf and HuLf suggesting Ru binding at different sites. It is well known the preference of 
Ru(III) NAMI A for histidine residues in other proteins, such as albumin and transferrin. A 
possible high-affinity binding site for ruthenium in HuHf could be provided by the 4-
symmetry related His173 imidazole rings in C4 channels. In HuLf, the corresponding site is 
absent because His173 is substituted by Leu173. These hypotheses need a structural 
confirmation. Unfortunately, until now our crystallization trials failed preventing the exact 
localization of ruthenium binding site(s) inside the two ferritin cages. 
 
4.5 Fe-loaded ferritins as a nanotherapeutic against cancer 
Although iron is an essential nutrient for cellular growth and homeostasis, its redox 
active form, namely free Fe2+, may become a threat for cells due to its ability to trigger 
reactive oxygen species based on the Fenton reaction, whereas the Fe3+ form is highly 
insoluble at physiological pH (25). Therefore, in order to prevent or attenuate oxidative 
damage and cell death and to provide a bioavailable Fe3+ form iron is cautiously transported 
and stored, in a non-redox active form, by transferrin and ferritin, respectively.  
In collaboration with the group of Prof. Aime in Turin, we investigated the 
administration of iron-loaded H-Ferritin (100% H chain) and Horse Spleen Ferritin (15% H 
chains and 85% L chains) (26) as a novel nanotherapy in cancer, by exploiting the capacity of 
these proteins to deliver high amounts of iron with the scope to trigger mechanisms of cell 
damage and death associated with a persistent LIP (labile iron pool) increase (Annex VI).  
To this purpose, HeLa cells were treated for 24 hours with different concentrations of 
human recombinant H-Ferritin or horse spleen Ferritin, in the L-rich natural heteropolymeric 
composition (Fig. 5).  
  
 
Figure 5. On the left, dose-dependent L- and H- Ferritin effects on HeLa cell viability measured by MTT assay. 
On the right, dose-dependent H-Ferritin50 and H-Ferritin350 effects on HeLa cell viability measured by MTT 
assay. In all experiments, cell viability was expressed as percentage relative to untreated cells. Data are presented 
as mean and SD of at least three independent experiments. 
 
Each ferritin is up-taken trough specific receptor mediated endocytosis. Internalized 
iron was significantly different on the basis of the different receptor uptake capacity. TfR-1 
mediated cellular uptake of human H-ferritin loaded with 50 or 350 iron ions, without any 
additional modifications, results in a high cytotoxicity on HeLa cells (Fig. 5). At variance, L-
ferritin, which is internalized through the SCARA5 receptor is significantly less toxic, even 
when loaded with 1000 iron ions. Confocal microscopy studies revealed that L-ferritin co-
localized with the lysosomal compartment, whereas only a small fraction of rhodamine 
labeled H-Ferritin undergoes to lysosomal degradation. Exploiting the endosomal-lysosomal 
compartment iron overload, Fe-loaded HuHf was found to be more toxic than the Fe-loaded 
L-ferritin. We were able to attribute that toxicity to the mobile iron pool associated to the 
presence of the ferroxidase center. This mobile iron pool is readily released during the 
endosomal-mediated H-ferritin internalization and is more prone to redox reactions with 
consequent ROS production causing toxicity. The iron-loaded HuHf was therefore proposed 
as a novel nanotherapeutic agent, named Ferritinoxis, able to put under stress critical 
pathways for cell survival.  
 
4.6 Highlights 
The results of this chapter can be summarized in three points: 
  
i) PEGylation of human H Ferritin has been performed and solid state NMR of 
sedimented PEG-protein has been proposed as a feasible method to evaluate the 3D structure 
maintenance upon functionalization. This approach represents a valid alternative for those 
systems that are too big for solution NMR or prevent crystallization like PEGylation.  
ii) Ferritin has been proposed as a drug delivery system for Ru-based drug, NAMI A. 
Since the antimetastatic properties of this molecule that put it in clinical phase II trials, we 
investigated its interaction with human ferritins. So far, we established that both HuHf and 
HuLf influence the NAMI A hydrolysis. Evidences of a NAMI A-ferritin adduct has been 
detected spectrophotometrically for HuHf. Nevertheless, we did not obtain crystals that 
diffract properly to show whether Ru-species are bound to ferritin. Other crystallization trials 
have been planned together with mass spectrometry approaches. The advantages to use 
ferritin as a container for NAMI A could be the ability to protect this molecule upon its 
release in the target area maximizing its efficacy and increasing its life-time before clearance.  
iii) We address the issue of stimulated cell death by supplementing the tumour cells 
with large iron loadings, in order to stress critical pathways for cell survival, through the 
administration of Fe-loaded ferritins. The administration of H-Ferritin or Horse Spleen 
Ferritin is proposed as a novel nanotherapy of cancer, named Ferritinoxis. 
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Chapter 5 
New redox activity for ferritin 
  
  
5.1 Ferritin as new lipid-binding protein. 
Fatty acids are involved in several physiological functions, including structural, 
signaling, and metabolic functions, and are therefore tightly regulated and transported via a 
series of both intracellular and extracellular fatty acid-binding proteins. These proteins also 
maintain free fatty acid concentration in the low micromolar range to reduce their toxicity and 
potential oxidative injury (1). Under conditions of tissue stress, such as ischemia and 
reperfusion, free fatty acids released by the action of calcium-activated phospholipases serve 
primarily signaling and substrate roles (2). Because of the unsaturation of many released fatty 
acids (e.g., oleic and arachidonic acids), they can be oxidized and facilitate peroxidation chain 
reactions. Hydrogen peroxide, which in the presence of free iron participate in the harmful 
Fenton chemistry, is one of the intermediates formed in these reactions. The radical products 
maintain the peroxidation cycle, further damaging lipids, proteins, nucleic acids, and 
ultimately activating apoptosis or cell death (3). A functional coupling between iron and fatty 
acid metabolism has been previously demonstrated (4). It has been suggested that ferritin 
plays a role in lipid metabolism. For example, application of free fatty acids to cells in culture 
causes an upregulation in ferritin expression, interpreted as part of a generalized stress 
response (5). Additionally, downregulation of L-ferritin in melanoma cell’s culture produced 
an enhanced response to oxidative stress and the resulting apoptosis, whereas the most 
resistant cells displayed the highest ferritin expression (6). The ability of lipids to directly 
bind to ferritin has been demonstrated through ITC and crystallography (4, 7); horse spleen 
ferritin has revealed that the pockets at the 2-fold intersubunit contacts are suitable to bind 
organic molecules such as arachidonic acid and sodium dodecyl sulfate. The crystal structure 
of the horse spleen ferritin (HoSf)-arachidonate complex has been solved (4), revealing that 
the bound ligand has a U-shaped conformation and the long tail of arachidonate 
accommodates close to the nucleation sites (Fig. 1). Interestingly, arachidonate bound to 
ferritin caused faster biomineralization accelerating iron uptake. 
  
 
Figure 1. Location of the arachidonate binding site in HoSf, a sight from the inner cage. Arachidonic acid 
in U-shaped conformation represented as yellow sticks at the interface of two subunits (cyan and blue cartoons). 
One arachidonate molecule was observed at each of the 12 intersubunit 2-fold pockets, very close to the 
carboxylate groups of nucleation sites (represented in sticks). (PDB id 4DE6). 
 
In collaboration with the group of Prof. Molinari (CNR, Milano and University of 
Verona), the interaction of apo HoSf with a pool of lipids has been investigated through NMR 
ligand-based experiments (Annex VII). DOSY and STD NMR experiments established a 
stronger interaction of ferritin with unsaturated fatty acids (arachidonate, ARA and oleate, 
OLA) with respect to saturated fatty acids (lauric acid, LAU), detergents (sodium dodecyl 
sulfate, SDS) and bile acids (chenodeoxycholic acid, CDA). These studies have been 
accompanied by mineralization assays through UV/visible spectroscopy aimed at verifying 
the existence of a functional role between ferritin/lipid binding and iron mineralization (Fig. 
2). 
  
 
Figure 2. Mineralization kinetics of ferritin in presence of different lipids. Kinetics of mineralization for 
HoSf alone (gray trace), incubated with 700 µM of OLA (blue), ARA (red), LAU (gold) and SDS (purple). The 
kinetics of biomineral formation was followed as the change of A350 nm after addition of 480 Fe2+ per cage. 
 
Oleate caused the highest increase in the initial rate of iron oxidation and the highest 
formation of ferric species as shown in the kinetic analysis following the peculiar absorbance 
at 350 nm over the time. 
Previous X-ray data showed that SDS binds HoSf at the two-fold intersubunit pocket 
in the same site as ARA even though with a weaker affinity (KD of 24±9 µM for OLA against 
60 µM for ARA) (4, 7) In order to confirm that OLA occupies the same site at the dimer 
interface in ferritin, NMR competition binding experiments were performed. OLA was added 
to HoSf:SDS complex to obtain a sample with HoSf:SDS:OLA ratio of 1:1:1. OLA could 
displace SDS and free SDS resonances emerged in the spectrum. 
The lipid binding pocket is located at a largely hydrophobic interface between two 
subunits. Open questions remain about the mechanism through which the lipidic molecules 
can reach this pocket and about the factors that induce a faster biomineralization. As far as the 
latter aspect is concerned, two main hypotheses can be formulated: 
i) the presence of OLA opens a new iron entry channel; 
ii) the terminal carboxylate of the lipid, which clearly points towards the inner cavity 
surface in the ARA X-ray structure, facilitates the reaction at the nucleation site (see Section 
3.4).  
It is not clear how the fatty acid gains access to the intersubunit pocket. Anyway, it 
seems that ferritin could protect unsaturated fatty acids from oxidation, limiting their 
  
participation in lipid peroxidation chain reaction, thus reducing their inflammatory effects. 
We tried to analyze the structure of ferritins from different families and we found that 
bacterioferritin hosts a heme group at the interface between two subunits along the 2-fold 
symmetry axes. The b-type heme group is placed exactly in the same hydrophobic 2-fold 
pocket with a similar orientation like ARA in the horse spleen ferritin cited above. The two 
carboxylate groups of propionates on heme b faces on the inner cavity in analogy with the 
carboxylic head of the lipid. In bacteria ferritin-bound heme seems to facilitate iron core 
mineralization via an electron transfer mechanism whose details remain unknown (8). Besides 
this structural analogy, it could be interesting to verify any functional similarity involving an 
electron transfer among lipids and the mineral iron core. 
To further exploit the role of the lipid on the ferritin reaction mechanism we have 
initiate an analogous characterization on the H-ferritin. Preliminary data have shown that 
OLA can still bind with high affinity but does not influence the reaction at the ferroxidase 
site. We still need to check whether it has any role on the overall biomineralization process.  
 
5.2 NMR study of the interaction between mitochondrial ferritin and 
cytochrome c 
Cytochrome c (cyt c) is small soluble heme protein loosely associated with the inner 
membrane of the mitochondrion. It plays as an electron carrier protein that is responsible for 
accepting an electron from cytochrome c reductase and for transferring an electron to 
cytochrome c oxidase (9). In addition to functioning as an electron carrier, cyt c promotes the 
assembly of a caspase-activating complex to induce cell apoptosis (10). These diverse 
functions of cyt c are associated with the protein–protein interactions between cytochrome c 
and its interacting proteins.  
Human cyt c form an electron transfer (ET) pair with ferritin depending on the redox state of 
the two systems, as reported in electronic spectroscopy studies (11, 12). The reaction was 
proposed to be of particular interest because it demonstrated that Fe2+ in the ferritin interior is 
readily oxidized to Fe3+ by a molecule too large to enter the protein interior. This reaction was 
demonstrated with horse spleen ferritin that is a cytosolic protein. Since cyt c is found in 
mitochondria, their different distribution let to conclude that they could not be physiological 
partners. After a decade, in 2001 the mitochondrial catalytically active ferritin (FtMt) was 
  
described for the first time. Human mitochondrial cyt c is a well-characterized protein in our 
lab. Thus, we hypothesized that an interaction between FtMt and cyt c. 
We therefore decided to investigate deeply the inter-protein ET process, trying to see whether 
it occurs via specific protein-protein interactions. The work was conducted by  
NMR. We expressed and purified unlabelled FtMt depleted of the signal peptide. 15N-labelled 
human cyt c was produced according to an already developed protocol (13) and used to 
monitor 1H 1D and 2D HSQC spectral changes upon addition of increasing amounts of FtMt. 
Both reduced and oxidized-states of cyt c were investigated. We clearly observed the 
occurrence of an ET process when mixing reduced cyt c with iron-loaded FtMt: in one 
dimensional 1H NMR spectra the diamagnetic iron(II) cyt c and the paramagnetic (S=172) 
iron(III) cyt c have clearly different signals patterns; appearance of paramagnetic signals 
unequivocally indicated heme iron oxidation induced by iron-loaded ferritin. The same 
phenomenon was observed with the HuHf. 2D 1H-15N NOESY spectra of 15N-enriched cyt c 
recorded in the absence and in the presence of iron loaded ferritin did not show any 
significant chemical shift perturbations. While chemical shift perturbations are extremely tiny, 
if any, significant signal broadening (in both 1D and 2D spectra) was observed (Fig. 3 and 4). 
 
  
 
Figure 3. 1D NMR spectra acquired at 700 
MHz spectrometer at 298 K. In blue the 
reference spectrum of reduced cyt c (400 µM 
protein in 50 mM NaPi pH 6.8; in red, cyt c in 
presence of 5 equivalents of apo HuHf (without 
iron); in green, cyt c in presence of 5 equivalents 
of apo FtMt. 
Figure 4. 1D NMR spectra acquired at 700 
MHz spectrometer at 298 K. In blue the 
reference spectrum of reduced cyt c (400 µM) in 
50 mM NaPi pH 6.8; in red, cyt c in presence of 
0.1 equivalents of holo FtMt (with iron); in green, 
DTT addition to revert cyt c at the reduced redox 
state.  
  
 
In order to understand if the ET occurred through the iron mineralized in the core or 
through the iron mobile pool (see Section 4.5) available at the catalytic site, we repeated the 
cyt c titration with holo L-ferritin that lacks the catalytic site and no ET occurred (see Scheme 
1). This indicated that only mobile iron ions at the catalytic site are able to participate in the 
redox exchange. 
 
 
 
 
This finding seems to contradict former observations of an ET between cyt c and horse 
spleen ferritin (11). In practice, horse spleen ferritin contains about 10% of H-type subunits 
which might be at the origin of the observed ET. 
 
Figure 5. 1D NMR spectra acquired at 700 MHz spectrometer at 298 K. In blue the reference spectrum of 
reduced cyt c (400 µM) in 50 mM NaPi pH 6.8; in red, cyt c in presence of 2 equivalents of holo HuLf (with 
iron); in green, add of other 2 equivalents of holo HuLf. Line broadening suggests interaction between the two 
proteins even though in absence of ET. 
 
While our data constitute a further proof of the presence of a redox accessible pool of 
iron in H-subunits, as proposed in Section 4.5, the structural interpretation of our NMR data is 
not straightforward. The lack of residue-specific chemical shift perturbations supports an 
Fe
3+
(holo FtMt/H ferritin) + Fe
2+
- (Red cyt c)            Fe
2+
(holo FtMt/H ferrritin) + Fe
3+
- (Ox cyt c) 
Fe
3+
(holo L ferritin) + Fe
2+
-(Red cyt c)              Fe
2+
(holo L ferrritin) + Fe
3+
-(Ox cyt c) 
Scheme 1. Schematic ET reaction between holo ferritins and reduced cyt c. 
  
unspecific interaction between the two proteins. The observed line broadening effects could 
be compatible with a general increase in solution viscosity due to the addition of the large 
ferritin nanocage, although we cannot rule out the presence of interaction equilibria on the 
quasi-fast chemical shift NMR time scale involving a small molar fraction of complexed cyt 
c. 
 
5.3 Highlights 
Besides its iron-biomineralization and storage function, ferritin has been proposed to 
exhibit other redox activities different from the iron oxidation in presence of dioxygen.  
Intrigued by ferritin as a new lipid-binding protein, we studied by NMR the interaction 
of HoSf with a variety of fatty acids. Ligand-based NMR experiments demonstrated that the 
stronger binders are unsaturated lipids such as oleate and arachidonate. Combining 
competition binding NMR experiments with previous crystallographic data, allowed us to 
conclude that oleate binds ferritin at the 2-fold intersubunit pocket, as already seen for ARA 
and SDS. The presence of oleate speeds up the biomineralization reaction, possibly 
contributing to a more efficient reaction at the nucleation site, which is located just below the 
fatty acid binding pocket. 
The lack of specific protein-protein interactions between cyt c and ferritins probably 
rules out a functional significance to this redox reaction. On the other hand, it provides a 
further evidence of the different redox activity of the biomineralized iron and iron at the 
ferroxidase sites. 
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Chapter 6 
Conclusions and perspectives 
 
  
  
My thesis project has been developed in the frame of the PRIN 2012 project, 
“Innovative chemical tools for improved molecular approaches in biomedicine”. In this 
project, human ferritins have been selected as the reference proteins to be structurally and 
functionally characterized, for a deeper knowledge of the mechanisms that regulate iron 
handling and storage. The long-term goal is that of rational design a novel ferritin-based cage 
able to efficiently encapsulate drug, imaging probe or theranostic agents and to modulate their 
release in response to specific chemical properties of the microenvironment typical of 
different pathological states. 
The results of my PhD activities contributes to the achievement of these goals. First of 
all, the development of efficient expression and purification methods for the high yield 
production of HuHf, HuLf and FtMt ferritins (Chapter 2) is crucial for focusing research on 
human proteins that, have clear advantages because it should not activate inflammatory or 
immunological response when administered to patients. Historically, most studies on 
mammalian ferritins instead had been obtained on the commercially available horse spleen 
protein. High-resolution time-lapse anomalous X-ray diffraction data on H-ferritin have led to 
the definition of the ferroxidase site and accessory binding site in the catalytic cavity (Section 
3.2). The ferroxidase site, where the substrate Fe(II) is oxidized by dioxygen, is unique among 
the diferric iron centers because of the low number of protein ligands and a single bridging 
carboxylate. The coordinating amino acids are conserved across the vertebrates H-type 
ferritins. The functional requirement of reaction turnover at this site explains the relatively 
loose coordination of the metal ions to the protein matrix. Each of the accessory sites that 
drive Fe(II) into the catalytic site consist of one/two ligands (His or Asp/Glu); these residues 
are generally not conserved across different species but their presence is needed to sustain the 
catalytic reaction cycles. Stopped-flow kinetic measurements on different wilt-type ferritins 
and newly designed variants have been crucial for the functional interpretation of the 
crystallographic results. With a similar approach that combines time-lapse diffraction and 
reaction kinetic measurements as well as the production of protein mutants, we identified a 
novel cluster that defines the nucleation site of L-ferritins (Section 3.4). Further details about 
the mineral growth are planned and will require the production and functional characterization 
of novel mutants. From this study, we derived a picture of the ferritin as a cage that controls 
specific iron trafficking pathways. The C3 channels are designed to assist the import of 
ferrous hexa-aquaions via an attractive electrostatic potential. In H-ferritins, the delivery of 
Fe(II) towards the ferroxidase sites under the form of partially hydrated ferrous ions is mainly 
  
controlled by Asp/Glu accessory sites that design a path from the inner cage to the interior of 
the 4-helix bundle. In L-type ferritins, a cluster of three glutamates blocks the iron at the inner 
cage surface and acts as a template for the formation of a novel (3-oxo)tris[(2-peroxo)(2-
glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) anionic cluster. 
The presence of a “mobile” iron pool in the catalytic site of H-ferritins, which has no 
counterpart in L-ferritin, is here proposed as the main source of redox active iron species. This 
observation has led us to suggest the use of iron-loaded H-ferritin cages as toxic agents for 
cancer cells overexpressing the TfR-1 receptor, which is involved in the selective import of 
H-cages with respect to L-cages (Section 4.5). This species causing the here named 
“Ferritinoxis”, are our first example of encapsulated inorganic materials with potential 
anticancer activity. Encapsulation of different metal derivatives, like the here proposed 
NAMI-A (Section 4.4), is another promising area that would require future deeper structural 
and in vitro/in cell functional characterization. The demonstrated interaction with fatty acids 
(Section 5.1) is encouraging to exploit ferritin-binding lipids conjugated with contrast agent or 
drugs as a further strategy. 
Last but not least, the demonstrated feasibility of ss-NMR of pelleted protein in 
PEGylated ferritin provides an important tool to monitor structural integrity in surface 
functionalized cages (Section 4.1). It could constitute a valuable means to analyze other 
human ferritins that are naturally glycosylated or artificially conjugated with different 
molecules. 
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Abstract 
X-ray structures of homopolymeric L-ferritin obtained by freezing protein crystals at increasing 
exposure times to a ferrous solution showed the progressive formation of a triiron cluster on the 
inner cage surface of each subunit. After 60 minutes exposure, a fully assembled (3-oxo)tris[(2-
peroxo)(2-glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) anionic cluster appears in human L-
ferritin. Glu60, Glu61 and Glu64 provide the anchoring of the cluster to the protein cage. Glu57 
shuttles towards the cluster incoming iron ions. We observed a similar metallocluster in horse spleen 
L-ferritin, indicating that it represents a common feature of mammalian L-ferritins. The structures 
suggest a mechanism for iron mineral formation at the protein interface. The functional significance 
of the observed patch of carboxylate side chains and resulting metallocluster for biomineralization 
emerges from the lower iron oxidation rate measured in the E60AE61AE64A variant of human L-
ferritin, leading to the proposal that the observed metallocluster corresponds to the suggested but 
yet unobserved nucleation site of L-ferritin. 
 
Significance Statement: Iron is an essential element in biology but has limited bioavailability. Ferritins 
are 24-mer iron-storage nanocage proteins that concentrate iron in their inner compartment as a 
bioavailable iron oxide biomineral. In L-type subunits, abundant in ferritins from organs involved in 
long-term iron storage, the biomineralization has been proposed to proceed through nucleation 
events involving iron(II) oxidation at the inner cage surface. Here we demonstrate the nature and 
structural features of these nucleation sites. Structures captured during iron uptake show that the 
formation of the iron biomineral proceeds via the assembly of a tri-nuclear iron cluster, anchored to 
the protein via glutamic acid side chains, and involving oxo and peroxo ligands that are produced 
during the iron(II) oxidation by dioxygen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
wentyfour-mer ferritins are ubiquitous iron-biomineralizing nanocage proteins. In mammals, 
they are generally heteropolymers composed by two different types of subunits, the heavy H 
and the light L (183 and 175 amino acids, respectively, in the human chains). The subunits self-
assemble to form a hollow structure with a central cavity capable of accommodating thousands of 
iron atoms in the form of an oxoferric biomineral (1, 2) (Fig. 1A). The relative ratios of the two types 
of subunits in the 24-mers vary in different tissues; ferritins in iron storage organs, such as liver and 
spleen, are richer in L-subunits, while those with fast iron metabolism such as brain and heart are 
richer in H-subunits (3). The H-subunit contains a ferroxidase center, composed by the so-called Fe1 
and Fe2 sites, capable of rapidly oxidizing Fe2+ to Fe3+ (4, 5); a relatively low number of amino acid 
ligands characterizes the two sites. In human H-subunit, Glu62 acts as a bridging ligand between the 
two metals; the metal at Fe1 is also bound to His65 and monodentate Glu27 while the metal at Fe2 
binds bidentate Glu107 (4). Accessories transient metal sites (Fe3, Fe4 and, in some cases, Fe5) have 
been identified by X-ray crystallography in the proximity of the ferroxidase site and they have been 
demonstrated to play a key role in the reaction turnover (4, 6). L-subunits lack the ferroxidase site, 
whereas a number of other residues are conserved with respect to the H-subunit (homology 53% 
between human L- and H-chains; see Fig. 1B) (7). Consequently, iron incorporation in nanocages rich 
in L-subunits is much slower. Nevertheless, even homopolymeric L-ferritins are able to biomineralize 
iron. The proposed mechanism involves the presence of a putative nucleation site on the inner cage 
surface of L-subunits. In several studies, the role of residues Glu57, Glu60, Glu61, and Glu64 (human 
H-chain aligned numbering, Fig. 1B), for an efficient biomineralization was inferred by site directed 
mutagenesis or chemical modifications (8, 9). Non-physiological metal ions like Cd2+ have been 
observed bound to the corresponding glutamates of the above mentioned human Glu residues in 
several mammalian L-ferritins (10-14), while the structure with iron of these homopolymeric L-
ferritins has not been yet reported. 
Here, we describe a structural study of iron binding to human and horse L-ferritins (HuLf and HoLf, 
respectively), were we observe the ferritin-mediated assembling of a tri-nuclear iron cluster on the 
inner surface of L-ferritin cages with a scaffold provided by Glu60, Glu61 and Glu64 ligands. The 
presence of these residues facilitates the biomineralization process, as demonstrated by different 
kinetics of biomineral formation between recombinant wild type (WT) homopolymeric HuLf and its 
triple variant E60AE61AE64A. All together, these results provide a direct evidence of the glutamate-
bound triiron cluster as the mineral nucleation site in L-ferritins. The cluster structure is unprecedent 
in biological systems although it shows striking structural similarities to a synthetic hexanuclear iron 
cluster proposed about 20 years ago as a possible model of ferritin biomineral (15). 
Results 
T 
  
Structural Studies on Iron-free HuLf and HoLf. Overall Structures. Crystals of iron-free HuLf were 
exposed to a concentrated ferrous ammonium sulfate (Mohr’s salt) solution and frozen after 15, 30 
and 60 minutes of diffusion of Fe2+ ions into the crystals. The same experimental approach was used 
to characterize the iron-loaded state of the HoLf ferritin. The structures of HuLf and HoLf before iron 
exposure were determined as reference structures. They show the typical quaternary structure of 
maxi-ferritins, consisting of the 24-subunit assembly to form a hollow cage. The asymmetric unit in 
both structures contains a single protein chain, representing the spatial and time average of all the 
molecular subunits found in the crystals. Each ferritin subunit shows the characteristic four-helix 
bundle tertiary structure completed by a fifth helix (Fig. 1A) (13, 16). The protein models are almost 
complete with the exception of the two initial and the three final residues of HoLf and the two 
starting residues in the HuLf sequence. The structure of the purified horse spleen ferritin is that of an 
L-chain homopolymer. 
Several cadmium ions have been observed bound to both iron-free HuLf and HoLf, in the 3-fold axis 
channel, on the 2-fold axis and on the internal surface of the protein shell, but none on the 4-fold 
axis channel (see SI Channels and Metal Ions Binding Sites) (17, 18). In the iron-free structures of 
both L-type ferritins two Cd2+ ions are coordinated by Glu57 and Glu60, and by Glu61 and Glu64, 
respectively. 
L-ferritin Subunits Provide the Scaffold for a Trinuclear Peroxo-bridged Cluster. Despite several 
structures of HuLf and HoLf ferritins have been determined in complex with different metal ions (13, 
16, 19), no structural observation of iron binding to the mineralization site have been reported in the 
literature, the only iron(III) ion reported in HoLf being bound to an exogenous ligand (20). To the goal 
of obtaining insights on the ferritin biomineralization process, we have obtained the crystal 
structures of the iron-loaded HuLf and HoLf cages. Besides observing the expected iron ions in the 
access 3-fold channels (SI Channels and Metal Ions Binding Sites), we could monitor iron binding 
inside the cavity. Iron binding to the inner cage surface is achieved with the involvement of the 
carboxylic side chains of three glutamic acids, namely Glu60, Glu61, and Glu64 in HuLf and the 
corresponding residues in HoLf (Fig. 2 and 3). Three iron ions are coordinated to the above 
carboxylate side chains, generating an oxo-centered trinuclear cluster (Fig. 2). The anomalous 
difference maps show that the triiron cluster is formed at 30 minutes of iron exposure (the 15 
minutes structure does not show any iron atom bound), but the best defined ligand set of the iron 
ions appears in the structures obtained after 60 minutes (Fig. 3A-D), which will be described in detail 
below. Fourier difference maps of both HuLf and HoLf show the presence of an atom in the middle of 
the iron cluster that has been interpreted as an oxide anion forming a 3-oxo bridge (Fig. 3B,D; see SI 
Structural Features of the Metal Cluster ). In the 60 minutes structure of HuLf (1.98 Å resolution) the 
  
oxide anion is located almost centrally in the plane formed by the three iron ions with coordination 
distances in the 1.8 – 2.0 Å range, all identical at 2σ significance level (Fig. 2 and 3B). The 
coordination displayed by the iron ions in the cluster is a distorted octahedral geometry. The 
carboxylate groups of Glu60, Glu61 and Glu64 symmetrically bridge the three Fe couples (Fig. 2) on 
the same side of the cluster. On the opposite side, each pair of iron ions results connected by an 
elongated electron density compatible with a diatomic molecule. The observed densities have been 
interpreted as due to three peroxide anions generating a second series of bridges (Fig. 3B). The 
arrangement of the three carboxylates, the three iron ions and the three peroxides follows an almost 
regular 3-fold symmetry centered on the oxide anion. A sixth ligand is present in the basal plane of 
each Fe ion: a water molecule for Fe1 and Fe2, and an oxygen from the carboxylate group of Glu57 
(monodentate) for Fe3. Glu57 bridges a nearby fourth iron aqua-ion present at lower occupancy 
(about 50%). A likely explanation of the described arrangement of the iron ions in this site, is that we 
have detected a (3-oxo)tris[(2-peroxo)(2-glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) 
anion. Remarkably, the L-ferritin cluster shows the same structure of the analogous portion present 
in a synthetic hexanuclear iron(III) cluster reported as a model of the ferritin mineral core (a detailed 
structural comparison is reported in SI Structural Features of the Metal Cluster) (15). The striking 
similarity to that model compound supports the presence of iron ions in the ferric state resulting in 
an overall trinegative charge of the assembly in HuLf, which can provide the driving force to attract 
new iron(II) ions to promote oxidation and biomineralization, as exemplified by the observed fourth 
iron ion approaching the cluster via Glu57. 
The comparison with the iron-free HuLf structure reveals that the formation of the oxo-centered 
trinuclear iron cluster occurs without modification of the protein fold, but with a rearrangement of 
the glutamate side chains involved in iron coordination. The Cd2+ ions present in the same site in the 
iron-free structure are displaced by iron. Upon formation of the iron cluster the carboxylate of Glu57 
shifts by ca 2.5 Å (and rotates on the -carbon by 60°) whereas the carboxylate of Glu60 moves by 
about 1.3 Å (and rotates on the -carbon by 50°). The formation of the cluster induces also the 
rearrangement of the side chains of several surrounding residues. In particular, the hydrophilic side 
chains of Arg68 and Glu140 contribute to stabilize the cluster through the formation of a network of 
water-mediated interactions involving Glu61 and the water molecule indicated as WatL in Fig. S2. 
The structures of HoLf exposed to an iron salt solution for the same time intervals confirm the 
formation of the oxo-centered trinuclear iron cluster in the mineralization site of L-type ferritins (Fig. 
3C,D). Only two peroxide anions can be modelled bridging the Fe1-Fe2 and Fe2-Fe3 couples (Fig. 3D). 
No density is present in the omit map in correspondence to the third peroxide observed in HuLf. Only 
an elongated maximum is found close to Fe1 and incoming Fe4 that has been interpreted as a water 
  
molecule. The lower resolution of this structure (2.22 Å) does not provide a satisfying modelling of all 
aqua-ligands that should complete the iron coordination in the cluster. However, the arrangement of 
the three iron ions in the cluster and of the incoming fourth iron ion, at lower occupancy, is almost 
superimposable with that present in HuLf (Fig. 3A,C). This confirms that the formation of such cluster 
is a general feature of L-subunits and suggests its functional relevance. 
Assessing the Functional Relevance of the Trinuclear Iron Cluster. The crystal structure indicates the 
key role of Glu60, Glu61 and Glu64 to act as template for the formation of the cluster. Our functional 
working hypothesis was that substituting these negatively charged glutamate residues with non-
polar alanine could alter the biomineralization process. To prove the functional role of the residues 
linking the triiron cluster to the protein matrix, we designed and produced the triple mutant 
E60AE61AE64A. The protein yield was 30 mg/L, meaning that these multiple mutations did not affect 
the expression efficiency. Moreover, the typical quaternary structure was maintained as 
demonstrated in size exclusion chromatography experiments (Fig. S1). A comparative kinetic analysis 
of the formation of ferric biomineral between WT HuLf and its variant E60AE61AE64A was performed 
spectrophotometrically. Temporal spectral changes monitored A350nm (see Materials and Methods) 
after the addition to protein solutions of different amounts of Fe2+ ions (3-18 Fe2+ per subunit) in 200 
mM MOPS, 200 mM NaCl pH 7 were acquired in parallel (Fig. 4). The same measurements were 
repeated also in absence of the protein to observe the contribution of spontaneous ferrous ions 
oxidation. In the absence of ferritin, precipitation of iron-oxo species is clearly observed through a 
decrease of the A350nm; the effect is stronger at higher concentrations of Fe2+ (Fig. 4C,D, blue curves). 
Differently, in the presence of HuLf, either WT or E60AE61AE64A variant, the iron is maintained in a 
soluble form and the A350nm reaches a plateau at incubation times that are dependent upon the 
number of added Fe2+ equivalents (Fig. 4: red and green curves). The initial velocity of Fe2+ oxidation 
is more rapid in the presence of WT HuLF with respect to the E60AE61AE64A variant, thus 
demonstrating a direct role of the mutated residues in the iron oxidation kinetics and therefore 
attributing a functional significance to the trinuclear iron cluster that forms at their site. This trend is 
more evident at lower iron concentration (3 and 6 Fe2+ ions per subunit, Fig. 4A,B), suggesting that 
the cluster plays a role in the initial steps of biomineralization. 
Discussion 
It is generally accepted that in ferritin cages lacking or containing a low number of ferroxidase-active 
subunits, the core biomineral formation proceeds via few key steps. The iron entry into the cage 
cavity proceeds through the iron channels at the 3-fold symmetry axes (Fig. 5) and is followed by 
oxidation at specific, yet unobserved, nucleation sites that facilitate the subsequent growth of the 
mineral (2, 4, 21, 22). Using X-ray crystallography, we detected for the first time iron bound at inner 
  
cage sites of L-subunits of recombinant homopolymeric human ferritin in the form of (3-oxo)tris[(2-
peroxo)(2-glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) anion; a very similar arrangement 
was here observed in HoLf. The protein ligands to iron are provided by Glu60, Glu61 and Glu64, while 
Glu57 appears to be involved in shuttling additional iron ions towards the cluster. The peroxo cluster 
is fully formed in HuLf after 60 minutes of Fe2+ diffusion through the crystals, while in the lower 
resolution structure of HoLf at the same diffusion time only two fully formed peroxide bridges could 
be modelled. The functional role to the observed trinuclear iron cluster, emerges from the 
comparative kinetic analysis of the ferritin-mediated iron oxidation reaction of WT and 
E60AE61AE64A variant HuLf cages. The three mutated residues have a clear role in accelerating the 
oxidation reaction at low iron contents. These results allow us to propose the three iron-carboxylate 
cluster as the site for the iron mineral nucleation site in L-ferritins. Indeed, the observed 
metallocluster appears to be a general characteristic of animal L-type ferritins, as it is found also in 
HoLf crystals. The chemical features of the observed triiron cluster partially confirm previous 
proposals about the nature of biomineral precursors. The observed L-ferritin trinuclear cluster can be 
considered as a portion of the hexanuclear synthetic cluster discussed in the Results section, which 
was proposed to represent a ferritin biomineral model (15). Other authors have suggested that an 
oxo-centered trinuclear iron cluster, which forms spontaneously on the surface of class Ib 
ribonucleotide reductase R2 protein from Corynebacterium ammoniagenes in crystals subjected to 
iron soaking, could mimic an early stage in the mineralization of iron in ferritins (23). In this case, 
however, the bridging ligands were provided by six carboxylates whereas no peroxide anions were 
detected (23). 
In analogy with the ribonucleotide reductase case, in L-ferritins, the presence of three adjacent Glu 
residues at positions 60, 61 and 64 is perfectly suited to provide cooperative binding of iron in a 
trinuclear center. In H-type subunits, like human H-ferritin (HuHf), this ideal arrangement of 
carboxylate side chains is disrupted by replacement of Glu60 with a His, with the concomitant 
increase in the conformational freedom of Glu61 side chain (6). Also Glu57 is replaced by His in HuHf 
(Fig. 1B). Consistently, the biomineralization reaction in H-ferritin cages does not require a nucleation 
site (24) and His57 and Glu61 are involved in controlling the access of ferrous ions to the ferroxidase 
site (6). The formation of ferric clusters of high nuclearity in ferroxidase active (H or H’) subunits has 
been inferred from Mössbauer (25-27) and NMR data (28, 29), but they have never been detected by 
time-lapse anomalous crystallography approaches. This supports the occurrence of a different iron 
mineralization process in ferroxidase active subunits leading to spatially disordered clusters that 
escape detection by X-ray crystallography. The observed peroxide ligands in the L-ferritin cluster 
might result from the initial oxidation of ferrous iron bound to the nucleation site and by the excess 
reductant (Fe2+) present in solution. The formation of a peroxide-complex in L-ferritins supports a 
  
mechanism for the mineral growth in the absence of the ferroxidase catalytic site, where the 
reaction between glutamate-bound Fe2+ and dioxygen provides the Fe-peroxide anionic catalyst able 
to attract and oxidize incoming Fe2+ aqua-ions. The reaction could be relevant in the contest of the 
proposed ferritin-mediated detoxification reaction involving both Fe(II) and H2O2 (30). In vivo, this 
reaction is important to attenuate harmful Fenton chemistry under conditions of iron overload. In 
vitro, it becomes the dominant one due to the lack of the protective role exerted by catalase that 
could disproportionate any H2O2 produced upon iron oxidation. Time-lapse crystallography shows 
here once more (4, 6, 31) its merit in capturing reaction intermediates within ferritin cages, thus 
leading to the identification of functional iron-binding sites and to a dynamic picture of their 
population by iron ions.  
Materials and Methods 
Protein Preparation. The plasmid encoding WT HuLf (32) was transformed into E. coli BL21(DE3)-
pLysS competent cells. The protein was expressed and purified following a home-made protocol 
developed for HuHf (33) with some modifications (17°C with 0.2 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 48 hours in rich medium Luria Bertani, LB). The subunit mass was 
analyzed by MALDI mass spectrometry. The retention volume obtained in the size exclusion 
chromatography demonstrated the 24-mer formation (Fig. S1). The E60AE61AE64A HuLf variant was 
expressed and purified as for WT; mutations were verified by MALDI peptide fingerprint analysis.  
HoLf samples were obtained by purification of the commercially available protein.  
Details on proteins’ preparation, purification, initial characterization and mineralization are provided 
in the SI Materials and Methods.  
Kinetic Measurements. The rate of the biomineralization reaction was determined 
spectrophotometrically upon addition of variable amounts of Fe2+ (3-18 Fe2+/subunit), as 
described in the SI Materials and Methods. 
Crystallography. A series of L-ferritin structures were determined by soaking HuLF and HoLf ferritin 
crystals with a freshly prepared [(NH4)2Fe(SO4)2]∙6H2O solution for exposure times of 15-60, minutes, 
followed by flash freezing in liquid nitrogen. The procedure, detailed in the SI Materials and 
Methods, follows with some modifications an established protocol that already allowed us to 
characterize iron oxidation in the ferroxidase site of human H- and Rana Catesbeiana H’- type 
ferritins (4, 6). Data collection, structure solution and refinement procedures are given in the SI 
Materials and Methods and in Table S1 and S2. The final coordinates and structure factors for 60 
  
minutes iron-loaded HuLf and HoLf have been deposited in the Protein Data Bank under the 
accession codes 5LG8 and 5LG2, respectively. 
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Fig. 1. Ferritin main structural features and sequence alignment. (A) Left, cartoon representation of 
the four-helix bundle subunit: helices III and I are solvent-exposed and linked by a long loop 
(magenta), helices II and IV locate on the inner cage surface; a fifth short helix at the C-terminal is 
tilted of 60° with respect to the bundle axis. Right, section of the human L-ferritin (HuLf) cage. The 
trinuclear iron clusters sprout into the 8 nm cavity, surrounded by the protein shell of 12 nm external 
diameter. (B) Alignment of amino acid sequences of human H-ferritin (HuHf), HuLf and horse spleen 
L-ferritin (HoLf) (FRIH_HUMAN, FRIL_HUMAN and FRIL_HORSE, respectively), performed by Clustal 
Omega. All sequences are depleted of the initiator methionine. In light blue, the residues binding the 
metal cluster in L-ferritin. In orange, the iron-binding amino acids in the ferroxidase site of the 
catalytically active H-subunit and the corresponding amino acids in the L-chains of HuLf and HoLf 
(both lacking the ferroxidase site). In magenta, the amino acids in the conserved pore responsible of 
iron entry. 
  
  
 
 
Fig. 2. Different views of the trinuclear iron binding site in HuLf. (A) Electrostatic surface 
representation of the trinuclear cluster binding site. Iron ions and water molecules are represented 
as cyan and red spheres, respectively. Peroxide molecules are shown as red ball-and-stick models. (B) 
Structure of the oxo-centered trinuclear iron cluster. Coordinating glutamates are highlighted as 
sticks. Iron ions, water and peroxide molecules are represented as in “A”. Coordination bonds to iron 
ions are shown as dashed red lines; coordination distances (Å) are also displayed. Two different 
orientations are proposed in panels A and B to better appreciate the structural features of the 
protein site and metal cluster. 
  
  
 
 
Fig. 3. The iron cluster in HuLf and HoLf. (A) Iron ions (cyan spheres) in HuLf are surrounded by the 
anomalous difference map (dark red mesh) contoured at 4.0 σ. (B) Omit map (green mesh) in HuLf 
contoured at 3.0 σ of peroxide and oxide anions involved in iron coordination. In both HuLf pictures: 
helix II, light blue cartoon; residues involved in iron coordination, light blue sticks. (C) Iron ions (cyan 
spheres) in HoLf are surrounded by the anomalous difference map (dark red mesh) contoured at 5.0 
σ. d, Omit map (green mesh) in HoLf contoured at 3.0 σ of peroxide and oxide anions, and the water 
molecule involved in iron coordination. In both HoLf pictures: helix II, yellow cartoon; residues 
involved in iron coordination, yellow sticks. 
  
  
 
Fig. 4. Kinetic measurements in WT and E60AE61AE64A HuLf variant. Kinetics of oxo-ferric species 
formation followed spectrophotometrically as the change in absorbance at 350 nm over 16 hours 
(960’). Different concentrations of Fe2+ were incubated, at room temperature, in 200 mM MOPS 200 
mM NaCl pH 7 buffer with 25 µM protein subunits of WT HuLf (red curves) and triple mutant 
E60AE61AE64A (green curves) or without protein (blank, blue curves). Addition of: (A) 3 Fe2+ ions per 
subunit; (B) 6 Fe2+ ions per subunit; (C) 9 Fe2+ ions per subunit; (D) 18 Fe2+ ions per subunit. 
  
  
 
 
Fig. 5. The properties of the 3-fold ion channel in ferritin. Electrostatic surface representation of a 
trimer of L-ferritin subunits where three monomers (gray cartoon) come in contact generating a 3-
fold channel responsible for iron entry. The external (left) and the internal (right) views of the pore 
circled with black lines show the negatively charged environment, due to the presence of conserved 
Asp131, Glu134 and Thr135 side chain residues. In HoLf, in position 135 there is a Ser, which is highly 
similar to Thr. 
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SI Structural Features of the Metal Cluster 
Structural features of the trinuclear iron cluster and similarities to model systems. Figures 
3B and 3D (main text) show the residual electron density present around the iron ions forming the 
cluster in HuLf and HoLf, respectively. The assignment of the residual electron density present in the 
center of the three iron ions to an oxide anion is based on the comparison of the coordination 
distances and on the chemical environment as well as on the similarity to several model compounds. 
Examples of Fe3(3-O) units are abundant in crystal structures of iron(III) complexes synthesized to 
mimic intermediates in the catalytic cycle of non-heme iron proteins (1-5) Fe3+- (3-O) distances in 
carboxylate-bridged ferric ions in model compounds are reported between 1.865(2) Å (2) and 2.01(1) 
(1) while in R2 ribonucleotide reductase example (6) range between 1.7 to 2.2 Å.  
Fe3+-peroxide distances in multiple peroxo-bridged models range between 1.997(7) Å and 2.106(5) Å 
(1, 2). In our HuLf 60 minutes structure we observe Fe-oxo distances between 1.80(15) and 2.03(15) 
Å and Fe-peroxo distances between 2.27(15) and 2.62(15) Å. The peroxo O-O bond lengths 
determined in our structure are all identical between experimental error to 1.46(15) Å. This 
compares well with the canonical 1.48(2) Å found in 2-peroxo models (7). The Fe – Fe distances in 
HuLf range between 3.21(15) and 3.45(15) Å and are comparable to those found in Fe3+- (3-O) 
models (eg: 3.278(3) - 3.196(2) Å) (2). 
The structure of the ferric cluster in the HoLf is somewhat less regular than that of HuLf as the Fe 
triangle shows one Fe-Fe distance of 3.3(2) Å and two longer Fe-Fe distances (3.8(2) Å and 4.0(2) Å). 
  
Only two 2-bridged peroxide anions could be modelled into the residual electron density (Fig. 3D 
main text).  
The above structural analysis lead to our interpretation of the cluster as a stable (3-oxo)tris[(2-
peroxo)(2-glutamato-O:O’)](glutamato-O)(diaquo)triiron(III) anion that constitutes a likely 
candidate for the nucleation site of the ferric mineral in L-ferritins. 
 
SI Channels and Metal Ions Binding Sites 
Twentyfour-mer ferritin cages have a 432 (O, octahedral) point symmetry. In correspondence to the 
3-fold and 4-fold symmetry there are eight and six channels respectively, connecting the protein 
exterior to the inner cavity. The 4-fold channels form at the encounter point of the C-termini of four 
subunits and the four symmetry-related helices V define the inner wall of the channel. The 3-fold 
channels occur where three subunits come into contact through the N-terminal ends of helices IV 
and the C-terminal ends of helices III. The two type of channels differ in their size and hydrophilicity 
(8). 
4-fold symmetry channel. The channel located on the four-fold symmetry axis results not occupied 
by any metal ion. This can be ascribed to the prevalent hydrophobic nature of the residues present in 
HuLf and HoLf channels, while Fe-bound His residues are present in both human H-ferritin and Rana 
catesbeiana H’-ferritin (9, 10). 
3-fold symmetry channel. It has been largely accepted that the channels present on the 3-fold 
symmetry in the ferritin protein shell constitute the preferential entry path of iron ions proceeding to 
the catalytic center. Very recently the transit of iron ions within these channels has been 
demonstrated through X-ray crystallography in homopolymeric H’-type ferritin from Rana 
catesbeiana and human H-type ferritin (9, 10). The hydrophilic nature of these channels is strongly 
conserved among the different ferritin types. 
A path of Cd2+ ions (discriminated according to the anomalous signal, still strong in the data collected 
below the Fe K-edge) is present inside this funnel-shaped channel. Three symmetry related Cd2+ ions 
are visible on the external portion of the channel (largest part) at a distance of ca 4.8 Å. Cd2+ ions in 
this sites results coordinated by two protein residues, His118 and Cys130, whereas the other four 
ligands completing the octahedral coordination geometry have been assigned to water molecules. 
The partial occupancy of Cd2+ ions in this site is also suggested by the two alternative conformation 
adopted by Cys130. In the first conformation, showing the side chain exposed on the 3-fold channel, 
  
it coordinates a Cd2+ ion (and has been refined with the same occupancy) whereas in the second, 
the side chain points to the adjacent helix III (and adopts the same conformation observed in HuHf 
showing magnesium ions inside the channel). Going from the outer to the internal part of the 
channel three further Cd2+ ions are clearly visible. One of them can be modelled in three symmetry 
related alternative positions coordinated by the carboxylates of Glu134. A further Cd2+ is placed at 
the inner end of the channel, located exactly on the 3-fold symmetry axis where it is coordinated by 
three symmetry related Asp131 and water molecules. A similar cluster of six Cu2+ ions has been 
previously observed in the 3-fold symmetry channel of Rana catesbeiana H’-ferritin (PDB: 3RE7) (11). 
In our HoLf structure only one Cd2+ ion is bound to Glu130 in the 3-fold axis channels. 
Other Cd2+ binding sites. In HuLf, four Cd2+ ions are bound at partial occupancy, to the cage 
surface by Asp15, Glu90, His136, Glu49 and Asp178, with their coordination spheres completed by 
water molecules. In HoLf two Cd2+ ions are bound to the protein surface, one to Asp84 and the other 
to Glu15 side chains. 
 
SI Materials and Methods 
Protein preparation. The WT HuLf homopolymer was expressed and purified according to an in-
house developed procedure (reported below), which presents some modifications with respect to 
that developed for the human H protein (12). The pET-21c plasmid encoding native HuLf was a kind 
gift of Prof. S. Torti (13). This vector was transformed into E. coli BL21(DE3)-pLysS competent cells 
(already used in our laboratory for ferritin expression). Several expression trials were performed in 
order to optimize the final protein yield. We tested different incubation temperatures (17°C, 25°C 
and 37°C), incubation times (4, 8, 16, 24 and 48 hours) and IPTG concentrations (0.2, 0.5 and 1 mM). 
Our best condition turned out to be 17°C, 0.2 mM IPTG for 48 hours in LB, avoiding the protein to be 
found in inclusion bodies as it occurred at higher temperatures or higher IPTG concentrations. In 
details, bacteria were grown in LB rich medium containing 100 mg/L of ampicillin and 34 mg/L of 
chloramphenicol at 37°C. Once the A600nm reached 0.6-0.8, the over-expression of HuLf was induced 
with 0.2 mM IPTG, shifting the incubation temperature to 17°C for 48 hours. The cells were 
harvested (7500 rpm for 15 minutes) and resuspended in 20 mM Tris-HCl pH 7.5. After sonication, 
the crude lysate was clarified by ultra-centrifugation (40,000 rpm for 40 minutes) and the soluble 
fraction heated at 65°C for 15 minutes to precipitate undesired proteins (40,000 rpm for 15 minutes). 
Subsequently, the supernatant was dialyzed against 20 mM Tris-HCl pH 7.5 buffer. Before 
chromatographic steps, the protein was precipitated with ammonium sulfate at 70% of saturation. 
  
Once the pellet containing protein was resolubilized, it was extensively dialyzed in 20 mM Tris-HCl pH 
7.5. Then the protein-containing fractions were recovered through the Q-Sepharose anionic 
exchange column eluting the sample with a linear NaCl gradient (0-1 M) in 20 mM Tris-HCl pH 7.5. 
Next, fractions with ferritin (identified with SDS-PAGE analysis) were pooled and further purified by 
size exclusion chromatography (HiLoad 16/60 Superdex 200 column, GE Healthcare) in 20 mM Tris-
HCl, 200 mM NaCl pH 7.5 (Fig. S1). 
Maldi-Mass spectrometry (MALDI-MS; Toscana Life Sciences Foundation, Siena) confirmed the 
calculated mass; the experimental value of 19888 Da corresponds to the mass of the WT HuLf 
subunit (20019.6 Da from ProtParam tool hrrp://web.expasy.org/protparam/) without the first 
methionine (131 Da). Trypsin digestion of the protein and the analysis of the fragmentation pattern 
obtained by MALDI-MS demonstrated the identity of HuLf subunit. 
Apoferritin from equine spleen was purchased from Sigma Aldrich (product code A3641) and further 
purified by size exclusion chromatography (HiLoad 16/600 Superdex 200pg, GE Healthcare). Mass 
spectra on the purified protein and on the dissolved crystal show the homogeneous presence of HoLf 
as later confirmed by the crystal structure (vide infra). 
Design and production of the triple mutant E60AE61AE64A. The proper oligonucleotide 
primers containing the three point mutations, were designed (QuikChange Primer Design tool) and 
purchased accordingly (Eurofins Genomics). We used pET-21c vector harboring the native gene as 
the DNA template, and we set up the site-directed mutagenesis reaction following the QuikChange 
Site-Directed Mutagenesis kit protocol (Agilent Technologies). The correct introduction of mutations 
was checked through Next-generation sequencing (Eurofins Genomics). The triple mutant 
E60AE61AE64A was expressed and purified in the same way as the WT protein. An aliquot of purified 
E60AE61AE64A was digested with trypsin and subjected to Maldi Peptide Mass Fingerprint analysis 
confirming the insertion of the desired mutations. 
Demineralization and iron-loading procedures. Iron and other metal ions were removed from 
purified ferritins by four dialysis steps using 4 L each of 20 mM Tris-HCl, 200 mM NaCl, 3 mM 
ethylenediaminetetraacetic acid (EDTA), ammonium thioglycolate (1:400), pH 7.5 buffer to reduce 
and chelate the iron, followed by four dialysis steps against 4 L each of 20 mM Tris-HCl, 200 mM NaCl 
pH 7.5. After removing metal ions from ferritins, known iron equivalents were added to ferritin 
variants as previously described (14). After removing metal ions from ferritins, for kinetic studies, 
known iron equivalents were added to ferritin variants preparing fresh ferrous sulfate stock solution 
in 1 mM HCl to avoid instantaneously oxidation of iron(II) to iron(III). 
Kinetic measurements. Kinetics of ferric-oxide species formation in absence and in presence of WT 
HuLf and E60AE61AE64A HuLf were monitored as the change in A350nm over the time. 25 µM 
  
protein subunits in 200 mM 3-(N-morpholino)propanesulfonic acid (MOPS), 200 mM NaCl pH 7 were 
incubated at room temperature after addition of 3, 6, 9 and 18 Fe2+ per subunit. Spectra were 
acquired at Varian Cary 50 Bio UV-vis spectrophotometer collecting one point every 30 seconds in 
the first 5 hours and every 15 minutes until 16 hours. 
Crystallization. Demineralized HuLf in 20 mM Tris pH 7.5 was concentrated to 9 mg/mL. Crystals of 
HuLf were grown using the hanging-drop vapor-diffusion technique at 281 K (15). Drops were 
prepared by mixing equal volumes of demineralized HuLf and a precipitant solution composed of 80-
100 mM Cd(NO3)2, 80-100 mM ammonium sulfate, and 200 mM sodium acetate pH 5. Drops were 
equilibrated over 800 µL reservoir solution. Octahedral shaped crystals appeared in 3-6 days and 
grew to final dimensions of about 200-400 µm in several days.  
HoLf crystals were grown by vapor diffusion hanging drop technique at room temperature. Drops 
were prepared by mixing 2 µL of HoLf solution (12-24 mg/mL in 0.15 M NaCl.) with 2 µL of precipitant 
constituted by 80 mM Cd(NO3)2, 800 mM ammonium sulfate, and 200 mM sodium acetate pH 5. 
Octahedral crystals, similar to those observed for HuLf, grew in a few days in drops equilibrated over 
800 µL reservoir solution. 
Iron loading was performed by soaking both L-type ferritin crystals with a freshly prepared 
[(NH4)2Fe(SO4)2]∙6H2O solution (approximately 40 mM) for the monitored exposure times of 15, 30, 
60, 90 and 120 minutes. Before flash freezing in liquid nitrogen crystals were washed in 
cryoprotectant solutions constituted by 40% v/v glycerol added to the precipitant solutions. 
Data collection, structure solution and refinement. Complete data sets for iron-free HuLf, HoLf 
and iron-loaded HuLf and HoLf were collected on the Elettra beamline XRD1 (Trieste, Italy) equipped 
with a Pilatus 2M detector, and on the DLS beamline I03 (Didcot, UK) equipped with a Pilatus 6M for 
crystals soaked for 15, 30 and 60 minutes. Crystals frozen after 90 and 120 minutes of exposure to 
iron appeared to have lost diffraction. The iron-free HuLf, HoLf data were collected for comparison. 
Data were integrated using either XDS (16) or Mosflm (17) and scaled with Scala (18) from the CCP4 
suite (19). The HuLf crystals belonged to the body-centered cubic space group I432, with unit-cell 
parameter a ~152 Å, varying slightly among the different crystals. On the other hand, the HoLf 
crystals belonged to the face-centered cubic space group F432, having unit-cell parameter a ~182 Å. 
Data collection and processing statistics are reported in Table S1. Initial models were obtained by 
molecular replacement using MOLREP (20) from the CCP4 suite. A subunit of either HuLf or HoLf 
were used as a search model, excluding non-protein atoms and water molecules. 
  
To unambiguously prove that the observed cluster is formed by iron ions full three-wavelength 
anomalous data (remote high energy 13500 eV, peak of the Fe K-edge at 7200 eV and immediately 
below the iron edge at 7050 eV), were collected for HuLf, while for HoLf we collected only the 7200 
and 7050 eV data. The positions of metal ions were determined from the anomalous Fourier 
difference maps calculated at 7200 eV and at 7050 eV, using FFT from the CCP4 suite. Iron can be 
easily distinguished from cadmium due to the disappearance of its anomalous signal in the 7050 eV 
map, where the anomalous signal of Cd2+ ions is still evident. Anomalous signals indicative of iron 
placement ranged between 15 σ and 4 σ in the anomalous difference map calculated with data 
collected at 7200 eV. 
The structures were refined with REFMAC5 (21) by using the high energy remote data in case of HuLf 
or the 7200 eV data in case of HoLf which were those at the highest resolution (Table S2). The 
refinement protocol involved sequential iterative manual rebuilding of the model and maximum-
likelihood refinement. Manual rebuilding and modelling of the missing atoms into the electron 
density and water molecules addition were performed with the molecular graphic software Coot 
(22). Partial occupancies for the iron and cadmium ions, for other ligands, and for several amino acid 
residues were adjusted to keep atomic displacement parameters close to those of the neighbouring 
protein atoms in fully occupied sites. Metal ions have been refined with anisotropic temperature 
factors. The occupancies of the water molecules or other ligands bound to the metal ions were kept 
the same as the parent metal ion. The final models were inspected manually and checked with Coot 
and PROCHECK (23). The final refinement statistics are reported in Table S2. Figures were generated 
with CCP4mg (24). 
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Figures 
 
 
Fig. S1. Purification of WT and E60AE61AE64A HuLf proteins. (A) Anionic exchange chromatograms 
obtained by a Q-Sepharose Fast Flow column with a 0-1 M NaCl gradient (dashed green line). In red 
and cyan, the elution profiles of WT and E60AE61AE64A HuLf respectively, followed by UV detector 
(FPLC, Akta system). (B) SDS-PAGE gel of fractions obtained by anionic exchange chromatography. 
Lane M: marker, lanes 1-6: main peak of WT HuLf profile, lanes 8-13: main peak of E60AE61AE64A 
profile (bands around 20 kDa corresponding to the protein monomers). (C) Size exclusion elution 
chromatograms (UV measure) of WT and E60AE61AE64A HuLf superimposed with one of an already-
characterized maxiferritin (violet curve; human H-ferritin sample) to demonstrate their 24-meric 
conformation. (D) SDS-PAGE analysis of fractions eluted with HiLoad 16/60 Superdex 200 column. 
Lanes M: marker, lanes 1-6: main peak of WT HuLf profile, lanes 7-12: main peak of E60AE61AE64A 
profile (bands around 20 kDa corresponding to the protein monomers). 
  
  
 
 
Fig. S2. Least-squares superimposition of iron-loaded HuLf (light blue) with iron-free HuLf (green). 
The three Cd2+ ions bound in the mineralization site in iron-free HuLf are replaced by Fe3+ ions and 
oxide after 60 minutes of exposure to Fe2+. Upon iron binding the side chains of Glu57, Glu60, Glu61, 
Arg68 and Glu140 change conformation. The two latter residues are involved in a H-bond network 
with three water molecules, one of which (WatL) ligates Fe2. 
  
  
Table S1. Data collection and processing. Values for the outer resolution shell are given in 
parentheses. 
 HuLf + Fe(II) 60’ HoLf + Fe(II) 60’ 
 
High energy 
remote 
Above iron K-
edge 
Below iron K-edge 
Above iron K-
edge 
PDB codes 5LG8 5LG2 
Diffraction source I03 (DLS) XRD-1 (Elettra) XRD-1 (Elettra) XRD-1 (Elettra) 
Wavelength (Å) 0.9184 1.7220 1.7587 1.7220 
Temperature (K) 100 100 100 100 
Detector Pilatus 6M-F Pilatus 2M Pilatus 2M Pilatus 2M 
Crystal-detector 
distance (mm) 
342 100 100 90 
Rotation range per 
image (°) 
0.15 0.5 0.5 0.5 
Total rotation range 
(°) 
75 60 60 60 
Exposure time per 
image (s) 
0.25 10 10 15 
Space group I432 I432 I432 F432 
a, b, c (Å)  151.42 151.47 151.64 181.35 
Mosaicity (°)  0.73 0.68 0.68 0.54 
Resolution range (Å) 
29.70-1.98 (2.09-
1.98) 
25.98-2.25 (2.37-
2.25) 
26.00-2.28 (2.40-
2.28) 
23.61-2.22 (2.34-
2.22) 
Total No. of 
reflections 
241127 (34962) 128079 (19118) 149132 (22337) 138083 (20118) 
No. of unique 
reflections 
20846 (2990) 14378 (2052) 13874 (1978) 13146 (1862) 
Completeness (%) 99.7 (100.0) 99.9 (100.0) 99.8 (100.0) 99.9 (100.0) 
Anomalous 
completeness (%) 
99.7 (100.0) 99.8 (100.0) 99.9 (100.0) 99.9 (100.0) 
Redundancy 11.6 (11.7) 8.9 (9.3) 10.7 (11.3) 10.5 (10.8) 
Anomalous 
redundancy 
5.9 (5.8) 4.6 (4.8) 5.7 (5.8) 5.6 (5.6) 
〈 I/σ(I)〉  16.8 (4.9) 12.6 (4.1) 14.0 (4.9) 12.6 (4.9) 
  
R r.i.m.  0.096 (0.481) 0.113 (0.456) 0.113 (0.449) 0.126 (0.401) 
Overall B factor from 
Wilson plot (Å2)  
15.4 15.9 16.6 14.2 
 
  
  
Table S2. Structure solution and refinement. Values for the outer resolution shell are given in 
parentheses. 
 HuLf + Fe(II) 60’ HoLf + Fe(II) 60’ 
PDB codes 5LG8 5LG2 
Resolution range (Å) 29.70-1.98 (2.03-1.98) 23.61-2.22 (2.28-2.22) 
Completeness (%) 99.6 (100.0) 99.8 (100.0) 
No. of reflections, working 
set 
19824 (1437) 12489 (905) 
No. of reflections, test set 1021 (67) 656 (49) 
Final Rcryst  14.2 (21.0) 16.5 (19.0) 
Final Rfree  17.7 (23.8) 22.4 (28.0) 
Cruickshank DPI  0.103 0.185 
No. of non-H atoms    
 Protein 1437 1364 
 Metal Ions (Fe, Cd) 13 (8, 5) 7 (4, 3) 
 Ions (oxide, peroxide, 
acetate, chloride, sulfate) 
16 (1, 6, 4, 0, 5) 6 (1, 4, 0, 1, 0) 
 Other 0 6 
 Water 208 154 
 Total 1674 1537 
R.m.s. deviations     
 Bonds (Å) 0.026 0.015 
 Angles (°) 2.214 1.625 
Average B factors (Å2)   25.88 28.35 
Ramachandran plot     
 Most favoured (%)  98.0 98.0 
 Allowed (%)  2.0 2.0 
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Abstract 
The interaction of the antimetastatic ruthenium drug NAMI A with ferritin was investigated 
to prepare NAMI A/ ferritin adducts with improved pharmacological performances. We 
observed that the presence of ferritin increases the rate of NAMI A hydrolysis; the resulting 
Ru species bind the protein at various molar ratios and relatively tight ruthenium/ferritin 
adducts are formed that may be separated and characterized. Distinct spectral features are 
observed for NAMI A /HuLF and NAMI A/HuHF adducts; the latter shows a characteristic CD 
spectrum. We also found that NAMI A produces a large inhibition of ferritin’s ferroxidase 
activity probably due to direct competition with iron ions at the catalytic site. The 
implications of these results are discussed. 
 
Introduction 
NAMI A is a well known ruthenium(III) medicinal compound showing attractive anticancer 
properties. NAMI A is commonly considered as a scarcely cytotoxic agent but manifests 
relevant antimetastatic properties both in vitro and in vivo. The latter properties were 
described in detail by Gianni Sava and coworkers through a number of research articles (1, 
2). Owing to its favorable pharmacological profile NAMI A was eventually admitted to clinical 
trials (3). 
As NAMI A is a quite reactive species that may undergo progressive and relatively rapid 
transformations, both in the blood and in tissues, before entering cells, we wondered 
whether it is possible to prepare NAMI A constructs that might protect the drug from 
transformation reactions for a longer time and/or might improve its uptake and/or 
pharmacological profile. 
To this end, we decided to study the reaction of NAMI A with ferritin. Ferritin is one of the 
main players in iron metabolism. The biological role of ferritin is the storage of ferric ions 
within its cavity under the form of a hydrated ferric oxide biomineral, thus preventing the 
uncontrolled accumulation of toxic iron species inside cells. Ferritins are polymers 
constituted by 24 subunits that self-assemble giving rise to an almost spherical nanocage. 
The ferritin cage has 2,3,4-fold symmetry (C2, C3 and C4 symmetry axes). The exterior and 
interior of the cage are connected via channels along C3 and C4 symmetry axes at subunit 
junctions. Mammalian ferritins are heteropolymeric twentyfour-mers formed by heavy chain 
(H) and light chain (L) subunits in a tissue specific ratio according to cell needs. All subunits 
share a common fold: a bundle of four antiparallel helices H1-H4, a fifth short helix H5 and a 
long solvent-exposed loop connecting H2 and H3. The H-subunit contains a binuclear 
ferroxidase center that catalyzes iron(II) oxidation. This antioxidant activity consumes iron(II) 
and dioxygen or hydrogen peroxide, the reagents that produce toxic free radicals in the 
Fenton reaction. The ferric products that form at the ferroxidase center are precursors of the 
  
biomineral. On the contrary, the L-subunits lack enzymatic activity; yet they are still able to 
store iron as a caged biomineral, although biomineralization proceeds at a slower rate. The L 
subunit contains a high number of carboxyl groups lining the ferritin cavity, which have been 
identified as iron nucleation sites.  
Ferritin has been also exploited as a drug delivery system due to the fact that cells have the 
natural ability to recognize and incorporate exogenous ferritin by specific receptors recently 
discovered. In particular, H-ferritin is recognized by the TfR1 (Transferrin receptor 1)(4) while 
L-ferritin by SCARA5 (Scavenger receptor class A type 5)(5), both overexpressed in specific 
tumor cells. 
In our study NAMI A was incubated with ferritin and the resulting NAMI A/ferritin adducts 
were characterized and then tested for biological activity. Notably as ruthenium(III) ions 
originating from NAMI A degradation mimic quite closely iron(III) ions, we decided to explore 
whether NAMI A inhibits the physiological function of ferritin and elucidate the underlying 
molecular mechanism of this inhibition. 
 
Materials and methods 
Protein expression and purification. Genes encoding HuHf and HuLf subcloned in pET-9a 
and pET-21c vectors (the latter is a gift by prof. S. Torti) (6) respectively, were transformed 
into E. coli BL21(DE3) pLysS competent cells. Bacteria were cultured in rich medium (LB) 
containing 50 mg/L of kanamycin or 100 mg/L of ampicillin and 34 mg/L of chloramphenicol 
at 37°C. HuHf was produced and purified as previously described (7, 8). Similarly, when 
A600nm reached 0.6-0.8, the over-expression of HuLf was induced with 0.2 mM IPTG, shifting 
the incubation temperature to 17°C for 48 hours. The cells were harvested (7500 rpm for 15 
minutes) and resuspended in 20 mM Tris-HCl pH 7.5. Lysis of cells was performed by 
sonication. The crude lysate was clarified by ultra-centrifugation (40,000 rpm for 40 minutes) 
and the soluble fraction heated at 65°C for 15 minutes to precipitate undesirable proteins 
(40,000 rpm for 15 minutes). Subsequently, the supernatant was dialyzed against 20 mM 
Tris-HCl pH 7.5 buffer and loaded into a Q-Sepharose column eluting the containing protein 
sample with a linear NaCl gradient (0-1 M) in 20 mM Tris-HCl pH 7.5. Next, fractions with 
ferritin (identified with SDS-PAGE analysis) were pooled and further purified with a size 
exclusion chromatography (HiLoad 16/60 Superdex 200 column). Iron and other metal ions 
were removed by four dialysis steps using 4 L each of 20 mM Tris-HCl, 3 mM EDTA, 
ammonium thioglycolate (1:400), pH 7.5 buffer to reduce and chelate the iron, followed by 
four dialysis steps against 4 L each of 20 mM Tris-HCl pH 7.5. Differently from HuHf, HuLf 
required ammonium sulfate precipitation (70% of saturation) followed by extensive dialysis 
in 20 mM Tris-HCl pH 7.5, before the anionic exchange column. 
  
Spectrophotometric studies. HuHf and HuLf (50 µM in subunits) were incubated with freshly 
prepared solutions of NAMI A at different molar ratios (1:2, 1:4, 1:8) in phosphate buffer (50 
mM sodium phosphate, 100 mM NaCl, pH 7.4). The hydrolysis experiments, both in presence 
of proteins or with NAMI A alone, were monitored spectrophotometrically at room 
temperature over 24 hours. The electronic spectra were acquired with a Varian Cary 50 Bio 
UV-vis spectrophotometer. 
Circular dichroism analysis. CD spectra to assess the formation of protein/NAMI A adducts 
were performed with a Jasco J-810 spectropolarimeter at 25°C. Samples of pre-incubated 
HuHf (protein concentration: 5 mM in subunits) with 2 equivalents of NAMI A were ultra-
filtered before the analysis. The mean of 5 accumulations, in the range of 300 and 700 nm 
wavelengths were calculated by subtraction of the buffer spectrum. CD data were obtained 
using a scanning speed set at 200 nm/min, band width and data pitch of 0.5 nm; 
temperature was maintained constant through the Jasco Peltier apparatus. 
Enzymatic activity measurements. After making the ferritin apo, single turnover 
oxidoreductase kinetic (2 Fe2+ ions per subunit) was monitored. Changes in absorbance at 
650 nm (diferric-peroxo or DFP) or at 350 nm (diferric oxo/hydroxo species; DFO(H)) were 
acquired after rapid mixing (< 10 ms) of equal volume of 100 μM HuHf as subunit (native or 
ruthenated ferritin with 2 NAMI A molecules per protein monomer) in 200 mM MOPS, 200 
mM NaCl, pH 7.0, with freshly prepared solutions of 200 μM ferrous sulfate in 1 mM HCl, in a 
UV/visible, stopped-flow spectrophotometer (SX.18MV stopped-flow reaction analyzer, 
Applied Photophysics). Routinely, 4000 data points were collected during the first 5 s. Initial 
rates of DFP and DFO(H) species formation were determined using data from three 
independent analyses through the linear fitting of the initial phases of absorbance changes 
at 650 and 350 nm traces (0.01− 0.03 s).  
 
Results  
The reaction of NAMI A with ferritin: spectrophotometric profiles. 
Due to the characteristic absorption bands in the UV-visible region, the solution behavior of 
NAMI A can be followed spectrophotometrically (9). In particular, we analyzed the 
interaction of different amounts of NAMI A with human ferritins in phosphate buffer (50 mM 
sodium phosphate, 100 mM NaCl, pH 7.4) over 24 hours of incubation at room temperature. 
The typical spectral profile of NAMI A alone in solution is characterized by the absorption 
band centered at 390 nm that progressively disappears, meaning that the first chloride 
group is lost and replaced by a water molecule. At this point, the increase in absorbance at 
340 nm is noticed followed by a decrease when the second chloride ligand is released and 
the second aquation occurs (9) (Fig. 1).  
  
 
The same time dependent profile is still present in the spectra acquired in the presence of 
ferritins (Fig. 2). The hydrolysis of NAMI A with human H ferritin (HuHf) occurred faster with 
respect to NAMI A alone even after few minutes of incubation. More interestingly, with 2 
equivalents of NAMI-A, we could detect the appearance of a new transition around 500 nm, 
after the two aquation processes, not referable to NAMI A or protein alone peaks. This 
change in the spectrum was in agreement with the shifted color of the solution from pale 
yellow once NAMI A was added to red/brown at the end of the exposure.  
On the contrary, in the reaction with HuLf, the hydrolysis seemed to proceed in the same 
way as the molecule alone in solution. Moreover, the UV-vis spectra with the L isoform did 
not evolve in the progressive exhibition of the band around 500 nm.  
 
  
Figure 5. Spectral evolution of NAMI A alone. Time-course UV-vis spectra of the hydrolysis 
of NAMI A alone (NAMI A concentration: 100 µM) dissolved in 50 mM NaPi and 100 mM 
NaCl, pH 7.4. Spectra were recorded over 24 hours at room temperature. 
NAMI A alone 
Figure 2. Spectral evolution of NAMI A in presence of ferritins. Time-course UV-vis spectra of 
the hydrolysis of NAMI A in presence of HuHf (1:2 molar ratio, protein concentration 50 µM in 
subunits; in the middle) and HuLf incubated with 2 NAMI A per subunits (1:2 molar ratio, protein 
concentration 50 µM in subunits; on the right) dissolved in 50 mM PB and 100 mM NaCl, pH 7.4. 
Spectra were recorded over 24 hours at room temperature. 
 
  
Recovery of the NAMI A-ferritin adduct, separation and CD characterization. 
At the end of the process, samples were extensively ultra-filtered to remove the excess of 
non-reacted compound. Electronic spectra were repeated on the filtered and on the flow-
through fractions confirming that ruthenium was associated to the protein, as shown from 
the still present transition in the visible region (Fig.3).  
 
 
 
 
 
 
In order to characterize deeply the final NAMI A/H-ferritin complex, we performed also 
circular dichroism analysis in the range of wavelengths from 300 to 700 nm after 24 hours of 
treatment. The CD spectrum revealed two bands: the first one is positive and centered at 
360 nm and the second one around 500 nm is negative (Fig. 4). 
 
 
Figure 3. Electronic spectra of ultra-filtered HuHf/NAMI A sample. Analysis of filtered 
sample (curve in red) and flow-through fraction (curve in blue).  
Figure 4. CD analysis of HuHf/NAMI A. CD spectra of HuHf pre-incubated with 2 equivalents of NAMI A 
for 24 hours. (Protein concentration: 5 mM in subunits). The negative absorption around 500nm 
confirmed the presence of a NAMI A/HuHf adduct. 
  
ICP-AES analysis on HuHf-NAMI A adducts showed an increased amount of Ru-species 
linearly proportional to the quantity of NAMI A incubated with the protein. This indicated 
that HuHf seemed still able to host other Ru-species upon the addition of 8 equivalents per 
subunits (data not shown). 
 
Inhibition of the ferroxidase activity in HuHf. 
Since ruthenium is similar to iron and can use the metabolic routes of iron, we hypothesized 
that it could enter the cage from the same channels and reach the iron binding sites. Thus, 
we wondered the possible effect of ruthenation on the enzymatic activity on homopolymers 
of HuHf, the subunit that contains the catalytic site for iron oxidation. In order to evaluate 
how Ru-metalation could affect the uptake and oxidation of iron ions, HuHf was incubated 
with NAMI A at 1:2 molar ratio (HuHf 100 µM in subunits) and the kinetic of iron oxidation of 
ruthenated ferritin (Ru-HuHf) was monitored by stopped-flow spectrophotometry. In other 
words, we added two molecule of NAMI A per subunit, since ferritin subunits contain 2 
ferroxidase sites each. The initial rates of formation of DFP (A650nm) and DFO(H) (A350nm) 
species for the native protein and for Ru-HuHf (Table. 1) were calculated as the changes in 
absorbance in the first milliseconds of traces at 650 nm and 350 nm (Fig. 5). In order to 
compare wild type HuHf with Ru-HuHf, subtraction of the blank curve with NAMI A alone 
was applied. We observed a notable inhibition of the ferroxidase activity in the case of Ru-
HuHf, both in the formation of ferric oxo species and DFP (Tab. 1). 
 
  
Table 3. Catalytic reaction rates. Initial rates of DFP formation (ΔA650 nm /Δt) and of DFO(H) species (ΔA350 nm 
/Δt) are showed as mean values from two independent analysis with SEM (standard error of the mean). The 
percentage of inhibition of the ruthenated protein with respect to wild type are listed. *The NAMI Absorbance 
values has been subtracted. 
 
Conclusions 
Thanks to characteristic time dependent changes of spectral profile in the UV-visible region, 
we could detect differences in the hydrolysis process of NAMI A attributable to the presence 
of the protein. In particular the rate of hydrolysis appears to be accelerated by HuHf while 
the presence of HuLf does not determine significant changes. The formation of a Ru-adduct 
with HuHf was established by UV-visible and circular dichroism spectroscopies, as well as by 
kinetic measurements that showed inhibition of the ferroxidase activity of HuHf. 
Crystallization trials failed till now, preventing to find out the exact localization of ruthenium 
binding site(s) inside ferritin. Nevertheless, the observed inhibition of the ferroxidase activity 
in HuHf and the different behavior between HuHf and HuLf strongly supports Ru-binding at 
the ferroxidase center. 
  
Figure 5. Kinetics of products formation in WT HuHf and Ru-HuHf proteins. Reaction progress 
of DFP (Abs 650 nm) and DFO(H) (Abs 350 nm) formation measured by stopped-flow 
spectrophotometer (mean ± SEM). The panels on the left represent plot of the changes in 
absorbance during 5 seconds, while the panels on the right show an enlargement of the first 
second of the reaction to highlight the differences in the initial rates. * The NAMI A 
absorbance values have been subtracted. 
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Abstract 
TfR-1 mediated cellular uptake of human H-ferritin loaded with 50 or 350 iron ions, without 
any additional modifications, results in a high cytotoxicity on HeLa cells. At variance, L-
ferritin, which is internalized through the SCARA5 receptor, is significantly less toxic, even 
when loaded with 1000 iron ions. We propose here that the different cytotoxicity of the two 
ferritin cages originates from the presence in H-ferritin of a pool of non-biomineralized iron 
ions bound at the ferroxidase catalytic sites of H-ferritin subunits. This iron pool is readily 
released during the endosomal-mediated H-ferritin internalization and is more prone to 
redox reactions with consequent ROS production causing toxicity. 
Introduction 
Ferritin is a protein highly conserved in all living forms, which stores iron in a bioavailable 
form. In animals, the 24-meric cage structure is assembled from two subunits, the heavy 
chain (H-chain) and light chain (L-chain) protein, or a mix thereof. The two distinct subunits 
share a similar fold and 53 % of sequence identity, but differ in their ability to handle iron. H-
subunits contain a catalytic center (ferroxidase or oxidoreductase site) where iron(II) is 
oxidized to iron(II) by dioxygen on the millisecond time scale. L-subunits lack the ferroxidase 
site; iron oxidation in L-type cages occurs on a time scale of the order of minutes and the 
protein mainly provide a shell to maintain the ferric oxide biomineral in a soluble form. 
The demineralized form of L-type ferritin (apoferritin) has been used for cellular delivery. 
More recently the selective ability of cells to internalized L- and H-cages through specific 
receptors has been demonstrated. 
Results 
Iron-loaded ferritins are toxic for HeLa cells. 
To compare the effect of H- and L-ferritin on tumor cells, we sought a tumor cell model that 
expresses both TfR1 and SCARA5 receptors, which have been demonstrated to act for the 
internalization of H- and L- cages, respectively. The choice of HeLa cells allows us to compare 
the behavior of the two proteins in the same cell line. In literature, a plethora of 
nanocarriers encapsulating different species within the natural horse spleen cage is 
available, as recently reviewed in (1). This cage has the advantage of being commercially 
available and can be considered a model of L-cages, as it contains only about 10% of H 
subunits. Horse spleen nanocages will be referred to as L-ferritin, hereafter. They have been 
studied in their apo form (apo L-ferritin) and loaded with an average of 1000 iron ions/cage 
(L-ferritin1000), as determined by ICP-MS from the commercially available iron-loaded 
protein. 
Recently the human H-ferritin has been proposed as a potentially superior carrier for 
anticancer drug delivery because, given its human origin, it should not activate inflammatory 
or immunological response (2). Efficient heterologous expression methods for human H-
ferritin (100 mg/L of purified protein, in our hands) (3, 4) make it attractive also from the 
  
economical point of view. H-ferritin can be loaded with variable amounts of iron. The first 2 
iron ions/subunit localize in the ferroxidase site; addition of more iron ions initiates the 
biomineralization reaction. Here, we investigated two differently iron-loaded H-ferritin 
cages: 
 i) one containing about 50 iron ions per cage (H-ferritin50, hereafter), which corresponds to 
the complete population of the 24 ferroxidase sites;  
ii) the other containing 350 iron ions per cage (H-ferritin350, hereafter), which corresponds 
to fully populated ferroxidase site plus formation of a biomineral core (expected size of the 
biomineral 5 nm, according to previous TEM analyses) (3). 
The amount of iron internalized by HeLa cells upon 24 h incubation in media containing 
variable amount of H- and L-ferritin was obtained by ICP-MS determination of the 
intracellular iron content (Fig. 1A). The relative amount of internalized iron when using H-
ferritin350 and L-ferritin1000 roughly correlates with the iron loading of the two cages. The 
amount of internalized iron after treatment with H-ferritin50 in the 1-8 M range was too 
low to be determined with sufficient accuracy. 
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Figure 1. A) Incubation of HeLa cells with increasing amounts of L-Ferritin (■) and H-Ferritin (○) for 24 h. 
After incubation, cell lysates were analyzed by ICP-MS to measure the amount of internalized iron that was 
normalized to the total protein cellular content, which in turn, is directly proportional to the cell number. 
Error bars indicated standard deviation of the data. B) On the left, dose-dependent L- and H- Ferritin effects 
on HeLa cell viability measured by MTT assay; on the right, dose-dependent H-Ferritin50 and H-
Ferritin350 effects on HeLa cell viability measured by MTT assay. C) HeLa cell viability measured by the 
MTT assay is reported as a function of the amount of internalized iron measured by ICP-MS normalized on 
the total protein cellular content (directly proportional to the cell number). In all experiments, cell viability 
was expressed as percentage relative to untreated cells. Data are presented as mean and SD of at least three 
independent experiments. D) ROS generation measured by DCFDA fluorescence emission (at 529 nm) after 
the incubation, for 24 h, of HeLa cells with 3µM apo and iron-loaded H- or L- Ferritin, respectively. 
Fluorescence emission was normalized to the internalized iron concentration (M). 
C 
  
Cell viability was determined by MTT assay after treatment of HeLa cells for 24 h with apo 
and iron-loaded H- and L-ferritins. While both apo forms do not show any appreciable 
toxicity, a clear effect is induced by the iron-loaded cages (Fig. 1B). The profiles of cellular 
cytotoxicity induced by the H- and L-cages are profoundly different. The L-induced effect is 
almost linearly dependent on the protein concentration. On the contrary, treatment with H-
ferritin50 and H-ferritin350 causes an abrupt decrease in cellular viability, which levels off at 
about 50% viability for ferritin concentrations  1 M ferritin. The attainment of a plateau 
value in cell viability for both iron-loaded H-ferritin nanocages can be interpreted in terms of 
iron-dependent downregulation of the Trf1 receptor expression; a well-known process in 
case of incubation of HeLa with an excess of holo-transferrin or Fe-citrate (5, 6). A flow 
cytometric analysis of the expression of TfR1 showed that the relative expression of this 
receptor with respect to untreated Hela cells decreases to 59% for cells treated with 1 M H-
ferritin350 and to 74% with 1 M H-ferritin50, suggesting that also iron-loaded H-ferritins 
activate a downregulation mechanism. No evidence has yet been reported of an iron-
dependent downregulation of SCARA5 expression, consistently with the lack of saturation 
effects in cytotoxicity when using L-ferritin1000. In spite of the larger intracellular iron 
internalization induced by L-ferritin-1000 with respect to H-ferritin350, the latter is much 
more toxic at lower protein concentrations. As illustrated in Fig. 1C, for a given iron 
concentration H-ferritin350 causes significantly larger reduction in cell viability, suggesting a 
different mechanism of action for H- and L-cages. Noteworthy, the difference in the 
cytotoxic effect exerted by treatment with H-ferritin50 and H-ferritin350 is smaller than 
expected on the basis of the cage iron content (Fig. 1B). This result suggests that the nature 
of the iron ions within the cage (ferroxidase-bound or biomineralized) might play a role. This 
aspect is further investigated in the following sections. 
Cytoplasmic ROS production was evaluated by measuring 2,7-Dichlorofluorescein diacetate 
(DCFDA) emission; its fluorescence intensity directly correlates with the steady-state 
concentration of intracellular ROS. The treatment with iron-loaded ferritins causes a 
significant increase in ROS production with respect to untreated cells and cells treated with 
the apo-ferritins (Fig. 1D). ROS generation normalized to the iron intracellular content for L-
ferritin1000 and H-ferritin350 was significantly higher for the latter. In conclusion, ROS 
production requires iron internalization into the cell, but it is not simply proportional to the 
metal concentration.  
The role of the TfR1 receptor and endosomal uptake. 
As reported (7), TfR1-imported H-ferritin is mainly localized in endosomes, following a 
pathway that resembles that of transferrin. We used confocal microscopy to demonstrate 
the different intracellular localization for rhodamine labeled L- and H-Ferritins. The former, 
indeed, colocalizes with the lysosomal specific marker Lamp-1, whereas only a small fraction 
of rhodamine labeled H-Ferritin is localized in the lysosomal compartment (Fig. 2A). 
Consistently, the cytotoxic effect of L-ferritin1000 is significantly reduced when the MTT 
assay was conducted in the presence of DFO mesylate, a lysosomal iron chelator, but is not 
  
affected by chloroquine (CHL), an agent that limits endosomal acidification. The opposite 
behavior is observed for H-ferritin350, where CHL essentially abolishes its cytotoxic effect 
(Fig. 2B). Mature endosomes are characterized by a low pH value (4.9-6.0) (8). In order to get 
more insights on the mechanism of iron internalization into HeLa cells, we tested in vitro the 
ability of H- and L-ferritins to release iron as a function of pH. As shown in Fig. 2C, while iron 
release at neutral pH values requires the presence of reducing agents, in H-ferritin350 (but 
not in L-ferritin1000) iron release spontaneously occurs at pH 5.0. The amount of released 
iron corresponds to about 16% of the total iron content in the H-ferritin350 cage i.e. roughly 
50 iron ions.  
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After 3h incubation of HeLa cells in the presence of L- or H-Ferritin 2.5 and 1 M, 
respectively, double membrane structures with the morphological features of endosomes 
enclosing electron-dense amorphous material compatible with hemosiderin bodies were 
observed only in the cells incubated with L-ferritin (Fig. 3).  
 
 
These hemosiderin bodies have been described as the initial product of ferritin degradation 
by lysosomal enzymes in iron-loaded cells (9, 10). In spite of the lower iron content delivered 
by H-ferritin, the fact that similar endosomes-lysosomes were not observed after the 
C 
 
Figure 3. T.E.M. photos of Hela cells treated with L-ferritin (A) and H-ferritin350 (B) (see material and 
methods for details). Arrows indicate representative endosomes. Only after L-Ferritin incubation (A) 
endosomes contain hemosiderin bodies. The arrowhead signs correspond to the plasma membrane 
(x30.000, lead citrate and uranyl acetate stained) 
 
Figure 2. A) Confocal Microscopy Representative images of HeLa cells incubated for 3 h with H- or L-APO-
Rhod (red) and stained with an anti-LAMP-1 antibody (green). Nuclei were counterstained with DAPI 
(blue). Arrows indicates the enlarged cells in the upper right panel. B) HeLa cell viability measured by the 
MTT assay after 24 of incubation with H-Ferritin350 (0.5 M) or L-Ferritin (2.5 M) in the absence and in 
the presence of (DFO mesylate) 150 M and Chloroquine (100 M). C) Reductive mobilization of iron from 
0.2 μM iron loaded H- and L- Ferritin in different media(on the left) and (on the right) in the presence of 
GSH (0.25 mM, pH=7), ASC (0.25 mM, pH=7) upon incubation in the presence of bipyridyl (1 mM) under 
aerobic conditions. T=0 corresponds to the instant after the addition of ferritin. 
  
treatment of HeLa with H-ferritin could be explained also taking in consideration the 
following points: a) the endocytic up-take pathway that involves the TfR1 avoids the 
lysosomal maturation process (see above), b) the rapid iron mobilization in the endosomal 
compartment due to the lower stability of H- than L-Ferritin at relatively low pH (see below). 
These results are in line with those obtained with the confocal microscopy (Fig. 2A). 
 
The higher H-ferritin toxicity originates from its peculiar iron cargo.  
The peculiar behavior observed for H-ferritin, which shows toxicity effects that are not 
proportional to the iron-loading suggests a different behavior between the biomineralized 
caged iron and the “mobile” iron pool constituted by those metal ions that are at the 
relatively weakly binding ferroxidase sites and low-populated accessory binding sites in the 
catalytic cavity (3). Indeed, the observed effects can be accounted for as originating by a 
pool of about 50 iron/cage over a total of 350 iron/cage. 
The not-yet biomineralized iron could be easier released upon acidification from the protein 
sited in the ferroxidase cavity, where the metal ligands are mainly provided by carboxylate 
and imidazole side chains, as observed in Fig. 2C. It might also be more prone to redox 
activity leading to a more significant generation of ROS (thus explaining the behavior 
observed by Fig. 1D). The differences with respect to L-ferritin arise from the fact that non-
active cages lack this “mobile iron pool” due to the absence of ferroxidase sites in their 
subunits. 
 
Human nanocages as MRI probes 
Horse spleen ferritin has been largely used as a carrier for MRI contrast agents; here, we 
investigate the relaxometric properties of H-ferritin with different iron loadings. 1/T1 NMRD 
profiles (at 25 °C, Figure 4A) were recorded for H-ferritin50, H-ferritin350 and L-ferritin1000. 
The profiles are not affected by addition of deferoxamine (DFO) that selectively binds the 
iron fraction eventually present on the external surface of the protein. The invariant profiles 
indicate the absence of weakly, externally coordinated iron ions. The higher millimolar 
relaxivities shown by H-ferritin50 at any field (Figure 4) arise from the paramagnetic Fe3+ 
ions bound to ferroxidase centers (48 per cage). This contribution is less pronounced in H-
ferritin350 and almost absent in L-ferritin1000. As reported (11), the differences in H/L ratio 
in ferritin cages determine different morphologies of the mineral core and this fact might 
influence the relaxivity profiles. T2-weighted MRI experiments were acquired on cells 
incubated for 24h in the presence of H-ferritin350 and L-ferritin1000. Different protein 
concentrations were used to obtain the same iron concentration (i.e., 0.38 mM). After 
incubation, cells were washed, transferred into glass capillaries, and placed in agar phantom 
to acquire MR images at 7 T. Cells incubated in the same medium without adding ferritin 
were used as a control. The T2-weighted RARE (TR/TE/ NEX = 5000/53/4) image confirms 
  
that the internalized amount of both H- and L-ferritins is high enough to induce a detectable 
contrast that is promising for tracking ferritins in vivo biodistribution (Figure 4B). Cells 
loaded with L-ferritin are more hypointense than those labeled with H-ferritin. The observed 
differences could be attributed to the presence of the mobile iron pool in H-ferritin, 
although the different structure of the biomineral core between H- and L-cages could also 
contribute.  
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Discussion 
 
A structural biology view of different toxicity of H and L chains. 
Recent X-ray crystallography studies have demonstrated that the ferroxidase site of human 
H-ferritin accommodates two iron ions, named Fe1 and Fe2, that are bound to few protein 
amino acid side chains: a bridging carboxylate group is provided by Glu62; Fe1 is then bound 
to His65 and monodentate Glu27; Fe2 to bidentate Glu107; the coordination sphere of each 
iron ion is completed by water molecules. Nearby, there are other two additional binding 
sites involving the side chains of His57, Glu58 and Glu62, where hydrated iron ions are 
bound with low occupancy. The emerging picture is that of a cage that uptakes ferrous hexa-
aquaions through the C3 channels and delivers them (as progressively de-hydrated ions) 
towards the ferroxidase site under the effect of attractive electrostatic gradient created by 
carboxylate residues. Given the low number of protein residues involved in the binding of 
the iron at the accessory binding sites and in the ferroxidase site, it’ s reasonable to propose 
that they could be more readily released and react. The Fe1 and Fe2 sites remains always 
populated during subsequent reaction turnover, while the biomineral growths. Their iron 
release upon lowering pH can be explained in terms of protonation of the acidic residues 
A B 
Figure 4. A) Profiles of 1/T1 1H-NMRD (pH 7.4, 25 °C) of H-Ferritin50 (▲),H-Ferritin350 () and L-Ferritin 
(); open symbols correspond to the same profile recorded in the presence of DFO. The relaxivities (r1p 
mM-1s-1) were normalized to the iron concentration. B) A T2-weighted RARE MR image of an agar phantom 
containing ca. 1 × 106 of (1) HeLa cells unlabeled; (2) Hela incubated for 24 h with H-ferritin and (3) L-
Ferritin. 
  
involved in their binding. At variance, in human L-ferritin and horse spleen ferritin, some of 
us have demonstrated that even the iron ions that react to form the biomineral precursors 
at the nucleation sites are blocked in a (μ3-oxo)tris[(μ2-peroxo)(μ2-glutamato-
κO:κO’)](glutamato-κO)(diaquo)triiron(III) cluster that is probably more stable and loses its 
importance when the biomineral growths. 
 
The apparent H paradox 
Our present findings rises an obvious questions. Why a human protein can be toxic for human cells? 
Here we have to consider a few key aspects: 
i) H-ferritin is a cytoplasmic protein; under the cytosolic pH its cargo is stable and is not 
readily released. 
ii) The natural cytoplasmic ferritin never undergoes endosomal-mediated import with 
consequent iron released induced by the low pH in endosome.  
iii) Only ferritin that could be externally administered via the blood stream can be 
internalized via TfR-1 receptors leading to endosomal internalization. 
Therefore, the toxicity of iron-loaded H-ferritin is due to tow main factors: the presence of a mobile 
iron pool, which has no counterpart in L-ferritins and the lability of this pool at the low pH 
encountered during the endosomal import. 
 
Materials and Methods. 
Horse spleen apoferritin and iron loaded ferritin (15% H chains and 85% L chains, hereafter 
called L-ferritin), Thiazolyl Blue Tetrazolium Bromide, DCF-DA, deferoxamine mesylate, 
chloroquine and all other chemicals were purchased from Sigma-Aldrich (St Louis, MO). 
Commercially available L-apoferritin and L-ferritin were used without any further 
purification. The number of Fe/cage of L-Ferritin was measured by ICP-MS and the protein 
concentration by the Bradford assay. 
H-Apoferritin production/purification. The gene-coding sequence for human H ferritin was 
custom-synthesized (GenScript, USA) and subcloned into pET-9a expression vector using 
NdeI and BamHI restriction sites. The expression plasmid was introduced by thermal shock 
into E. coli strain BL21 (DE3) pLysS cells. Transformants were selected in LB agar 
supplemented with 50 mg L-1 kanamycin. Cells were grown at 37°C until A600 nm reached 
0.6−0.8, and subsequently induced with isopropyl 1-thio-β-D-galactopyranoside (IPTG, 1 mM 
final concentration) for 4 h. Human H ferritin was purified from the harvested cells, as 
described previously (3, 4). Briefly, cells were broken by sonication and the cell free extract 
obtained after centrifugation (40 min, 40,000 rpm, 4 °C) was incubated for 15 min at 65 °C as 
the first purification step. After removal of the aggregated proteins (15 min, 40,000 rpm, 4 
°C), the supernatant solution was dialyzed against Tris-HCl 20 mM pH 7.5; applied to a Q-
Sepharose column in the same buffer and eluted with a linear NaCl gradient of 0−1 M in Tris 
20 mM, pH 7.5. Fractions containing ferritin, identified by Coomassie staining of SDS-PAGE 
  
gels, were combined and further purified by size exclusion chromatography using a Superdex 
200 16/60 column.  
Iron loading in H-apoferritin. Iron loading of human recombinant homopolymer H-
apoferritin (100% H chain) was carried out by adding a FeSO4 solution (200 mM in HCl) to 
the protein (9 M) dissolved in MOPS (100 mM) / NaCl (100mM) at the protein/Fe ratio of 
1:500 and 1:50. After the addition the samples were vigorously vortexed for 5’ and then left 
at 25°C for 2 hours and at 4°C overnight. The formed H-ferritins were purified by two cycle of 
dialysis at 4°C using 1 L of Hepes 4mM/NaCl 150mM as external buffer. Final iron 
concentration has was measured by ICP-MS. Residual protein concentration was measured 
by the Bradford assay using Bovine Serum Albumin (BSA) as standard.   
Labeling of H- or L-ApoFerritin with Rhodamine B. H- or L-apoFerritin solutions (2 mg/ml) 
were prepared in 0.1 M sodium carbonate buffer, pH 9. Rhodamine isothiocyanate (Rhod) 
(Sigma Aldrich) was dissolved in anhydrous DMSO at 1 mg/ml. For 1 mg of protein, 50 l of 
Rhod solution were added very slowly in 5 μl aliquots under stirring. Then, the reaction 
mixture was incubated in the dark for 16 h at 4°C. Afterwards, NH4Cl was added to the 
reaction to a final concentration of 50 mM and stirred for 2 h at 4°C. The unbound Rhod was 
separated from the conjugate by dialysis in PBS, pH 7.4, using a 14000 Da cut-off membrane. 
Finally, the concentration of Rhod and protein were measured by a fluorometer FluoroMax 4 
spectrofluorometer (Horiba Jobin Yvon, Edison, USA) and a spectrophotometer (6715 
UV/Vis. Spectrophotometer Jenway, Essex, UK) with the Bradford method, respectively. 
ICP-MS. Iron concentration was determined by using inductively coupled plasma mass 
spectrometry (ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy). Sample digestion 
was performed with concentrated HNO3 (70%) under microwave heating at 160°C for 20 
minutes (Milestone MicroSYNTH Microwave labstation).  
NMRD profiles. The 1/T1 nuclear magnetic relaxation dispersion profiles (NMRD) of water 
protons were measured over a continuum of magnetic field strengths from 0.00024 to 0.5 T 
(corresponding to 0.01–20 MHz proton Larmor frequency) on a Fast Field Cycling 
relaxometer (Stelar Spinmaster FFC 2000 relaxometer) equipped with a resistive low 
inductance air cored silver solenoid. The relaxometer operates under complete computer 
control with an absolute uncertainty in the 1/T1 values of ±1%. The typical field sequences 
used were the non-polarized (NP) sequence between 20 and 8 MHz and the pre-polarized 
(PP) sequence between 8 and 0.01 MHz. The observation field was set at 16 MHz. T1 was 
determined by the saturation recovery method; 16 values of delay () between pulses were 
used. The number of averaged experiments was 2.  
HeLa cell line. Cervical carcinoma (HeLa) cell line was obtained from the American Type 
Culture Corporation. They were cultured in RPMI 1640 medium (Lonza) containing 10% (v/v) 
fetal bovine serum (FBS), 2 mM glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin. 
Cells were incubated at 37 ºC in a humidified atmosphere of 5% CO2. The cell line was 
  
routinely tested to verify the absence of mycoplasma contamination (MycoAlert™ PLUS 
Mycoplasma Detection Kit, Lonza). 
Uptake experiments. For uptake experiments, HeLa cells were seeded at a density of 6 × 105 
cells in a 25 cm3 culture flask and placed in a wet (37 °C) 5% CO2 air atmosphere incubator. 
At 24 h post seeding, cells were incubated with increasing concentrations of the above-
mentioned H- or L-ferritins. After 24 h of incubation, cells were washed three times with 10 
mL ice-cold PBS, detached with trypsin/EDTA. The Fe content in each cell line was 
determined by ICP-MS. For MRI analysis (see below) cells were transferred into glass 
capillaries. The protein concentration (proportional to the cell number) was determined 
from cell lysates by the Bradford assay, using BSA as a standard. 
Fluorescence Activated Cell Sorting (FACS) analysis of Transferrin Receptor expression. In 
order to perform FACS analysis, 2x105 Hela cells were seeded in 3.5 cm of diameter culture 
dishes. The day after, cells were treated for 24h with Fe(III) citrate (Sigma Aldrich) 0.34 mM, 
human holo transferrin (Sigma Aldrich) 10 and 20 µM or H-Ferritin 1µM loaded as previously 
described. For the experiment, cells were grown in Roswell Park Memorial Institute medium 
(RPMI) medium (Lonza). At the end of the incubation, the medium was removed and the 
cells were washed three times with PBS. Then, they were treated with a non enzymatic 
dissociation solution (Sigma Aldrich) for 15 min at 37°C, transferred in 15 ml falcon tubes and 
counted in PBS. Cell number was determined using a cell sorting chamber (Burker-Turk 
chamber). The cells were divided in falcon tubes containing 1x106 cells for each one.  
All samples were centrifuged (1100 rpm for 5’), the supernatant was removed, and the cells 
were further washed with PBS and centrifuged (1100 rpm for 5’). All the samples were then 
incubated in 10% FBS (0.5 ml) for 30’ at 4 °C, then spun down (1100 rpm for 5’), washed with 
PBS (3 ml), and then this washing step was repeated once more. The PE conjugated antibody 
(mAb anti human CD71, BD Pharmingen) selective for Transferrin Receptor 1 (TfR1) was 
added to the samples previously described (20 μl in 100ul of 0.1% BSA/PBS) and to a non-
treated sample of Hela cells. As a negative control, a mouse isotype control antibody PE 
conjugated (Miltenyi Biotec) (5ul in 100ul of 0.1% BSA/PBS) was incubated with a non-
treated sample of Hela cells. The incubation was performed at 4 °C for 40’. All samples were 
then washed with PBS (2 × 3 ml) and centrifuged (1100 rpm for 5’). Finally, cells were diluted 
in PBS (250μl) and evaluated for their PE fluorescence on a flow cytometer (Becton 
Dickinson, FACS Calibur). Their PE fluorescence was analyzed using the CELLQUEST PRO 
program: the mean fluorescence intensity of the treated samples has been calculated as a 
percentage with respect to the non-treated Hela cells.  The experiments were performed in 
duplicate. 
MTT assay. MTT assay is based on the tetrazolium salts reduction to formazan by 
mitochondrial succinate dehydrogenase (SDH), which is quantified spectrophotometrically. 
5×103 Hela cells were seeded in a 96-well microtiter plate at 37 °C and 5% CO2 air 
atmosphere. 24 h later, the cells were incubated for 24 h at 37 °C and 5% CO2 with 
increasing concentration of iron-loaded H- and L-Ferritin and H- and L-apoFerritin. 
  
Furthermore, H-Ferritin (0.5 µM) and L-Ferritin (2.5 µM) were also incubated in absence or in 
the presence of DFO mesylate (150 µM) or chloroquine (100 µM) for 24h. After this time, the 
medium was removed and 100 l of Thiazolyl Blue Tetrazolium Bromide dissolved in 
medium at the concentration of 0.45 mg/mL was added into each well and the plate was 
incubated for 4 h at 37 °C and 5% CO2. Then, the medium was removed, 150 µl of DMSO 
were added into each well to solubilize the formazan salt crystals produced by the 
metabolism of live cells and the microplate was incubated at room temperature for 30 
minutes. Finally, absorbance was read at 570 nm with iMark microplate reader (Biorad). Cell 
viability was reported as percentage of death cells observed in treated samples relative to 
that observed in control cells. The experiment was performed in triplicate and the data were 
graphically presented as mean ± SD. 
Iron mobilization from H- and L- ferritin. Iron loaded H- and native L- Ferritin (0.2 µM) have 
been incubated up to 3h at 25°C in different buffers (Hepes/NaCl pH=7.4; 0.1 M acetate 
buffer pH=5) and in human serum (Seronorm Human, Sero AS, Billingstad, Norway) in the 
presence of 1 mM 2,2′-bipyridine under aerobic conditions. Incubations of proteins in 
Hepes/NaCl buffer at pH=7.4 have been repeated in the presence of glutathione (0.25 mM) 
or ascorbate (0.25 mM) and of 1 mM 2,2′-bipyridine. The concentration of the reductively 
mobilized iron cations from ferritin was measured by following the absorption of the Fe(II)–
bipyridine complex at 530 nm (ε = 8650 M−1 cm−1). 
Laser scan microscopy studies. Co-localization determination among H/L-apoferritns and 
lysosomes were carried on as follow. Cells were seeded in a Ibidi μ-Slide 8 well at a density 
of 5x104 cells/ml and incubated at 37°C and 5% CO2 for 24 h, in order to allow them to 
adhere to the slide surface. Then, cells were incubated with H or L-Apoferritin rhodamine 
labeled (20 nM) for 3 h. At the end of the incubation cells were washed three times with PBS 
and fixed in cold methanol at 4°C for ten minutes. Afterwards, cells where rinsed twice with 
PBS for ten minutes each one. In order to block the non-specific binding sites, cells were 
treated with 5% normal goat serum during thirty minutes. Then, cells were incubated 
overnight at 4°C with a mouse monoclonal IgG1 anti-human Lamp-1 (H4A3 from Santa Cruz 
Biotechnology Inc, Dallas, Texas, USA). After washing twice in PBS for ten minutes, cells were 
incubated with a goat polyclonal IgG (H+L) fluorescein labeled anti-mouse antibody one hour 
at room temperature (Molecular Probe, Eugene, Oregon USA). Finally, cells were washed 
with PBS three times for ten minutes each one and air dried. Nuclei were counterstained 
with DAPI. Coverslips were mounted with a glycerol/water solution (1/1, v/v). Observations 
were conducted under a confocal microscopy (Leica TCS SP5 imaging system).  
Transmission electron microscopy (TEM) studies. For TEM analysis, HeLa cells were treated 
for 3 h at 37°C with H-Ferritin 1 M or L-Ferritin 2.5M, respectively. Control cells were 
incubated under the same conditions without ferritin addition. Then cells were fixed with 2.5 
% glutaraldehyde solution in 0.1 M phosphate buffer pH 7.4 and post-fixed in osmium 
tetroxide solution. Then, samples were dehydrated in 3 x 10 min in 70% ethanol, 2 x 15 min 
  
in 100% ethanol, and 2 x 15 min in 100% propylene oxide, and embedded under vacuum in 
EMbed 812 resin (Electron Microscopy Sciences, Hatfield, PA, USA). 70 nm slices were 
sequentially stained with, saturated uranyl acetate,  0.25% lead citrate and 0.04% bismuth 
subnitrate to enhance ferritin detection 29. Samples were analyzed under a Jeol Jem 1400 
transmission electron microscopy (Peabody, MA, USA). 
Measurement of reactive oxygen species (ROS) production. Intracellular ROS production 
was detected using the non-fluorescent cell permeating compound, 2’,7’-dichlorodihydro-
fluorescein diacetate (DCF-DA). In order to evaluate the effect of  H- and L-Ferritin on the 
ROS production, Hela cells were seeded at a density of 1 x 105 cells in a 3.5 cm of diameter 
dishes and were placed for 24 h in a wet (37 °C) 5% CO2 air atmosphere incubator. Iron-
loaded H- and L-Ferritins and H- and L-apoferritins (without iron content) were incubated at 
protein concentration of 3 µM for 24 h at 37°C, 5% CO2. After the incubation, cells were 
washed two times with PBS and incubated with 5 µM of DCF-DA for 30’ at 37°C, 5% CO2 in 
pre-warmed EBSS buffer. Cells were then washed two times with PBS and detached using a 
cell scraper in 100ul of PBS. Cells were then sonicated in ice for 5’’ at 30% power and the 
protein content of cells were determined by the commercial Bradford method. The 
fluorescence of cells lysates (30000 cells) was measured using a fluorometer microplate 
reader Promega Glomax-multi detection system (Promega Corporation, 2800 Woods Hollow 
Road Madison, WI 53711 USA) using a blue module (ex 490 nm, em 510-570 nm) on samples 
containing 10 g of cell proteins in 200 l of PBS.  The fluorescence intensity was then 
normalized to the intracellular iron concentration measured by ICP-MS (2.05 and 0.495 µM 
for L- and H-ferritin, respectively).  
MRI. All the MR images were acquired on a Bruker Avance 300 spectrometer (7 T) equipped 
with a Micro 2.5 microimaging probe (Bruker BioSpin). Glass capillaries containing 1 × 106 
cells were placed in an agar phantom and MRI was performed using a T2-Weighted RARE 
sequence protocol (TR/TE/NEX = 5000/53/4; FOV= 1.2 cm; MTX 128x128). 
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Introduction 
Ferritin-like proteins are a family of well-characterized iron storage proteins with an 
essentially ubiquitous distribution in all life forms (1-3). They are formed by 12 (in the case of 
the prokaryotic DNA-binding proteins from starved cells, DPS) or 24 (classical ferritins and 
bacterioferritins) identical or similar subunits self-assembled into a globular shell containing 
an iron core consisting of a ferric oxy-hydroxide mineral similar to ferrihydrite (4). In the 
classical 24-mer ferritins the structure of each subunit is a helix bundle composed of four α-
helices, (A, B, C, D) and a fifth C-terminal short α-helix E (Figure 1a). The subunits are 
assembled into a spherical-shape structure with 4-3-2 symmetry, which form a hollow 
complex with an approximately 8 nm diameter cavity capable of storing up to 4500 iron 
atoms (Figure 1b). In eukaryotes, native cytosolic ferritins are the product of self-assembly of 
two types of highly homologous subunits: “light” (L, 20 kDa), and “heavy” (H, 22.8 kDa) 
subunits, with up to 53% identity. The H subunit is characterized by the presence of a di-iron 
binding site embedded inside the 4-helical bundle which is responsible for the interaction with 
oxygen and confers ferroxidase activity, namely is responsible for the enzymatic oxidation of 
Fe2+ to Fe3+. The L subunit, without a ferroxidase center, still catalyzes Fe2+ oxidation but at a 
much slower rate (5) and plays a role in iron nucleation and mineralization (6, 7), i.e. it can 
provide a means to control the overall capacity of iron storage improving the overall iron-
sequestering process. Ferritins display a dynamic iron-storage function, central to cellular iron 
homeostasis. Fe2+ sequestration prevents spontaneous oxidation to Fe3+ and production of 
toxic free radicals, thus displaying also oxidative stress protection. The nanocage composition 
in terms of H and L-subunits is tissue specific, with ferritins from liver and spleen, involved 
in long-term storage of iron, being richer in L-subunits, whereas those from heart and brain, 
with more active iron metabolism, being richer in H-subunits (6, 8). For example for the horse 
spleen ferritin (HoSF), here investigated, its average composition is generally stated to be 
roughly 15% H-subunit and 85% L (H4L20), (9) corresponding to a mixture with a L-subunit 
content roughly sixfold greater in abundance than the H-subunit (8, 10).  
Crystallographic studies of mammalian ferritins revealed that the pockets at the 2-fold 
intersubunit are available to bind organic molecules, including protoporphyrin (11), 
anaesthetics (12) and fatty acids (13). Thus it has been suggested that, besides its iron-storage 
function, ferritin plays a role in lipid metabolism (13), as also inferred by a series of data on 
the functional coupling between iron and fatty acid metabolism (14-18). The crystal structure 
of the HoSF-arachidonate complex (PDB id 4DE6) revealed that the bound ligand has a U-
  
shaped conformation (characteristic of fatty acids located in the fatty acid binding protein 
cavity (19)) and is close to residues known to form the nucleation site, which includes E53, 
E56, E57, E60 and E63 (HoSF numbering, Figure 1c). (13, 20-25). Of interest, the ferritin-
bound arachidonate, appeared to contribute to ferrihydrite mineralization by accelerating iron 
uptake. Intracellular free fatty acid concentration might thus have a signaling role in 
accelerating iron storage via its incorporation within the ferritin cage. Ferritin may as well 
protect unsaturated fatty acids from oxidation, limiting their participation in lipid peroxidation 
chain reaction, thus reducing their inflammatory effects (13, 26). 
Intrigued by the possible role of ferritin as a new fatty acid binding protein we have here 
investigated the interactions of apo horse spleen ferritin (HoSF) with a pool of lipids, 
employing a series of 1D 1H-NMR, diffusion (DOSY) and saturation transfer (STD) NMR 
experiments. Unsaturated fatty acids (arachidonate and oleate) exhibited better binding 
properties with respect to saturated fatty acids (lauric acid), detergents (sodium dodecyl 
sulphate) and bile acids (chenodeoxycholic acid). These studies have been accompanied by 
mineralization assays through UV/visible measurements, aimed at clarifying whether 
functional coupling exists between mineralization and ferritin/lipid interactions. The initial 
rate of mineralization exhibited the highest increase in the presence of oleate (OLA), with 
respect to saturated fatty acids and other lipids.  
Oleate was also shown to efficiently bind to recombinant homopolymeric human ferritin H 
(HuFH), although no effect was observed on ferroxidase activity.  
Results and Discussion 
Interaction of HoSF with lipids. The 1H NMR spectrum of commercial, freshly dialyzed apo 
HoSF, dissolved in 20mM phosphate buffer in D2O at pH 7.5, is reported in Figure S1a. The 
high molecular weight of the 24-mer (approximately 480 kDa), translates into a reduced 
tumbling rate and a fast nuclear transverse relaxation, giving rise to severely broadened 1H 
resonances (2). The observable residual broad resonances occurring in the aliphatic region are 
likely due to superficial mobile ferritin sidechains and/or to the contribution of smaller HoSF 
oligomer species or to the presence of impurities (vide infra). In order to probe the 
interactions of ferritin with lipids, we firstly exploited ligand based NMR experiments, which 
are not limited by the size of the protein. Indeed, small ligand molecules, when reversibly 
bound to the proteins, retain similar NMR properties as the large macromolecule, leading to a 
change in their observed parameters, such as chemical shifts, linewidths and/or intensity (28). 
  
At the same time a non-interacting ligand would exhibit unaffected resonances when added to 
ferritin.  
In addition to 1H ligand-observed NMR experiments, a diffusion spectroscopy-based 
approach (DOSY) (29), which uses gradient pulses to measure translational diffusion, was 
employed to study the interactions of selected lipids with this “NMR-oversize” system. Small 
molecules bound to macromolecules diffuse at the slower rate of the macromolecule rather 
than at their typical rate. The acquisition of DOSY spectra, in the presence and absence of the 
target protein, can identify binding events from the change of the diffusion properties of the 
observed ligand partner.  
Polyunsaturated, monounsaturated and saturated fatty acids (Figure S2) together with 
detergents and bile acids were tested for their binding to HoSF. In order to correctly interpret 
any spectral perturbation in terms of specific binding to the macromolecule, we first selected 
two small molecules, namely sucrose and tert-butyl alcohol, as control samples for non-
interacting ligands. Sucrose density gradient centrifugation is in fact used to purify and 
analyze recombinant ferritins (9, 30), while tert-butyl alcohol is an inert molecule (31). The 
1H NMR (Figure S3), and DOSY spectra (data non shown) of these ligands were unaffected 
by the presence of HoSF thus confirming the absence of any spurious (viscosity) effect due to 
the protein.  
Polyunsaturated arachidonate (ARA) was tested first. The structure of the complex (PDB 
4DE6) (13) has been reported together with an estimate of KD 60 M, derived from ITC 
experiments. ARA is localized at the intersubunit 2-fold pocket (13), thus indicating that 
twelve equivalents of FA are bound per 24-mer, which was the basis to calculate the protein 
ligand molar ratio to be employed in the NMR experiments. 1H NMR experiments and DOSY 
spectra performed on HoSF after progressive addition of ARA showed that the resonances of 
free ARA started to appear at a ARA:HoSF ratio > 1 (referred to binding sites), as shown in 
Figure 2, confirming that twelve binding sites are saturated by the lipid. The absence of any 
chemical shift change of the free ligand (when in stoichiometric excess) indicates that it is in 
slow exchange with the bound one, suggesting a sub-micromolar affinity. Resonances of the 
free ARA appear at a diffusion coefficient consistent with the formation of emulsion particles 
(2-4 mer units; for the assessment of molecular weight see Experimental). It should be further 
mentioned that the resonances of HoSF occurring at 0.7-0.9 ppm in the spectrum of HoSF, 
could in principle be due either to impurities of the commercial samples and/or to highly 
mobile sidechains and/or to the presence of small HoSF oligomeric species. DLS and size 
exclusion chromatography experiments performed on the commercial HoSF sample 
  
confirmed that the predominant species is the protein 24-mer (Figure S4) 
The interaction of HoSF with monounsaturated oleate (OLA), monitored through 1H-NMR 
and DOSY performed at different OLA:HoSF ratios exhibited a behavior similar to that 
observed for ARA, with the resonances of the free oleate bulk methylene groups (1.2 ppm) 
being visible only at L:P ratio of 2 (Figure 2). These methylene resonances display a diffusion 
coefficient consistent with either a monomeric or a sodium hydrogen dioleate, an insoluble 
swelling "acid soap" compound (32). CD spectra performed on samples of apo HoSF and 
HoSF in complex with OLA, confirmed that the native secondary structure of the protein is 
conserved in the complex (data not shown). 
Lauric acid sodium salt (LAU), as an example of saturated fatty acid, was also tested for its 
interactions with HoSF. At LAU:HoSF ratio of 1, the resonance of LAU at  1.2 ppm, 
corresponding to the bulk methylene groups, was clearly visible at the same chemical shift of 
the free species, and exhibited linewidth broadening with a substantial attenuation with 
respect to free LAU at the same concentration (Figure 3a). Diffusion measurements confirmed 
the presence of free lauric acid already at LAU:HoSF ratio of 1 (Figure S5). These data 
indicate that LAU binds to HoSF, although with decreased affinity. 
Previous crystallographic and ITC data have shown that sodium dodecyl sulphate (SDS) binds 
specifically to a HoSF internal cavity, at the dimer interface, occupying the same binding site 
described for ARA and with a KD of 249 M (33). SDS has a 12-carbon tail, as LAU, but 
attached to the bigger sulfate polar group, thus allowing an evaluation of the role of the polar 
head steric hindrance. The NMR data, here acquired, were consistent with a weaker binding 
of SDS to HoSF with respect to LAU, indicating an unfavorable role of the bulky polar head. 
Indeed, in the 1H NMR spectra a substantial line broadening (twofold linewidth increase) was 
observed for SDS methylene resonances (1.2 ppm) in the presence of HoSF (Figure 3b), 
suggesting that binding occurs on an intermediate exchange regime on the chemical shift time 
scale, at variance with all the other tested FAs, which exhibit a slow exchange regime. In 
agreement with this observation, in the DOSY spectra of SDS:HoSF, performed at different 
molar ratios, the free SDS resonance was already observable at SDS:HoSF ratio of 0.5 (Figure 
2). CD spectra on HoSF:SDS samples confirmed that there is no effect of the detergent on the 
native secondary structure of the protein (Figure S4b). 
Finally, we tested the interaction of HoSF with chenodeoxycholate (CDA), a lipid belonging 
to the bile acid family, a group of amphipathic molecules displaying two different surfaces, 
the hydrophobic  side with angular methyl groups and the hydrophilic  side characterized 
by the presence of hydroxyl groups. The angular C18 methyl resonance of CDA occurs at 
  
0.57 ppm, a region free from any HoSF resonance, which can therefore be employed to 
monitor the appearance of free CDA upon interaction with HoSF, as shown in Figure 4. The 
observed behavior paralleled that observed for SDS as a substantial linewidth broadening was 
observed for CDA methyl resonance at all the CDA:HoSF ratios, together with a small 
chemical shift change, indicating an intermediate exchange regime, typical of a weak binder.   
 
Effect of NaCl addition to ferritin-FA complexes. An increased salt concentration may favor 
binding when hydrophobic effects dominate protein-ligand interactions (27, 34). Addition of 
salt may also lead to a drop in the critical micellar concentration (CMC) value of FA 
molecules, which can possibly further influence the equilibria established in solution (35, 36). 
The presence of 150 mM NaCl did not alter the observed spectra of HoSF in the presence of 
oleate, but had significant effects for weaker binders. Figure 3a shows that in the presence of 
NaCl, the binding of LAU to ferritin is favored, as indicated by a further decrease of the 
residual resonance of LAU methylene groups, with respect to the same sample solution 
without NaCl. The addition of NaCl favors as well the binding of SDS with a further 
linewidth broadening of the bulk methylene resonance at 1.2 ppm (Figure 3b).  
 
Competition experiments. NMR competition binding experiments were further performed in 
order to check whether oleate occupies the same ARA/SDS binding site, at the dimer interface 
(Figure 1c). Oleate was added to HoSF:SDS complex to obtain a sample with 
HoSF:SDS:OLA ratio of 1:1:1. The resulting spectrum showed an increase of the free SDS 
resonance intensities, indicating that oleate could displace SDS. The amount of displaced SDS 
reached a maximum after 24 hours. The displaced SDS resonances are slightly shifted with 
respect to those of free SDS, indicating the presence of fast exchange between SDS free and 
bound to the OLA:HoSF complex (Figure 5). The observed chemical shift changes of SDS 
cannot be ascribed to the formation of a mixed OLA:SDS micelle, as deduced from NMR 
control experiments performed by adding incremental amounts of OLA to free SDS in 
phosphate buffer at the same concentration (data non shown).  
 
STD experiments. Ligand-observed saturation transfer difference (STD) experiments are 
among the most appealing NMR experiments to monitor weak ligand binding (KD ≈ M-mM) 
in the presence of large protein partners (37), via magnetization transfer from the large protein 
to the smaller ligand. STD spectra were obtained for all the investigated ferritin complexes, 
using a 50-fold molar excess of ligand (calculated on the basis of the number of binding sites). 
  
Control STD experiments performed in the presence of sucrose, yielded, as expected, no 
signal. STD spectra of ARA and OLA, in the presence of HoSF, exhibited small signal 
enhancements (Figures 6b,c). All SDS resonances, at variance, exhibited a substantial 
enhancement (Figure 6d) in the STD spectra. kon, koff and R1 rates contribute to determine the 
observed strengths of the ligand signals. For ARA and OLA, at the employed lipid 
concentration, equilibrium exists in solution between monomers and micellar aggregates 
(critical micellar concentration, CMC, are expected to be smaller than 0.1 mM), while higher 
CMC values (8 mM) are reported for SDS (ref). Thus different koff  and R1 may affect the 
resulting spectra while kon is expected to be roughly the same for the investigated molecules. 
The observed lower net saturation transferred to the pool of free ARA and OLA ligands is 
however consistent with the titration data depicting a tighter binding with respect to SDS. The 
spectrum of Figure 6d reflects the proximity of all the SDS protons to HoSF, consistent with 
X-ray data showing the ligand embedded in the protein cavity (33). Competition binding STD 
experiments were performed by adding OLA to the SDS:HoSF complex, in equimolar 
amounts, confirming the higher affinity of OLA and its ability to displace SDS, as inferred 
from the loss of the C1 methylene resonance ( 3.96 ppm), the only signal characterizing SDS 
with respect to OLA (Figure 6e). The other observed resonances (0.8-1.2 ppm) are likely due 
to the bound OLA methyl and methylene resonances. They appear broader and with a reduced 
intensity than SDS resonances (Figure 6d), in agreement with the expected lower koff. CDA 
binds as well to HoSF (Figure 6f), with a lower affinity than OLA. Indeed, in the competition 
STD experiment with OLA (Figure 6g), CDA resonances disappear with the concomitant 
appearance of OLA signals.  
 
Iron mineralization. In order to investigate the correlation between the binding abilities of 
different FAs and the kinetics of mineralization, commercial apo HoSF was first 
demineralized and then incubated with or without lipids. The kinetics of biomineral formation 
was followed by UV absorption as the change in absorbance at 350 nm, to monitor the 
formation of diferric oxo/hydroxo species ((Fe3+O)x) during oxidative deposition of iron (38) 
in the apo and lipid-bound ferritin forms. A high loading of Fe2+ (480 Fe2+ per HoSF cage) 
was here employed, in order to overcome the lack of iron turnover at the ferroxidase centers 
of the protein (HoSF contains few H chains) and to favor the nucleation and growth of the 
incipient core, namely to ensure that the mineralization reaction occurs to an appreciable 
extent (7, 10). The addition of OLA, ARA, and LAU significantly enhances the initial 
mineralization rate of HoSF. (Figure 7). However, the FAs have different effect on the 
  
mineralization process, with ARA and LAU displaying the same absorbance of apoferritin 
after 20 minutes and OLA showing an increase of the total amount of ferric oxide species at 
plateau, and thus possibly favouring the oxidation of Fe2+ on the mineral core surface. 
A further screening, performed varying the number of insaturation on the C18 alkyl chain 
(C18:1 oleic, C18:2 linoleic, C18:3 linolenic acids), indicated that the increase of the 
insaturation number significantly lowered the enhancement of the initial mineralization rate 
observed with oleate, thus suggesting the relevance of the fatty acid conformation (Figure S5). 
An inhibition of iron mineralization was observed in the presence of the weakest binder SDS, 
albeit reported crystallographic data showed that SDS occupies the same binding site later 
described for ARA. Thus, the steric hindrance of the polar head plays some structural role in 
contrasting the flow of iron through the described hydrophilic three-fold channel.  
The comparison of the kinetic data translates into an initial rate for the formation of Fe3+Ox 
species almost 10 times faster in the presence of OLA and ARA (Table 1), thus confirming 
the hypothesis that FAs enhance iron mineralization, favouring iron uptake, as recently 
observed in in vitro (HepG2 hepatocytes) and in vivo (in rats) experimental models (39).  
All together these findings suggest that OLA, ARA and LAU influence the mineralization 
process presumably modelling the environment of the surrounding side-chains, favouring iron 
storage. (10).  
 
The ensemble of the binding and mineralization experiments clearly shows that oleate is a 
strong binder displaying the highest effect, among the tested lipids, on HoSF mineralization. 
In view of the relevance of investigations on functional coupling between lipid transport and 
iron mineralization, it is important to gain more information on the interactions of oleate with 
the human protein.  
 
Interaction of recombinant HuHF with oleate. The binding of oleate with recombinant HuHF, 
displaying a sequence identity of 51% and a similarity of 75% with HoSF, was tested by 
NMR. 1H NMR spectra of OLA:HuHF, at different ratios, confirmed that resonances of free 
oleate at  0.75 (C18 methyl), 1.2 (bulk methylene groups) and 1.47 ppm (C3 methylene) 
became clearly visible only at OLA:HuHF ratio of 2 (Figure 8a). DOSY spectra highlight the 
presence of OLA resonances diffusing as dimeric free species only at OLA:HuHF ratio of 2, 
(Figure 8b) paralleling the behavior of HoSF .  
It was further shown that the OLA complex maintains its secondary structure also upon 
increasing the temperature (Figure S3).  
  
 
Materials and Methods 
Protein Preparation. Horse spleen apoferritin (HoSF) was purchased from Sigma-Aldrich. 
For NMR experiments the protein was first dialyzed with 10 mM potassium phosphate buffer 
(pH 7.4) and then exchanged into D2O buffer. For mineralization measurements HoSF was 
further demineralized by extensive dialysis against four changes of at least 20-fold volume 
excess of 20 mM Tris buffer at pH 7.4 containing 2.5 mM EDTA and 2% ammonium 
thioglycolate, followed by extensive dialysis against 20 mM Tris buffer pH 7.4. Human H 
ferritin (HuHF) was expressed and purified as described previously (40).   
NMR experiments. NMR experiments were performed at 25°C using a 600 MHz Bruker 
Avance III spectrometer equipped with a triple resonance TCI cryogenic probe. 1D NMR 
spectra were recorded with 64 scans and a spectral width of 14026 Hz. Spectra were 
referenced to the dioxane signal (3.69 ppm) used as internal standard. All spectra were 
manually phased and baseline corrected using TOPSPIN 3.2 (Bruker, Karlsruhe, Germany).  
STD experiments were recorded using a 1D pulse sequence incorporating a T1 filter to 
remove disturbing protein signals (41-44). “On-resonance” irradiation of HoSF (50M in 
subunits) was performed in the aromatic region (7.2 ppm), which is free from ligand 
resonances, while “off resonance” irradiation was set at 35 ppm, a value outside the range of 
HoSF resonances. The irradiation was performed with a train of selective Seduce-shaped 
pulses of 50 ms duration, for a total saturation time of 3 s.  
2D 1H-DOSY experiments were recorded with a 600 MHz Bruker DMX spectrometer 
equipped with a triple resonance TXI probe. The convection-compensated two dimensional 
double stimulated echo bipolar pulse (DSTE-BPP) sequence was employed (45). Matrices of 
2048 (t2) by 80 points (t1) were collected. The z axis gradient strength was varied linearly 
from 2 to 98% of its maximum value (53 G/cm). The gradient pulse duration was 1.8 ms, 
while the time period between the two gradient pulses was set to 70 ms to allow the detection 
of free ligand species. DOSY with a longer big delta (200 ms) were also recorded to estimate 
the diffusion time of larger molecules and evaluate the presence of monomeric and/or 
oligomeric ferritin. Water suppression in DOSY experiments was achieved with a standar 
Bruker library DSTE DOSY sequence (46)  with the addition of a sculpting module for water 
suppression. Self-diffusion coefficients were derived by fitting NMR data to Stejskal and 
Tanner equation (47). Dioxane (45 M) was added as internal reference to correlate relative 
diffusion coefficients with MW of molecules and their aggregates in solution. This approach 
also allows to minimize erroneous D estimates deriving from temperature fluctuations and 
  
changes in sample viscosity and density. 
Iron mineralization. The kinetics of biomineral formation were followed monitoring the 
increasing of absorbance at 350 nm with a Cary 30 UV/visible Spectrophotometer (Agilent 
Technologies). The change of absorbance was monitored after the addition of ferrous sulfate 
(freshly prepared solution in 1 mM HCl) to HoSF (2.08 M protein cages) incubated with 
(700 M) or without lipids in 200 mM MOPS, 200 mM NaCl, pH 7.0. Initial rates of 
mineralization were calculated from the linear fitting of the initial phases of the 350-nm traces 
(0 - 30 s) from three independent measurements.  
Size Exclusion Chromatography and Dynamic Light Scattering. 5mg of commercial HoSF 
were analyzed by SEC using an AKTA Prime (GE Healthcare) equipped with a Sephacryl S-
100 HR XK 26/100 column (GE Healthcare) equilibrated in 20 mM Tris, 150 mM NaCl, pH 
7.5. Fractions showing an absorbance at 280 nm were analyzed by SDS-PAGE. With the use 
of SEC calibration standards (GE Healthcare), the peak eluting in the void volume was 
consistent with the molecular weight of apo HoSF. In order to investigate the size of HoSF, 
DLS measurements were performed in triplicate at 25°C on apo HoSF before and after SEC 
using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) operating at =633 nm and 
equipped with a back scattering detector (173°). Each measurement was the average of 20 
data sets acquired for 10 seconds.  
Circular Dichroism Spectroscopy. CD spectra were acquired in the far-UV with a Jasco J-810 
spectropolarimeter using a 0.1 cm path length quartz cuvette and 10 μM protein concentration 
(in subunits) in 20 mM Tris buffer at pH 7.5, in the presence (5M) or absence of ligands. 
The CD spectra were first measured at 25 °C, the samples were then incubated in termostated 
cells at the desired temperatures (in the range 25−85 °C) for 5 min and the corresponding CD 
spectra were acquired. The final spectrum was calculated as the mean of 10 scans between 
200 and 260 nm wavelengths after subtraction of the corresponding buffer spectrum. 
Stopped-Flow Kinetics. Single turnover oxidoreductase kinetics (6 Fe2+/subunit) was 
monitored in apo HuHF and in complex with OLA. Changes in absorbance at 650 nm 
(diferric-peroxo or DFP) or at 350 nm (Fe3+O)x, were measured in the same conditions of iron 
mineralization in a UV/visible, stopped flow spectrophotometer (SX.18MV stopped-flow 
reaction analyzer, Applied Photophysics).  
  
  
 
Table 1. Initial rates of biomineral formation at 480 Fe eq. per cage 
 
Sample Initial rate (A350nm/min)* 
HoSF 0.02873 ± 0.007310 
HoSF-OLA 0.2621 ± 0.04628 
HoSF-ARA 0.2486 ± 0.07781 
HoSF-LAU 0.1607 ± 0.06061 
  
HuF in progress 
HuF-OLA in progress 
*calculated from the linear fitting from three independent measurements 
 
  
  
Figures 
 
 
Figure 1. Structure of HoSF (PDB 4DE6). a) Four helix (A,B,C,D) bundle and the fifth short 
E helix; b) ferritin 24-mer; c) dimer interface hosting the arachidonate lipid.  
 
 
 
 
 
 
 
  
 
Figure 2. DOSY spectra of the complexes. Left panels: Superposition of DOSY spectra 
recorded at 600 MHz and 25°C of a sample of 97 M HoSF in NaPi buffer pH 7.8 (black), 
ARA:HoSF at different ratios (red), free ARA at the same concentration of each complex 
(blue). The resonance at 1.2 ppm observed in the ARA:HoSF 2:1 spectrum, corresponding to 
the C17-C19 methylene resonances of free ligand, is indicated with an arrow. A grey dashed 
line indicates the diffusion coefficient of free ARA, consistent with the presence of oligomers 
of 2-4 units. Peaks visible in the aliphatic region of the protein spectra (0.7-0.9 ppm) were 
characterized by diffusion coefficients consistent with the presence of impurities of the 
commercial samples and/or to highly mobile sidechains). Central panels: superposition of 
DOSY spectra recorded at 600 MHz and 25°C of a sample of 90 M HoSF in NaPi buffer pH 
7.8 (black), OLA:HoSF at different ratios (red), free OLA at the same concentration of each 
complex (blue). The resonance at 1.2 ppm observed in the OLA:HoSF 2:1 spectrum, 
corresponding to the free ligand, is indicated with an arrow. A grey dashed line indicates the 
diffusion coefficient of the main species observed for OLA, consistent with the presence of 
dimers; Right panels: superposition of DOSY spectra recorded at 600 MHz and 25°C of a 84 
M HoSF sample in NaPi buffer pH 7.8 (black), SDS:HoSF at different protein:ligand ratios 
(red), free SDS at the same concentration of each complex (blue). The resonance at 1.2 ppm 
observed in all HoSF:SDS spectra, corresponding to the free ligand, is indicated with an 
arrow. A grey dashed line indicates the diffusion coefficient of the main species observed for 
SDS, consistent with the presence of dimers. 
  
 
Figure 3. Interaction of HoSF with lauric acid sodium salt (LAU) and SDS. a) superposition 
of 1D spectra recorded at 600 MHz, 25°C, phosphate buffer, D2O, pH 7.5 of 85M apo HoSF 
(black), LAU:HoSF ratio of 1 (blue), LAU:HoSF ratio of 1 in the presence of 150 mM NaCl 
(red) and a sample of pure LAU at the same molar concentration of the complex (green). The 
spectrum of apo HoSF is reported to show that at  1.2 ppm only the ligand resonances can be 
observed. Signal intensities were normalized using dioxane resonance as an internal standard; 
b) superposition of 1D spectra recorded at 600 MHz, 25°C, phosphate buffer, D2O, pH 7.5 of 
85M apo HoSF (black), SDS:HoSF ratio of 1 (blue), SDS:HoSF ratio of 1 in the presence of 
150 mM NaCl (red)  and a sample of pure SDS at the same molar concentration of the 
complex (green).  
 
  
 
 
 
Figure 4. Interaction of HoSF with CDA. Superposition of 1D NMR spectra of a 70 M 
HoSF sample in phosphate buffer, pH 7.5, 25°C (black), after addition of CDA at CDA:HoSF 
ratio of 1 (blue) and free CDA at the same concentrations of the complex (green). A zoom on 
the C18 methyl resonance occurring at 0,57 ppm where HoSF does not exhibit any resonance, 
is reported to highlight the observed line broadening.  
  
 
 
Figure 5. NMR competition experiments. Superposition of 1D spectra recorded at 600 MHz, 
25°C, phosphate buffer, D2O, pH 7.5 of a 85M HoSF:SDS 1:1 sample (black); 
HoSF:SDS:OLA mixture at 1:1:1 ratio (blue), the same mixture after 24 hours (red) and, for 
comparison, pure SDS solution at the same concentration of the previous spectra in the 
presence of 150mM NaCl (green). The arrows indicate the chemical shift difference between 
free and SDS displaced by oleate.  
  
  
 
 
 
Figure 6. STD NMR experiments. STD spectra of 50 M HoSF in the presence of 1.25 mM 
ligands, performed at 600 MHz in phosphate buffer, H2O, pH 7.2. The ON and OFF 
resonance spectra were irradiated at 7.2 and -35 ppm, respectively. An irradiation time of 3s 
was employed. The different ligands employed were: a) sucrose; b) ARA; c) OLA; d) SDS; e) 
same sample as d) after the addition of the competitor OLA at the same concentration of SDS; 
f) CDA; g) same sample as f) after the addition of the competitor OLA at the same 
concentration of CDA. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 7. Kinetics of mineralization for HoSF alone (gray trace), incubated with 700 M of 
OLA (blu), ARA (red), LAU (gold) and SDS (purple). The kinetics of biomineral formation 
was followed as the change of A350 nm after addition of 480 eq of Fe
2+ per cage. 
  
 
Figure 8. Interactions of HuHF with oleate. a) Superposition of 1D spectra performed at 600 
MHz in phosphate buffer, D2O, pH 7.5 of 95M apo HuHF (grey), with the different 
complexes obtained in the presence of oleate at OLA:HuHF ratios of 0.5 (red), 1 (blue) and 2 
(green). 1D spectrum of free oleate at the same concentration of the complex with 
OLA:HuHF ratio of 2 is reported in the upper part of the panel for comparison (black). 
Dashed lines identify resonances of free oleate which became clearly visible only at 
OLA:HuHF ratio of 2. b) Superposition of DOSY spectra recorded at 600 MHz and 25°C for 
samples of free OLA (black), OLA:HuHF at ratios of 0.5 (red), 1 (blue) and 2 (green). A 
dashed lines is drawn corresponding to the molecular weight of the sodium hydrogen dioleate. 
Peaks observed at lower diffusion values are due to residual contribution from protein signals. 
  
  
Supplementary Figures 
 
 
 
 
Figure S1. 1D 1H NMR spectra recorded at 600 MHz, 25° C, of ferritin samples in 20 mM 
phosphate buffer, pH 7.5: a) 85 μM apo HoSF; b) 95 μM recombinant apo HuF. Minor 
impurities are marked with asterisk. 
 
  
  
 
 
Figure S2. Structures of the polyunsaturated (ARA), monounsaturated (OLA), saturated 
fatty acids (LAU), detergents (SDS) and bile acids (CDA) analysed. Their sodium salts were 
employed in the experiments for solubility reasons. 
  
  
 
 
 
Figure S3. 1D 1H NMR spectra recorded at 600 MHz, 25° C, of ferritin samples in 20 mM 
phosphate buffer, pH 7.5: a) 85 M apo HoSF treated with an equimolar amount of sucrose. 
The region 5.35-3.3 ppm has been selected to highlight the sucrose resonances; b) pure 
sucrose solution at the same concentration of spectrum a). The comparison of the two spectra 
evidence the lack of any effect in the presence of HoSF; c) 85 M apo HoSF treated with an 
equimolar amount of tert-buthyl alchool; d) pure tert-buthyl alchool solution at the same 
concentration of spectrum c). In spectra c and d only the highfield region, displaying the 
single methyl resonance of tert-buthyl alchool, is shown.  
  
  
 
 
 
 
Figure S4. a) Elution profile of size-exclusion chromatography. Size separation was obtained 
with a Sephacryl S-100 (GE Healthcare) column. The red line corresponds to the elution 
profile of the proteins used as standards for the calibration; the blue line refers to the 
chromatogram of the sample containing the horse spleen ferritin; b) Hydrodynamic size of 
ferritin measured by dynamic light scattering. The distribution curve is the average of three 
independent measurements.  
 
  
  
 
 
 
Fig. S5. Superposition of DOSY spectra recorded on a HoSF sample 85M treated with a 
stoichiometric amount of LAU, HoSF:LAU at 1:1 ratio (red) and on a sample of free LAU at 
the same concentration of the complex (black). The DOSY spectra were recorded at 500 MHz 
and 25°C. The region including the LAU methylene groups (1.2 ppm) and the terminal methyl 
group (0.8 ppm) is shown. Horizontal lines indicate the logD value, corresponding to a 
molecular weight consistent with the presence of dimeric (red) and trimeric (black) species, in 
the presence and absence of ferritin, respectively. The effect of binding of lauric acid is 
reflected on the observed decrease of the molecular weight of the free LAU species in the 
presence of ferritin, which decreases LAU concentration in solution by sequestering it.  Red 
peaks at high field and higher D values are due to protein mobile loops. The observed 
smearing is due to truncation effects as the DOSY spectrum has been optimized for 
observation of small species (see Material and Methods).  
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